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Foreword
This year’s annual report of the European Monitoring
Centre for Drugs and Drug Addiction is accompanied by
additional online elements including our new statistical
bulletin, now in its second year, which has grown to
include over 200 source tables of quantitative data
detailing the European drug situation.
The EMCDDA has been working with the Member States of
the European Union for more than 10 years to develop a
comprehensive picture of the European drug phenomenon.
The quantity and quality of the data now available to
inform the analysis in this year’s annual report reflect not
only the technical achievements of the scientific working
groups that provide the information, but also the
commitment of policy-makers across Europe to invest in
and support the data collection process. This is a concrete
example of the benefits of working together at the
European level. Member States differ not only in respect of
the drug problems they face, but also in the ways in which
they have responded to these challenges. Despite these
differences, there has also now emerged what can be
regarded as a European perspective on the drugs issue.
A strong consensus now exists on the need to base actions
on a sound understanding of the situation, to share
experiences on what works and to act together whenever it
is possible to achieve common benefits. These aspirations
can be found in the new EU strategy and action plan on
drugs and also form the key themes of our reporting here. 
Our annual report highlights many important areas of
concern about the way drug use is impacting on both
citizens and the communities in which they live. We draw
attention to emerging problems with which we are now
confronted, such as the rising use in parts of Europe of
stimulant drugs, and cocaine in particular, or the continued
growth in the number of young Europeans who are
experimenting with drugs. Clearly, there is still much to be
done to improve the response to drug use in Europe.
Nevertheless, in this report we are also able to point to a
number of positive developments, not least the overall
expansion of services for those with drug problems and
signs of stabilisation or even a decline in some of the more
damaging aspects of this phenomenon. Thus, this report
not only highlights some of the key problems that we are
facing, but also sheds light on what is likely to be the way
forward in effectively addressing drug problems in Europe. 
We are pleased to note that once again this year there has
been an increase in the data available from the new
Member States of the European Union. As well as
reporting on the situation in the enlarged Union, when
available, we also include data from Bulgaria, Romania
and Turkey and some analysis on important international
developments. The global nature of the drug problem
means that we must locate our European analysis within
a broader context. The trafficking and use of drugs are
inextricably linked with many of today’s most pressing
concerns. Drug use impacts on global health and
development, crime and personal safety, and international
security. Our report is focused very much on the European
picture, but we cannot afford to ignore the fact that we are
addressing a problem with global dimensions. 
Marcel Reimen
Chairman, EMCDDA Management Board
Wolfgang Götz
Director, EMCDDA
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Reitox national focal points
Reitox is the European information network on drugs and drug addiction. The network is comprised of national focal points
in the EU Member States, Norway, the candidate countries and at the European Commission. Under the responsibility
of their governments, the focal points are the national authorities providing drug information to the EMCDDA.
The contact details of the national focal points may be found at:
http://www.emcdda.eu.int/?nnodeid=1596

Introductory note
This annual report is based on information provided to the EMCDDA by the EU Member States and candidate countries
and Norway (participating in the work of the EMCDDA since 2001) in the form of a national report. The statistical data
reported here relate to the year 2003 (or the last year available). Graphics and tables in this report may reflect a subset
of EU countries: the selection is made on the basis of those countries from which data are available for the period of
interest.
An online version of the annual report is available in 22 languages and may be found at
http://annualreport.emcdda.eu.int
The 2005 statistical bulletin (http://stats05.emcdda.eu.int) presents the full set of source tables on which the statistical
analysis in the annual report is based. It also provides further detail on the methodology used and over 100 additional
statistical graphs. 
Country data profiles (http://dataprofiles05.emcdda.eu.int) provide a top-level, graphical summary of key aspects of the
drug situation for each country.
Three in-depth reviews accompany this report and explore the following issues: 
• drug-related public nuisance: trends in policy and preventive measures; 
• alternatives to imprisonment: targeting offending problem drug users in the EU; and,
• buprenorphine: treatment, misuse and prescription practices.
The selected issues are available in print and online (http://issues05.emcdda.eu.int) in English only.
The national reports of the Reitox focal points give a detailed description and analysis of the drugs problem in each
country and are available on the EMCDDA website (http://www.emcdda.eu.int/?nnodeid=435).
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Piecing together the European picture
This section provides an overview of the main
developments and trends in the European drug situation.
This is arrived at by piecing together information derived
from different sources and by taking into account both the
strengths and weaknesses of the currently available
evidence base. This year’s commentary includes an
assessment of how the new data available in 2005
contribute to our understanding of the medium- to long-term
trends in the European drug situation.
Polydrug use problems complicate both our
understanding of, and response to, drug use problems
Throughout much of this report, the analytical approach
adopted is to focus on each of the main substances used.
This substance-specific approach is conceptually easy to
understand and has the additional advantage that most
indicators of drug use are based on substance-specific
behavioural measures. The disadvantage of this approach
is that it does not reflect the fact that polydrug use is a
major factor in drug problems in Europe. Analysis of the
public health impact of drug use needs to take into account
the complex picture of the interrelated consumption of
psychoactive substances, which include both alcohol and
tobacco. For example, in Europe cannabis is often smoked
with tobacco, and this has implications both for the harms
likely to be associated with this behaviour and for
informing drug prevention activities. Toxicological
analyses of drug deaths often reveal the presence of a
number of substances, and the concurrent consumption of
alcohol is known to increase the risks associated with both
heroin and cocaine use. Furthermore, focusing on trends in
one substance can be misleading if the interrelationship
between different drug types is ignored; for example, in
this report there is some evidence that the availability of
synthetic opiates is increasing, an important consideration
in any analysis of trends in heroin use. Similarly, it may be
wise to consider the possible overlap in trends in the use of
different stimulant drugs, and consider in any analysis the
extent to which observed changes might be due to shifts in
consumption patterns.
As most of those who present to treatment centres in
Europe for a drug problem will have used multiple
substances, there is a need to develop better methods of
reporting this key aspect of drug use and to understand
how polydrug use will impact on the effectiveness of
interventions.
Young people and drug use — increasing use
of cannabis, but different patterns emerging
Drug use in Europe remains largely a phenomenon of the
young, and of young men in particular. Data from
population and school surveys provide a useful insight into
the way in which patterns of drug use in Europe have been
developing since the mid-1990s. Available for inclusion in
this year’s annual report are data from the latest round of
the European school survey project on alcohol and other
drugs (ESPAD), which provides a valuable source of data
for monitoring drug use in the school populations and for
detecting trends over time.
Taking all the available data together, it is clear that the
use of cannabis differs considerably between countries.
Although the predominant European trend since the mid-
1990s has been upward, some countries exhibit a more
stable pattern. For example, although rates of cannabis
use in the United Kingdom since the 1990s have been
particularly high, they have remained stable over this
period. In addition, there has been little change in the
levels of cannabis use in several low-prevalence countries,
including Finland and Sweden in the north of Europe and
Greece and Malta in the south. Most of the increases in
cannabis use recorded in ESPAD since 1999 have
occurred in the new EU Member States. Analysis of school
data and general population survey evidence suggests
that, on most measures, the Czech Republic, Spain and
France have now joined the United Kingdom to form a
group of high-prevalence countries.
There is growing concern in Europe about the negative
impact of cannabis use, although information on the extent
to which the use of this drug is resulting in public health
problems is scarce. Data available on drug treatment
demands in Europe place cannabis second only to opiates,
although cannabis still accounts for only 12 % of all
treatment demands and the overall picture is greatly
influenced by the situation in relatively few countries. Data
on the regular and intensive use of cannabis are essential
for developing an understanding of the likely connection
between cannabis use and public health, but currently this
information is limited. Although the available data suggest
that as many as 3 million people, mostly young males,
Commentary — identifying drug trends in Europe
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may be using cannabis on a daily basis in Europe, the
extent to which this group might be experiencing problems
because of their use of the drug is not known.
What is happening to problem drug use — is recruitment
into heroin use and drug injecting in decline?
Among the most methodologically challenging areas in
monitoring drug use is the task of estimating the numbers
of people using drugs in a chronic and particularly
damaging fashion. The EMCDDA problem drug use
indicator has been developed to estimate this type of drug
use, and in the majority of EU countries, problem drug use
indicators principally reflect the use of opiates and
injecting use. Current estimates suggest there are probably
between 1.2 and 2.1 million problem drug users in the EU,
of whom 850 000 to 1.3 million are likely to be recent
injectors. Problem drug use prevalence estimates over time
are patchy, making it difficult to identify long-term trends.
However, in the EU-15 Member States, indicators broadly
suggest that the rapid recruitment into heroin use that most
countries had been experiencing peaked at some time in
the early 1990s and was followed by a more stable
situation thereafter. Although several countries have
continued to report increases since 1999, there are recent
signs that this situation is not uniform, with prevalence
estimates showing no consistent picture at EU level.
In particular, the new Member States deserve special
mention, as they appear to have experienced heroin
problems later and to have a more fluid situation.
Additional sources of information for assessing problem
drug use are the numbers of drug-related deaths and
treatment demands. Analysis of drug-related deaths (most
commonly due to opiate overdose) suggests that the victims
constitute an ageing population, with recorded deaths
among drug users younger than 25 having fallen since
1996. An important qualification is that data from the
newer EU countries, although limited, show until recently
an upwards trend in the proportion of deaths among those
under 25, although a degree of stabilisation now appears
to have occurred. Overall, although the number of drug-
related deaths in the EU remains at a historically high
level, it seems likely to have peaked.
In most countries, heroin remains the principal drug for
which clients seek treatment. In some countries, trends in
heroin use among new treatment clients can be tracked
historically and show a small decrease in absolute
numbers since 1996. Similarly, in some countries a trend
suggesting an ageing population of opiate users is
reported, although again this observation does not apply
to all countries, and in some of the new Member States —
again based on limited data — opiate users entering
treatment for the first time appear to be relatively young.
In some European countries, notably the EU-15 Member
States, injecting among new opiate users requesting
treatment has been in decline for some time, and across
Europe less than half of new clients requesting treatment
for opiate use now report injecting. Again, this trend
generally does not hold among the new Member States,
where injecting remains the predominant mode of
administration among heroin users accessing services.
In summary, there is no simple answer to the question of
whether heroin use or injecting across Europe is now in
decline. In many respects, today’s picture — in terms of
recruitment into heroin use and injecting — looks more
positive than it did in the early 1990s in the EU-15 Member
States. There is evidence that the situation in many countries
is now relatively stable, with signs even of an ageing
population, perhaps reflecting reduced incidence.
However, in some of the new Member States, where
escalating heroin problems are a more recent occurrence,
injecting continues to be the predominant mode of opiate
administration, and from the data available current trends
in heroin use are difficult to interpret.
The use of cocaine and other stimulants — no room
for complacency
Europe remains a major market for stimulant drugs, and
indicators suggest that for Europe as a whole the trend in
amphetamine, ecstasy and cocaine use continues to be
upwards. Ecstasy has, on many measures, overtaken
amphetamines as Europe’s second most used drug after
cannabis. However, in the United Kingdom, which since
the 1990s has on most measures had the highest
prevalence rates of ecstasy and amphetamine use, both
general and school population recent survey data suggest
that rates of use of both drugs may be falling, quite
dramatically for amphetamine and to a more limited extent
for ecstasy. Nevertheless, prevalence rates in the United
Kingdom remain relatively high in comparison with other
countries, although the difference is now less marked, as a
number of countries now report similar rates of use,
resembling the picture described above for cannabis.
Prevalence of cocaine use varies considerably in Europe,
but again the trend generally appears upwards. Survey
data suggest that, in Spain and the United Kingdom in
particular, cocaine use increased substantially during the
late 1990s, and recently there have been further, albeit
small, increases. In both of these countries, estimates for
the recent use of cocaine among young adults now exceed
those for ecstasy and amphetamine.
Commentary — identifying drug trends in Europe
The public health impact of stimulant use in Europe is
difficult to quantify, although the evidence suggests that we
should not be complacent about current consumption
patterns. Cocaine-related treatment demands are
increasing. Although there is considerable variation
between countries, cocaine accounts for about 10 % of all
treatment demands across Europe. The use of crack
cocaine, a form of the drug particularly associated with
health and other problems, remains limited in Europe.
Reports of crack cocaine use are generally restricted to
a few major cities, but within the communities where this
drug is used the resulting harm can be considerable.
A number of practical and methodological issues make the
assessment of the number of stimulant-related deaths in
Europe difficult. Though small in comparison with reported
opiate-related deaths, the number of stimulant-related
deaths may be increasing and is probably under-reported.
Although data are currently very limited, a number of
countries indicate that cocaine plays a determining role
in around 10 % of all drug-related deaths. Ecstasy-related
deaths remain rare in most EU countries, although
reporting procedures could be improved.
Bucking the global trend — no sign of significant
methamphetamine problems in Europe
Methamphetamine is a drug known to be particularly
associated with health and social problems. Globally, there
is considerable concern about growing methamphetamine
problems, and rates of use appear to be high or increasing
in the USA, Australia, parts of Africa and much of south-
east Asia. To date, the use of methamphetamine in Europe
has largely been restricted to the Czech Republic, which
has a long-established problem with this drug. Elsewhere in
Europe, there are only sporadic reports that
methamphetamine is available, with some reports of
seizures and occasional mentions of importation from the
Czech Republic to neighbouring countries. However, given
that many European countries have strong links with parts
of the world where methamphetamine problems exist, and
considering the growing nature of the European market for
stimulants, the potential for the spread of methamphetamine
use cannot be ignored and thus this remains an important
area for vigilance.
Expanding and developing services for those
with drug problems
Services for those with drug problems can make a positive
difference both to individual drug users and to the
communities in which they live. This fact is recognised
within many national drug policies, and a commitment to
expanding services for those with drug problems is found
within both the old and the new EU action plan on drugs.
Although it is difficult to map comprehensively the scale of
provision for those with drug problems in Europe, several
indicators strongly suggest that both treatment services and
some forms of harm reduction services have increased
considerably. That said, the nature and scale of different
types of services vary considerably between countries. One
area of service provision that has clearly expanded during
the last decade is that of opioid drug substitution treatment,
especially in those countries with relatively high levels of
injecting heroin use. Methadone accounts for just under
80 % of substitution treatment in Europe, and more than
90 % of substitution treatment in specialist services, but
buprenorphine is becoming an increasingly popular
pharmacological option and probably accounts for about
20 % of substitution treatment in Europe. (For more
information on the use of this drug see ‘Buprenorphine:
treatment, misuse and prescription practices’ in the selected
issues section that accompanies this report.) It is currently
estimated that the number of people in drug substitution
treatment in Europe is in excess of 500 000, which would
suggest that between one quarter and one half of those with
opiate problems may be enrolled in substitution treatment.
Substitution treatment is not the only option for those with
opiate problems, but there are insufficient data on other
therapeutic approaches to make reliable estimates of the
provision of these services at EU level. Considerable
progress has been made in developing models of care for
those with opiate problems, and the evidence base for
judging effectiveness in this area is relatively robust. This is
not the case with users of other types of drug, who are
presenting in increasing numbers at European treatment
services. The consensus is far weaker on the most
appropriate therapeutic options for those seeking help for
stimulant or cannabis problems, for example, and
developing effective treatment options for these sorts of
clients is likely to become an increasingly important
challenge.
Drug use, HIV infection and AIDS — interventions
are increasingly available and may be influencing
overall trends
The expansion of treatment services is not the only area in
which services for problem drug users have improved.
Needle and syringe exchange programmes, which provide
drug injectors with sterile equipment, are now found in
virtually all EU Member States, and in most countries the
medium-term trend has been for an increase in both the
scale of activities and the geographical coverage. In some
13
Annual report 2005: the state of the drugs problem in Europe
14
Drug use in Europe is still lower than in the USA — but prevalence estimates are now similar in some areas
Levels of drug use in the USA have historically been considerably higher than those in European countries. To a large extent, this
remains true today, but comparison of data on recent use (last year prevalence) suggests that in a few European countries levels of
cannabis, ecstasy and cocaine use among young adults are now similar to those in the USA (see graphics below). And in the case
of the recent use of ecstasy by young adults, US estimates are below those in several European countries, possibly reflecting the
strong European link in the historical development of the use of this drug. However, overall, the European population average
remains lower than the US average on all measures. In many European countries, widespread drug use occurred later than in the
USA, and this may be reflected in the higher US lifetime prevalence estimates (see Figures 1, 2 and 3 in the 2005 statistical
bulletin), which to some extent can be thought of as cumulative indicators of use levels over time.
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Member States, pharmacies also play an important role in
extending the coverage of these kinds of programmes.
Specialist programmes are often integrated into broader
services for those with drug problems, especially low-
threshold agencies, and as such are often regarded as a
way of making contact with active drug users and perhaps
of providing a conduit to treatment and other services.
Overall, the incidence of AIDS due to drug injecting has
been in decline for some time. Heterosexual contact has
now overtaken injecting drug use as the highest risk
factor for the development of AIDS in Europe. This may
be attributable to the increasing availability of highly
active antiretroviral therapy (HAART) since 1996, the
increase in treatment and harm reduction services and
declining numbers of drug injectors in most affected
countries. Estimates from the WHO suggest that in most
European countries over 75 % of those needing HAART
have access to it. However, coverage is estimated to be
poor in a number of Baltic countries, and this may be
reflected in an increase in new AIDS cases among drug
injectors in at least some countries in this area. At one
time rates of new HIV infections were also increasing
dramatically in some Baltic countries, but recent rates
have declined equally dramatically, probably due to the
saturation of the populations most at risk; moreover,
arguably, an increase in service provision may be having
an effect in some areas.
Among most of the other new EU Member States, HIV
prevalence rates remain low, as they do in many of the 
EU-15 Member States. Of those EU countries where HIV
prevalence rates were historically high among drug
injectors, most have seen a significant decrease and then
stabilisation. This is not to say that these problems have
disappeared: despite methodological difficulties that make
trends difficult to interpret at the national level, some recent
studies report new transmissions among certain
subpopulations of drug injectors, emphasising the need for
continuing vigilance.
Overall reports of legal sanctions for the possession
or use of drugs
Comparable data at the European level on most aspects
of the relationship between drugs and crime are largely
lacking. The main exception is drug law offences, which
are recorded crimes against drug control legislation.
Although comparisons between countries must be made
with caution, it seems that between the late 1990s and
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NB: In the USA, the survey was conducted in 2003, and the age range is 16–34 years (recalculated from original data).
In the European countries, most surveys (17 out of 19) were conducted between 2001 and 2004, and the standard age range is 15–34 (in some countries
the lower end may be 16 or 18 years).
The European average prevalence rate was calculated as the average of the national prevalence rates weighted by national population of 15- to 34-year-
olds (2001, taken from Eurostat).
Sources: USA: SAMHSA, Office of Applied Studies, National Survey on Drug Use and Health, 2003 (www.samhsa.gov) and (http://oas.samhsa.gov/nhsda.htm#NHSDAinfo).
Europe: Table GPS-11 in the 2005 EMCDDA statistical bulletin. Based on Reitox national reports (2004).
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Developments in drug policies — some common
elements are apparent, but within the context
of respecting national differences
As a reading of this report will clearly demonstrate, across
Europe there are considerable differences between
Member States in terms of both the drug problems they face
and the policies and the scale and nature of interventions.
Despite this, there are some common elements in the drug
situation facing most countries. At a policy level, Member
States express a general political commitment to develop
a balanced and evidence-based response, in line with
international commitments and, while acknowledging that
drug policies remain a national responsibility, also look to
the benefits that can accrue from improved cooperation at
the European level. These aspirations are expressed in the
EU drug strategy and action plans. The EU drug strategy
and action plan 2000–04, while it has not achieved all of
the ambitious targets set, is evidence of an important
development in the way Member States, EU institutions and
specialist agencies can work together to coordinate and
measure progress in the drug field. The new EU drug
strategy 2005–12 seeks to take forward this process.
2003 drug law offences increased in many EU countries.
Increases were particularly marked in some of the new
Member States. In most countries, the majority of reports
are for the possession or use of drugs. In most Member
States, the majority of offences involve cannabis, and since
1998 in most countries the proportion of cannabis
offences has either increased or remained stable. In
contrast, the proportion of offences that are heroin related
has fallen in many countries.
In many European countries, there is a growing concern
about the wider impact of drug use on the communities in
which it occurs. Issues related to public safety and the
exposure of young people to drugs are among the more
commonly cited concerns that can be grouped under the
title of ‘Drug-related public nuisance’ — this issue is
explored in detail in the selected issues section
accompanying the annual report, and continuing the
criminal justice theme is a selected issue devoted to a
review of strategies to divert those with drug problems
away from custodial sentences and towards treatment
(‘Alternatives to imprisonment: targeting offending problem
drug users in the EU’).
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Introduction
Policy developments in the field of drugs among EU
Member States are inevitably heterogeneous, reflecting the
variety of approaches at national and European level.
However, this does not preclude the existence of common
features that merit analysis.
During the reporting period, foremost among these
features is the way in which drug strategies are evaluated
in different Member States. The implementation of national
drug strategies is evaluated in several EU countries.
Although the effects of evaluation on drug policy as a
whole cannot yet be determined, evaluation has already
yielded some promising results: we now have a greater
understanding of successes and failures, and in some
cases a result of evaluation has been that more resources
have been allocated to enable unrealised strategy
objectives to be achieved. Moreover, the evaluation of the
EU strategy and action plan 2000–04 represents the first
outcome of an important process in which Member States,
EU institutions and specialised agencies are working
together to measure progress in the field of drugs.
Other policy developments taking place over the reporting
period include reduction in some countries in penalties
for drug use and an increase in the severity of penalties
for drug trafficking and drug-related offences threatening
minors.
A strategic approach to drug policy
in the European Union
The EU drug strategy 2005–12, adopted by the European
Council in December 2004, takes into account the results
of the final evaluation of progress made during the
previous period (2000–04). It aims to add value to the
national strategies while respecting the principles of
subsidiarity and proportionality set out in the treaties. It
sets out two general goals for the EU with regard to drugs:
• to achieve a high level of health protection, well-being
and social cohesion by complementing the Member
States’ action in preventing and reducing drug use and
dependence and drug-related harm to health and the
fabric of society;
• to ensure a high level of security for the general public
by taking action against drug production and supply
and cross-border trafficking, and intensifying
preventive action against drug-related crime through
effective cooperation between Member States.
These two goals cover the six priorities identified in the
2000–04 EU strategy on drugs. The new strategy
reiterates the integrated, multidisciplinary and balanced
approach of combining measures to reduce both demand
and supply. It concentrates on these two policy areas and
on two cross-cutting themes — ‘international cooperation’
and ‘information, research and evaluation’ — and on
‘coordination’.
In February 2005, the European Commission presented
the European Parliament and the European Council with a
communication on an EU drug action plan for the period
2005–08. The EMCDDA and Europol were consulted in
the drafting of this action plan. The Commission also
consulted civil society. The action plan, which takes
account of the results of the evaluation of the previous
plan, is designed in such a way that, for each action, the
actors involved are clearly identified and assessment tools,
indicators and dates for achievement are specified. This
should facilitate follow-up monitoring of the actions as well
as providing more effective guidance regarding the
implementation of the plan. The Commission will carry out
annual progress reviews of the action plan, as well as an
impact assessment, before proposing a plan for 2009–12.
Following the lead of the EU, national drug strategies have
been adopted in most Member States. Of the 29 countries
considered in this report, 26 operate their national drug
policy according to a national plan, strategy or similar
document. As far as the rest of the countries are
concerned, in Italy the national plan was approved by the
National Committee for the Co-ordination of Anti-drug
Activities in March 2003 and is under consideration by
regions and autonomous provinces; Malta and Austria
indicated that procedures for drafting and adopting a
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(1) For further information and definitions, see the EMCDDA website (http://www.emcdda.eu.int/?nnodeid=1360).
(2) No information on this subject is available for Malta, Slovakia and Turkey.
(3) COM(2004) 707 final.
(4) European Council (16–17 December 2004) — Conclusions.
(5) Among which is the EMCDDA–Europol statistical snapshot (1999–2004) (http://snapshot.emcdda.eu.int).
Evaluation of drug strategies provides
first results
The EU drug strategy (2000–04) was evaluated during the
reporting period. The Justice and Home Affairs Council of
25–26 October 2004 examined the Commission report on
this final evaluation (3). It aimed to assess the extent to
which the action plan attained the objectives of the drug
strategy and the impact of both the drug strategy and the
action plan on the drug situation in the EU. It also
contributed to the debate leading to the endorsement (4)
of a new drug strategy. The Commission was assisted in its
evaluation task by a steering committee (drawn from the
Commission, the four Member States holding the
presidency during 2003–04, the EMCDDA and Europol).
The lack of precise and quantifiable operational objectives
represented a serious constraint in this exercise.
The communication on the final evaluation and its
annexes (5) highlighted the main achievements in the drug
field at national and EU level and the areas where further
national drug strategy were under way at the time
of writing (1).
New national drug strategies have been adopted in seven
EU countries (see Table 1). The principle that drug policies
should be global and multidisciplinary seems to be
accepted in all the national drug strategies of Member
States, in accordance with the EU approach on drugs.
However, there can be fundamental differences in the
content of different countries’ national strategies, for
example in the implementation of interventions, which may
vary despite use of the same terminology; in the role of
evaluation in the strategies, which can range from
important to marginal; and even in the adoption or
otherwise of important policy approaches such as harm
reduction. Indeed, among the 26 policy or strategy
documents examined (2), harm reduction appears to be the
issue over which there is most difference of opinion: it
features prominently in 12, is included among the
discussion of other subjects in nine, and is not mentioned
in five.
Table 1: New national drug strategies
NB: n.a., data not available.
(1) Data supplied by staff of national focal points.
(2) Quantifiable targets in the Luxembourg strategy not available for supply reduction.
(3) The Cyprus strategy notes that, in order to meet the objective of the strategy, financial and human resources will be made available — no specification 
of figures in the text.
Country Title Timetable Objectives Quantifiable Performance Responsibility Budget 
or date targets indicators for execution for execution
of adoption
Estonia National strategy on the prevention 
of drug dependence 2004–12 ✓ ✓ ✓ n.a. n.a.
Estonia Goal-oriented action plan 
of the strategy 2004–08 ✓ ✓ ✓ ✓ ✓
France Action plan against illicit drugs, 
tobacco and alcohol 2004–08 ✓ ✓ ✓ n.a. ✓
Cyprus National drug strategy 2004–08 ✓ n.a. n.a. n.a. ✓ (3)
Lithuania (1) Strategy on national programme 
on prevention of drug addiction 2004–08 ✓ n.a. ✓ ✓ ✓
Luxembourg Strategy and action plan on drugs 
and drug addiction 2005–09 ✓ ✓ (2) ✓ ✓ ✓
Slovenia (1) Resolution on the national 
programme in the field of drugs 2004–09 ✓ n.a. n.a. ✓ ✓
Finland Drug policy action programme 2004–07 ✓ n.a. n.a. ✓ n.a.
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(6) See the selected issue, ‘Public expenditure in the area of drug-demand reduction’ in the EMCDDA annual report 2003
(http://ar2003.emcdda.eu.int/en/page077-en.html).
(7) In Belgium, Spain, France, Luxembourg, the Netherlands, Finland, Sweden and the United Kingdom — for detailed references, see the EMCDDA website
(http://www.emcdda.eu.int/?nnodeid=1357).
progress is needed. It emphasised that progress had been
made towards reducing the incidence of drug-related
health problems (including HIV infection and hepatitis) and
the number of drug-related deaths (target 2 of the EU drug
strategy), and, in particular, in improving the availability
of treatment (target 3). Regarding target 1, reducing drug
use, no significant progress was observed. Similarly, no
decrease in the availability of drugs was found (target 4).
Nevertheless, targets 4 and 5, taken together, appeared to
be a catalyst for several EU-level initiatives that have
strengthened law enforcement measures against drug
trafficking and supply. During the period of the plan,
several major initiatives emerged to combat money
laundering (target 6.1) and to prevent the diversion of
precursors (target 6.2), in particular through the
amendment of Community legislation on the control of
trade in precursors.
The communication also underlined the need for further
research, for instance on the biomedical, psychosocial and
other factors underlying drug use and addiction, especially
in areas where information is still scarce (e.g. the long-term
use of cannabis or synthetic drugs). The need for regular
consultation of civil society in the formulation of EU drug
policy was highlighted. The Commission also
recommended extending the EU strategy from five to eight
years, covering the implementation of two consecutive EU
action plans over the period, to allow full implementation
and fine-tuning of initiatives to match the strategy
objectives.
A number of evaluation exercises conducted at national
level during this reporting period are worthy of comment.
Of particular interest are evaluations carried out by
countries that adopted a more ‘structured’ approach to
their national drug strategy, the elements of which can be
summarised as the formal documenting of objectives,
defining and quantifying targets, identifying the authority
responsible for implementation and specifying the date for
the achievement of objectives. This approach makes it
easier for countries to report on the tasks that have been
accomplished and to identify problematic issues, therefore
enabling action to be taken where needed.
Examples of such an approach can be found in the
strategies of the Czech Republic, Ireland, Luxembourg,
Poland and Portugal, where evaluation of the national
drug strategies revealed, or has the potential to reveal,
actions that have been achieved and unaccomplished
tasks that still have to be acted on. An example of how a
structured approach can help an evaluation of progress
made can be found in the 2004 evaluation of the
Portuguese national drug strategy. External evaluators
concluded that progress had been made in achieving some
of the 30 main objectives of the Portuguese action plan,
with eight objectives fully achieved and 10 partially
achieved; however, a lack of information meant that other
objectives were difficult to evaluate, and five objectives
were judged not to have been achieved. In Germany, a
steering committee (National Council for Drug Addiction)
has been established to guide the 2003 action plan
towards implementation and monitor the outcome.
The adoption of a national drug strategy, or the evaluation
of the success of a previous one, has resulted in an
increase in the drug-related budget in some countries.
For example, in Greece there has been a steady increase
in expenditure on healthcare-related services; in Hungary
funds have been mobilised to fund the as yet
unimplemented elements of the strategy; and in
Luxembourg the drug-related budget of the Ministry of
Health increased from about EUR 1 million in 1999 to
almost EUR 6 million in 2004. However, in all Member
States, public expenditure on the drug issue represents
only a small part of total public expenditure (between
0.1 % and 0.3 %). This may partly explain the observation
that, across the EU, there is no direct link between
economic growth and associated changes in general
budget and changes in the level of public expenditure on
the drug issue.
In several EU countries, spending on supply reduction
continued to account for the bulk of public expenditure
(an estimated 68–75 % of the total drug-related
expenditure) (6). However, in a few countries, including
Malta and Luxembourg, spending on demand reduction
was apparently higher than expenditure on supply
reduction (demand reduction expenditure accounting for
66 % and 59 % of total drug expenditure respectively).
However, it is not clear whether the reported differences in
budgetary allocations represent a fundamental difference
in policy priorities or reflect a bias in data collection.
The lack of availability of information on direct public
expenditure on the drug issue continues to be a problem.
However, there are signs that, alongside growing
academic interest in this area (7), there is growing political
commitment to the identification and description of drug-
related public expenditure so that national expenditure on
drugs can be included as a key element in cost–benefit
evaluations. Together with the Reitox network and the
European Commission, the EMCDDA is now developing
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(8) Coffee shops can hold stock of up to 500 g of cannabis for sale but they can only acquire it through illegal markets. This is the so-called ‘back door
problem’.
(9) MILDT (2004), p. 43, cited in the French national report.
(10) www.partywise.be
(11) The ‘Talk to Frank’ campaign on the risks of cannabis use (http://www.talktofrank.com/).
(12) Decision No 1786/2002/EC of the European Parliament and of the Council of 23 September 2002, adopting a programme of Community action in the
field of public health (2003–08) — Commission Statements (OJ L 271, 09.10.2002, pp. 1–12).
methodology that will allow consistent and credible
estimates of drug-related public expenditure within the EU,
as requested by the EU action plan of 2005.
This first evaluation process at national and European level
represents a valuable feedback mechanism, informing
decision-makers of the extent to which their decisions have
been implemented, and at what cost, and enabling them to
increase efforts in those areas where problems have been
recorded or assessment has produced unfavourable
findings. Although clear evidence of the impact of national
drug strategies on the overall drug phenomenon is not yet
available (EMCDDA, 2004a), the approach of ‘counting
the score’ is a positive sign and, hopefully, will trigger a
general trend in Europe towards the detailed assessment
of each national drug strategy.
Debates in national parliaments
and media
Societal concerns about the drug phenomenon are
reflected both in the media and in parliamentary debates.
During the reporting period, among the data on
parliamentary debates provided in the Reitox national
reports, the most reported subjects were ‘harm reduction’
or interventions that fall under this category, ‘cannabis
use’ and ‘drug-related crime and related modifications
of drug laws’.
The advantages and disadvantages of substitution
therapies and harm reduction measures compared with
drug-free approaches stimulated animated parliamentary
debates in the Czech Republic, Estonia, France, Ireland
and Norway. Subjects of heated political debate included
the proposal to make the syringe exchange programme
permanent in Sweden, even though it would be under
strictly controlled conditions, and the temporary
establishment of injecting rooms in Norway (see the
selected issue on national laws and public nuisance).
Cannabis remained an important topic of debate,
particularly in Germany, where the main focus was on
cannabis use by young people, and in Luxembourg and
Portugal, where it has been proposed that it should be
made available on medical prescription. The use of
cannabis, or more generally drug use in school and by
young people, was widely reported by the media in
Belgium, the Czech Republic, Germany, Cyprus,
Luxembourg and Austria. In the Netherlands, media
attention was attracted by the reported increase in the
tetrahydrocannabinol (THC) concentration of cannabis
cultivations (nederwiet) and the possible health
consequences of highly potent cannabis. In Poland,
cannabis was the most reported substance in the media,
accounting for 865 of a total of about 2 500 references
to drugs. Bills advocating its legalisation were presented
in Belgium, Denmark and in some city councils in the
Netherlands, with the aim of solving the ‘back door
problem’ (8), provoking strong and public opposition from
most members of parliament and government ministers.
The prospect of changes in the drug laws has attracted
media attention and generated political debate in France
and Italy. In France, a proposal to replace prison
sentences for drug use with fines was abandoned because
of concerns that such a change would be ‘interpreted as a
sign that drugs are not very dangerous’ and lead to ‘a new
increase in use and use at an earlier age’ (9). In Italy the
media echoed the vigorous parliamentary debate on
changes to the 1990 law and a differentiation in sanctions
for possession of drugs attracted media and political
attention in the Czech Republic.
Ad hoc research to analyse media messages has been
undertaken in the Czech Republic, Greece, Luxembourg,
Poland and Portugal, and national media campaigns
targeted at young people in particular have been
developed in Belgium (10), Poland and the United
Kingdom (11).
New developments 
in EU programmes and legislation
Important EU initiatives relating to drugs that were
identified during the reporting period took place in the
fields of public health, drug trafficking and the control
of precursors and synthetic drugs.
Public health
At the European level, drug prevention is included in the
health determinants strand of the public health
programme (12). The 2004 work plan of this programme
focused on the Council recommendation of 18 June 2003
and the development, with the involvement of the
EMCDDA, of an appropriate base for an inventory of
activities in the EU. The Commission encouraged
stakeholders to submit proposals involving a lifestyle
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(13) OJ L 335, 11.11.2004, p. 8; see also EMCDDA annual report 2004 (http://ar2004.emcdda.eu.int).
(14) OJ L 47, 18.2.2004, p. 1.
approach to addressing the abuse of all substances with
addictive potential, especially in recreational places
(e.g. nightclubs) and prisons. It was particularly interested
in the development of best practice and improvements
in communications and the dissemination of information
involving modern techniques. The Commission selected
four projects in 2004, which aimed to prevent risk-taking
behaviour, to harmonise international knowledge on the
biomedical side-effects of doping, to reinforce the transfer
of knowledge on responses to drug consumption and to
extend to the new Member States an existing web resource
of information on licit and illicit drugs.
Drug trafficking
In 2004, a number of instruments were adopted at EU
level to counter drug trafficking. The Council framework
decision 2004/757/JHA of 25 October 2004 laid down
minimum provisions on the constituent elements of criminal
acts and penalties in the field of illicit drug trafficking (13)
and is a key instrument in tackling drug trafficking through
the establishment of minimum penalties for such offences in
Member States.
Agreement on a Council decision on information
exchange, risk assessment and control of new
psychoactive substances was reached by the Council in
December 2004. This decision provides a framework for
effective information exchange on new psychotropic
substances as well as a mechanism for bringing them
under control at EU level.
The Council adopted on 30 March 2004 a
recommendation regarding guidelines for taking samples
of seized drugs. It recommends that, where this is not
already done, Member States introduce a system of taking
samples in accordance with internationally accepted
guidelines. The Council also adopted a resolution on
cannabis and a progress report in relation to the
implementation plans on demand and supply reduction of
drugs and the supply of synthetic drugs.
On 11 February 2004, the European Parliament and the
Council adopted Regulation (EC) No 273/2004 on drug
precursors (14). This establishes harmonised measures for
the intra-Community control and monitoring of certain
substances frequently used in the illicit manufacture of
narcotic drugs or psychotropic substances, with a view to
preventing the diversion of such substances. In particular,
it provides guidelines for Member States to adopt the
measures necessary to enable their competent authorities
to perform their control and monitoring duties and
information on how to recognise and notify suspect
transactions. On 22 December 2004, the Council adopted
Regulation (EC) No 111/2005, laying down rules for
monitoring the trade in drug precursors between the
Community and third countries.
Following on from a Council resolution from November
2002, the European Commission presented a study on a
generic and emergency list approach to the control of
synthetic drugs at the Council’s horizontal working party
on drugs (HDG) in November 2004. It also presented
suggestions for possible further improvements in the
methods of mapping distribution networks of synthetic
drugs in the EU to the HDG in April 2004.
New national laws
Young people
Changes in the national legislation of several Member
States during the reporting period included measures to
protect young people from offenders or to respond to the
possibility that they might wish to take drugs.
Protection may be delivered by direct or more general
approaches. In Hungary, the March 2003 law aims to
protect persons under the age of 18 against misuse of
narcotic drugs, and punishments for adults will be more
severe for offences involving minors. In Estonia,
amendments at the beginning of 2004 provide stricter
penalties with respect to most drug-related crimes,
including inducing minors to consume drugs illegally.
In Denmark the Euphoriants Act was amended in July
2004; the distribution of drugs in restaurants, discotheques
or similar places frequented by children or young people is
now deemed to be a significantly aggravating
circumstance. Such offences should always be punished
with a prison sentence, and it is intended that the average
prison sentence for such offences will be increased by one
Setting up a sustainable health monitoring system
The establishment and operation of a sustainable health
monitoring system is among the key objectives of the public
health programme (2003–08). The Commission has
pursued consultations with Member States and international
bodies with a view to consolidating a set of European
Community health indicators. In this context, ‘drug-related
deaths’ and ‘consumption of psychotropic drugs’ were
included in the draft core indicators list, thereby reinforcing
structural links with the EMCDDA as a potential data
producer.
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(15) Young people and drugs: a legal overview (http://eldd.emcdda.eu.int/?nnodeid=5620).
(16) Drug law and young people 2000–2004 (http://eldd.emcdda.eu.int/?nnodeid=9937).
(17) Seven countries have legislated since 1999: Belgium, France, Luxembourg, Poland, Portugal, Slovenia and Finland.
(18) http://eldd.emcdda.eu.int/?nnodeid=5036
action plan over the five-year period. For an in-depth
analysis of measures targeting young drug-using offenders,
see the selected issue on alternatives to imprisonment.
Harm reduction
During 2003 and 2004, several laws touching on the
issue of harm reduction were passed.
In France, a law passed in August 2004 adopting the five-
year public health policy plan incorporates the policy on
harm reduction for drug users into the public health
regulations, giving harm reduction an official definition
and bringing it within the jurisdiction of the state.
In Finland, a government decree amended the
Communicable Disease Act to state that communicable
disease specialists in health centres should undertake
prevention work, including the provision of health
counselling for intravenous drug users and the
implementation of needle and syringe exchanges as
necessary. In Luxembourg, the Grand-Ducal decree of
December 2003 regulates the national syringe distribution
programme by defining facilities and professionals
authorised to provide syringes to drug users. This continues
a trend towards permitting possession and supply of sterile
syringes via explicit legislation (17) supported by the
outgoing EU action plan 2000–04, which requested the
development of provision of prophylactics. Further legal
information can be found in the ELDD topic overview
‘Legal framework of needle and syringe programmes’ (18).
The Misuse of Drugs Act in the United Kingdom was
amended in August 2003 to allow doctors, pharmacists
and drug workers to legally supply swabs, sterile water,
certain mixing utensils (including spoons, bowls, cups and
dishes) and citric acid to drug users who obtained
controlled drugs without a prescription. In June 2004, the
Norwegian parliament adopted, for three years, the
Temporary Act Relating to a Trial Scheme of Drug Injection
Rooms. This exempts users of an injection room from
punishment for the possession and use of a single dose of
drugs and allowed a designated injection room to open in
February 2005.
In the Czech Republic, several non-governmental
organisations (NGOs) provide tablet testing services,
which aim to reduce the risk of an unknown or unexpected
substance being consumed, although the legality of such
schemes is hotly debated. There were no criminal
prosecutions in 2003, and the only case brought so far by
the police (a case from 2002) was rejected by the public
third. Similarly, in Spain, since October 2004 trafficking
near schools is an aggravating circumstance, and, in
addition, the age limit for a ‘young person’ enlisted to
commit trafficking offences has been increased from 16 to
18. Direction on the new legislation in England and Wales
has been issued through the Cannabis enforcement
guidance (ACPO, 2003), which gives advice on how to
deal with people found in possession of cannabis in or
near premises such as schools, youth clubs and play areas.
Measures in response to young people taking drugs
included two cabinet regulations adopted in Latvia in
December 2003. One outlined procedures for the
obligatory institutional treatment (with parental consent)
of children caught misusing drugs and the other specified
actions to be taken when drugs or other intoxicants are
found in a school. In England and Wales people under
18 years old arrested for cannabis offences continue to
receive a reprimand or final warning or are charged by
the police, depending on the seriousness of the offence.
After a final warning, the young offender will be referred
to a youth offending team (YOT), which will make
arrangements for treatment or other support.
In the Czech Republic, the Act on Juvenile Justice, which
took effect in 2004, modifies the conditions governing
young people involved in penal code offences, which take
precedence over general laws. Penal measures should be
imposed only when necessary, and educational measures
may include prohibition of substance use or an obligation
to undergo treatment. The maximum limits for non-custodial
sentences also are now half those applying to adults.
In Poland, a ministerial regulation of January 2003
establishes specific forms of educational and preventive
activities among drug-endangered children and youths.
Schools must put in place educational and preventive
strategies.
In October 2003, the European Legal Database on Drugs
(ELDD) published a comparative study on the laws
regarding drugs and young people (15), which formed the
basis for a paper assisting the Commission’s evaluation of
the EU action plan 2000–04, published in October
2004 (16). The latter found that a total of 22 laws, passed
by 11 Member States (out of 15), addressed the issues in
the action plan concerning young people. The majority of
the laws aimed to provide alternatives to imprisonment,
though six countries passed laws intended to reduce the
prevalence of drug use, particularly among young people.
Overall, however, comparatively little original legislative
attention seems to have been given to those points of the
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(19) For further details see EMCDDA thematic paper, Illicit drug use in the EU: legislative approaches (http://www.emcdda.eu.int/?nnodeid=7079).
prosecutor. The office of the supreme prosecutor has since
issued guidance on the subject.
In line with these legislative developments, harm reduction
services are generally recognised by the new EU strategy
and action plan as a valid response to the demand for
increased access to needle exchanges to reduce the drug-
related risks to individual health and society as a whole.
Penalties
During the reporting period several countries also made
changes in their drug legislation to the penalties that can
be imposed for various offences, besides those reviewed
above and that specifically involve young people.
For example, it was reported last year that Belgium and
the United Kingdom effectively lowered the penalty for
non-problematic cannabis possession. In Belgium, a new
directive issued in February 2005 clarified the exceptions
to this reduced penalty, calling for full prosecution in cases
involving ‘disturbance of public order’. This includes
possession of cannabis in or near places where
schoolchildren might gather (schools, parks, bus stops) and
also ‘blatant’ possession in a public place or building.
In Denmark, a May 2004 amendment to the Euphoriant
Substances Act, together with a public prosecutor’s
circular, stated that the possession of drugs for own use
will now normally be punishable by a fine rather than the
warnings issued previously.
These follow the pattern of changes to possible penalties for
users and traffickers that has emerged over the last few
years, as reported by the EMCDDA (19). For example,
in 2003 Belgium created a new category of offence that
allows non-problematic cannabis users not to be
prosecuted, Greece reduced the maximum penalty for drug
use from five years to one year, and Hungary removed the
offence of drug use from its penal code. In 2002, Estonia
removed the offence of repeated use or possession of a
small amount of illicit drugs for personal use (with its
associated maximum three-year prison sentence), although
Lithuania added the offence of possession to its penal code,
with a potential punishment of imprisonment for up to two
years. In 2001, Luxembourg decriminalised cannabis use
and removed the associated prison sentence for simple
cannabis use not associated with aggravating
circumstances, and Finland enacted the drug user offence,
with a lower maximum sentence of imprisonment and
summary penal proceedings by the prosecutor. In 2000,
Portugal enacted administrative sanctions for drug use,
though in the same year Poland removed the exemption
from punishment previously possible for the offence of
possession. This pattern does not, however, reflect a
lessening of control over the effects of drug use on society,
as can be seen in the selected issue on public nuisance and
the restrictions on possession near young people, above.
For those suspected of trafficking, the trend is to increase
the possible penalty. In Denmark, the maximum penalties
for trafficking offences were raised by over 50 % in March
2004. At the beginning of 2004, Estonia enacted stricter
penalties with respect to most drug-related crimes,
particularly in the presence of aggravating circumstances.
In the United Kingdom, the maximum penalty for trafficking
class C drugs has increased from five to 14 years’
imprisonment. In addition, recent years have seen an
increased emphasis on sentences for the specific offences
of distributing to young people (above) and for trafficking
offences in Greece in 2001, in Lithuania in 2000 and in
Ireland in 1999. This unanimous growth in the severity of
penalties for drug trafficking is reflected in the European
framework decision of October 2004, laying down
minimum provisions on the constituent elements of criminal
acts and penalties in the field of illicit drug trafficking.
Drugs in the workplace
Two countries reported moves to legislate on drugs in the
workplace. In Finland, the Act on Protection of Privacy
in Working Life (759/2004) aims at regulating and
enhancing the privacy of the employee in relation to drug
testing in working life. The Act states that the employer and
personnel must draw up an anti-drug programme for the
workplace, including prevention plans and treatment
options and listing those jobs that require a drug test
certificate. During the recruitment process, an employer
can ask only the successful candidate for a drug test
certificate. The employer has the right to use the
information on the certificate if the job calls for precision,
reliability, independent consideration or alertness, and if
performance under the influence of, or dependent on,
drugs could endanger life or health or result in
considerable damage. During employment, the employee
must provide a certificate only if there is just cause to
suspect that he or she is addicted to or working under the
influence of drugs.
In Ireland, the Safety, Health and Welfare at Work Bill was
published in June 2004. One section requires that
employees ensure that they are not under the influence of
any intoxicant(s) while at work to the extent that they
would endanger their own safety, health or welfare at
work, or that of any other person. It also requires
employees, if reasonably required by their employer, to
submit to any appropriate, reasonable and proportionate
tests by a competent person.
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perceived phenomenon, and drug testing for anything
other than actual influence may raise complicated legal
issues of privacy under certain national and international
laws. Meanwhile, private investment continues with the
aim of improving the accuracy and user-friendliness of the
testing kits.
Prevention in specific settings, such as in the workplace, is
highlighted in the new EU action plan. The increased
emphasis on targeted prevention may be a counterweight
to the general trend towards the reduction in the severity of
penalties for drug users, perhaps as a result of concern
about the prevalence and frequency of drug use in the EU.
However, there are no clear figures on the true size of this
Drug-related public nuisance: trends in policy
and measures, in EMCDDA 2005 annual report:
selected issues
Public nuisance is an emerging concern within drug policy
debate, at both national and European level. Behaviours
and activities usually covered by the term ‘drug-related
public nuisance’ have long existed in most of the Member
States, candidate countries and Norway. Hence, we are
looking not at new phenomena, but rather at a new
tendency in drug policy, apparent in at least some Member
States, to categorise and collate these phenomena under
an umbrella concept, and to set the reduction in their
occurrence as an objective of national drug strategy.
To what extent is this tendency shared by European
countries? Is there a consensual definition for this concept?
How are the nature and the extent of the phenomena to be
assessed? What are the policies aiming to achieve and
what types of interventions are being implemented,
regardless of whether or not they are specifically and
explicitly designed to reduce drug-related public nuisance?
Are any evaluation results already available and are quality
standards for intervention established? All these are among
the core questions that this selected issue aims to address.
By presenting a timely review of the development of drug-
related public nuisance in the policy debate in Europe, the
EMCDDA aims to inform policy-makers and the public at
large about the nature of the phenomenon and the trends
and measures in this area of drug policy.
This selected issue is available in print and on the Internet
in English only (http://issues05.emcdda.eu.int).

27
Comparable data on young people’s use of alcohol and
drugs come largely from surveys of 15- to 16-year-old
school students. The European school survey project on
alcohol and other drugs (ESPAD) conducted surveys in
1995, 1999 and, most recently, 2003. The 2003 survey
(Hibell et al., 2004) provides comparable data from
22 EU Member States as well as Norway and three
candidate countries (Bulgaria, Romania and Turkey). Other
school surveys (e.g. in the Netherlands, Sweden and
Norway) and ‘health behaviour in school-aged children’
(HBSC) surveys also provide data on drug use among
school students, and generally the findings are very similar.
Prevalence and patterns of drug use
Cannabis
The latest ESPAD survey data, from 2003, reveal that the
highest lifetime prevalence of cannabis use among 15- and
16-year-old school students is in the Czech Republic
(44 %) (Figure 1). The lowest lifetime prevalence estimates
(less than 10 %) occur in Greece, Cyprus, Sweden,
Norway, Romania and Turkey. Countries where the rate is
higher than 25 % include Germany, Italy, the Netherlands,
Slovakia and Slovenia (27 % and 28 %), while the highest
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The European school survey project on alcohol
and other drugs (ESPAD): a growing resource
for understanding trends in drug and alcohol use
in young people
ESPAD is an important source of information on drug and
alcohol use among European school students and is
invaluable for recording trends over time. ESPAD surveys
were conducted in 1995, 1999 and 2003. The use of
standardised methods and instruments among nationally
representative samples of school students aged 15 to
16 years provides a high-quality and comparable data set.
Participation in ESPAD has grown with each survey, and
both EU Member States and non-EU countries participate.
In 1995, a total of 26 European countries participated
(including 10 countries that joined the EU in May 2004).
This figure increased to 30 in 1999, while the 2003 survey
involved an impressive 35 countries including 23 EU
Member States (including the 10 countries that joined the
EU in 2004) and three candidate countries (Bulgaria,
Romania and Turkey) and Norway. Spain did not
participate in the study, but the 2003 ESPAD report presents
national data from the Spanish school survey (PNSD).
The comparability of the ESPAD school survey is based on
standardisation of target age group and method and timing
of data collection, use of random sampling, the robustness
of questionnaire design and assurance of anonymity.
The survey questions focus on alcohol consumption (lifetime,
12-month and 30-day prevalence, average consumption,
binge drinking) and use of illicit drugs (lifetime, 12-month
and 30-day prevalence including measures of how
frequently drug use occurred during these time windows).
Some of the main findings of the 2003 survey in the EU
Member States, candidate countries and Norway were:
• Cannabis is by far the most commonly used illicit drug;
• Ecstasy is the second most used illegal drug, but
experience is relatively low;
• Experience of amphetamines and LSD and other
hallucinogens is low;
• Although prevalence of use is relatively low, magic
mushrooms are the most commonly used hallucinogens
in 12 EU Member States;
• Other substances used by school students include
tranquillisers and sedatives without a doctor’s
prescription (with a highest reported national level of
17 %), and inhalants (national maximum 18 %);
• The 30-day prevalence of binge drinking (defined as
consuming at least five drinks in a row) varies
considerably between countries.
Information on ESPAD and the availability of the new report
can be found on the ESPAD website (www.espad.org).
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are more marked for students who report having used
cannabis 40 or more times in their life (22).
Older students (17–18 years) were included in national
school surveys conducted in 11 Member States and
Bulgaria. Lifetime prevalence of cannabis use in this age
range varied from less than 2 % in Cyprus to 56 % in the
Czech Republic, while current (last month) cannabis use
ranged from less than 1 % in Cyprus to nearly 30 % in
France. In all countries that conducted surveys, except
Cyprus, prevalence estimates among older students were
higher than those for 15- to 16-year olds (23).
Between 1999 and 2003, in the Czech Republic there was
an increase of 5 % in the number of school students who
reported having tried cannabis at the age of 13 or
younger. Thirteen other EU countries reported small
increases (1–3 %) (24). A decrease (of 1 %) was reported
only in the Netherlands and the United Kingdom.
lifetime prevalence estimates, ranging from 32 % to 40 %,
are reported in Belgium, France, Ireland and the United
Kingdom. In most countries, since 1995, there has been a
consistent increase in the number of school students who
have ever tried cannabis (20). However, country variations
are marked.
New data from 2003 ESPAD surveys of 15- to 16-year-old
school students show that lifetime prevalence of cannabis
use ranges from 3 % to 44 %. Between 2 % and 36 % of
school students report having used the drug in the last
12 months, while use in the last month ranged from 0 % in
some countries to 19 % in others (21) (Figure 1). There are
relative variations in the different prevalence rates.
For example, lifetime prevalence is highest in the Czech
Republic, but current (last month) use is highest in Spain
and France (22 %).
In nearly all countries, prevalence of cannabis use is
higher among males than in females. Gender differences
Figure 1: Lifetime, last year and last month prevalence of cannabis use among 15- to 16-year-old school students in 2003
(1) Turkish figures are based on one major city in each of six different regions (Adana, Ankara, Diyarbakir, Istanbul, Izmir and Samsun).
(2) German data are based on six regions only (Bavaria, Brandenburg, Berlin, Hesse, Mecklenburg-Western Pomerania and Thuringia). 
(3) Spain did not participate in the ESPAD survey. The data included here are based on a Spanish survey conducted in November–December 2002. Drug prevalence
questions may be considered comparable to the ESPAD questions, but other aspects of the method mean that the Spanish data are not strictly comparable.
Source: Hibell et al., 2004.
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(20) See Figures EYE-1 (part ii) and EYE-1 (part ix) in the 2005 statistical bulletin.
(21) See Chapter 3 for a more detailed account of cannabis use among school students.
(22) See Figure EYE-1 (part iii) in the 2005 statistical bulletin.
(23) See Tables EYE-1 and EYE-3 in the 2005 statistical bulletin.
(24) See Figure EYE-1 (part vii) in the 2005 statistical bulletin.
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(25) A second Eurobarometer survey (Eurobarometer, 2004), ‘Young people and drugs’, was conducted in 2004. This non-probability sample survey
comprised 7 659 young people aged 15 to 24 in the 15 Member States included in the previous 2002 survey.
(26) See Figure EYE-1 (part v) in the 2005 statistical bulletin.
(27) See Figure EYE-1 (part vi) in the 2005 statistical bulletin.
(28) See Figure EYE-1 (part viii) in the 2005 statistical bulletin.
(29) See Figure EYE-2 (part iv) in the 2005 statistical bulletin.
(30) See Figure EYE-2 (part i) in the 2005 statistical bulletin.
(31) See Figure EYE-2 (part v) in the 2005 statistical bulletin.
According to a recent Eurobarometer (2004) study (25), the
number of young people aged 15–24 years who declared
that they had been offered cannabis rose from 46 % in
2002 to 50 % in 2004. In the same period, the number of
young people who reported that they knew people who
had used cannabis also rose from 65 % to 68 %.
ESPAD surveys show that school students’ perceptions of
cannabis, both of the risks associated with use and of the
availability of the drug, are strongly correlated with lifetime
prevalence of cannabis use. The relationship between risk
and prevalence is an inverse one (26), i.e. high perceptions
of risk are associated with low prevalence of use and vice
versa, but the perception of availability is directly
correlated with lifetime prevalence of use (27).
Young people in countries with higher than average
prevalence estimates for cannabis use may be increasingly
disposed to regarding cannabis use as ‘normal’. Most
countries that report relatively high estimates of lifetime use
of cannabis also report relatively high estimates for ‘binge’
drinking (defined as drinking five or more drinks in a row)
during the last 30 days (28), suggesting that the two
behaviours may be part of a common lifestyle. Exceptions
to this pattern are displayed by France, Italy and Bulgaria,
where cannabis use is relatively high but binge drinking is
relatively low.
Other drugs
Prevalence of ecstasy use was higher than that of
amphetamine use in 14 of the EU and candidate countries
reported in the 2003 ESPAD survey (29). The lowest levels
of lifetime use of ecstasy (2 % and under) were found in
Denmark, Greece, Cyprus, Lithuania, Malta, Finland,
Sweden, Norway, Romania and Turkey. Higher prevalence
rates, ranging from 3 % to 4 %, were reported in Belgium,
Germany, France, Italy, Latvia, Austria, Poland, Portugal,
Slovenia, Slovakia and Bulgaria. The countries with
highest lifetime prevalence rates for ecstasy use were the
Czech Republic (8 %); and Estonia, Spain, Ireland, the
Netherlands and the United Kingdom (all 5 %).
Regarding prevalence rates over different periods, the
highest rate of lifetime prevalence of ecstasy use in 2003
was 8 %, compared with 5 % for use during the last
12 months (recent use) and 2 % for use during the last
month (current use).
Consecutive surveys show that, generally, lifetime
prevalence of ecstasy use among 15- and 16-year-old
school students increased over the period 1995 to 2003,
with the greatest increases occurring in the Czech Republic
and most of the new Member States (30). However, lifetime
prevalence figures from the 1999 ESPAD surveys reveal
fluctuations in some countries. The decreases in ecstasy use
that occurred in the United Kingdom took place before
1999, and may be partly attributable to extensive media
coverage of ecstasy-related deaths during the late 1990s.
Psilocin and psilocybin — magic mushrooms
Psilocin and psilocybin, the psychoactive ingredients of 
so-called ‘magic mushrooms’, are included in Schedule 1
of the 1971 UN Convention and thus are controlled in all
Member States. However, the legal status of magic
mushrooms, as well as the extent to which any legal
restrictions on their growth and consumption are enforced,
varies between Member States, i.e. mushrooms may be
controlled, uncontrolled or controlled if ‘processed’, a
status that is not entirely legally clear.
The ESPAD survey reported on the use of ‘magic
mushrooms’ for the first time in 2003. Prevalence estimates
for use of ‘magic mushrooms’ among 15- to 16-year-old
school students exceeded or equalled those for LSD or other
hallucinogenic drugs in most of the countries that
participated (31). In addition, compared with lifetime
experience of ecstasy use, lifetime prevalence of magic
mushrooms use was higher in Belgium, Germany and
France and the same in the Czech Republic, Denmark, Italy,
the Netherlands and Poland. Lifetime prevalence of magic
mushrooms use was zero in Cyprus, Finland and Romania,
rising to 4 % in Germany, Ireland and the United Kingdom,
and to 5 % in Belgium, France and the Netherlands.
Prevalence is highest in the Czech Republic (8 %). Trend
data for the use of magic mushrooms are not available.
New developments in prevention
Individuals’ values and behaviours are influenced by what
they perceive to be the normality in their social environment,
and this is especially true of young people. If they perceive
experimental cannabis use as ‘normal’ and socially
acceptable (associating it with low levels of risk and easy
availability), this may be a key influence on their values
and behaviour regarding cannabis use (Botvin, 2000).
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ground, and Member States are now increasingly linking
tobacco control policies with drug prevention.
School-based prevention
In all Member States, schools are considered the most
important setting for universal prevention, and there has
been a noticeable increase in the emphasis placed on
school-based prevention in national strategies and in the
structured implementation of this approach. This is
reflected in the expansion of school drug policies
(Figure 2) and the development of specific modular drug
prevention programmes for schools as well as improved
teacher training.
More countries than before have introduced (Denmark has
its first school-based life skills programme), expanded
(Germany) or are planning (France and Italy, in their
national strategies) more structured prevention programmes.
For example, in 2003, prevention programmes were being
implemented in 60 % of Polish schools.
The challenge for prevention is to provide young people
with social and cognitive strategies to manage these
influences. It is therefore not realistic to assess the
effectiveness of prevention policies using data on drug use
by young people, particularly not estimates of
experimental use, as they reflect societal norms and not
genuine problem behaviour.
Instead, prevention should be evaluated against a number
of clear criteria: well-defined objectives, target groups and
actions set out in national strategies and based on the
international knowledge base; quality control measures;
the development of selective prevention measures and of
family-based prevention; and regulatory measures on legal
drugs aimed at influencing the social norms that imply
condonation of or consent to particular consumption
behaviours.
As far as evaluation of prevention strategies is concerned,
the new national strategies in France and Italy exhibit
important advances over their previous policies in that the
role of prevention is now better defined, as is the
importance of structured programmes and priority areas
for taking action. In almost all Member States, a tendency
towards more strategic approaches is apparent, and
vulnerable groups are increasingly being envisaged in the
overall planning.
Normative and structural measures
Control measures on legal drugs help to establish the
normative foundations on which other prevention measures
can be built. Societal norms that support tobacco and
alcohol use and tolerate their influence on behaviour are
well-known risk factors for a sympathetic attitude to and
use of illicit drugs (Becoña, 2002). Contrary to popular
belief, societal norms are influenced more by control
policies than by mass media campaigns or educational
approaches (Hawks et al., 2002; Canning et al., 2004).
Eurostat (2002) compared tobacco control measures and
smoking indicators in children/adolescents in EU Member
States and found a relationship between the rigidity of
tobacco control policies (advertising ban, age limits on
purchasing, restrictions, etc.) and smoking habits. Smoking
rates among adolescents were found to be higher in
countries with relatively lenient policies (e.g. Denmark,
Germany and the United Kingdom) than in countries with
stricter controls (e.g. France, Sweden and Norway). It is
known that the impact of prevention interventions is limited
if they are counteracted, or at least not supported, by
societal norms and policies. EU and WHO initiatives
(Aspect Consortium, 2004) in this field have gained
Figure 2: Development of school policies
NB: German-speaking Belgium = sporadically found.
Sources: Reitox national focal points.
Cyprus
Malta
Belgium and Luxembourg
Seldom or not available
Sporadically found
Very common
Regularly available
No information
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Greece provides a particularly good example of moving
prevention policies away from traditional information-based
and individualistic (counselling) approaches towards the
implementation of a true public health strategy that can
maximise coverage through programme-based approaches.
The number of school-based prevention programmes in
Greece more than doubled between 2000 and 2003, and
family-based programmes increased threefold over the
same period. Malta and the United Kingdom also increased
the role of programme-based approaches in their
prevention policies: the ‘Blueprint programme’ seeks to
determine how international research on effective drug
prevention can be adapted within the English school
system, and is based upon evidence suggesting that
combining school-based education on drugs with parental
involvement, media campaigns, local health initiatives and
community partnerships is more effective than school
interventions alone. Six million pounds (EUR 8.5 million)
has been allocated to this programme over five years (32).
Monitoring and quality control
Controlling and improving the quality of prevention is
highly dependent on first having a meaningful overview of
existing activities and their contents. Accordingly, Member
States are giving increasing importance to monitoring
prevention programmes, as exemplified by new schemes in
Germany (33) and Norway (34) and by the Hungarian
research project ‘Lights and shadows’, which collected
information on the content, objectives, methodology, target
groups and coverage of school-based prevention
programmes. Monitoring is also implemented in the Czech
Republic as well as through ‘Ginger’ in Flanders.
Unfortunately, Spain has abandoned ‘IDEA prevención’,
which for many years was the best-developed monitoring
and quality system on prevention in Europe.
Information systems on prevention also help to track the
occurrence of ineffective practices and programme
components. For instance, one-off information sessions or
lectures by experts or police officers are still common in
several Member States, despite the unanimous conclusions
from research that these interventions are at best
ineffective, if not harmful (Canning et al., 2004).
Only by systematically recording prevention activities can
the content of prevention programmes be reviewed and, as
a result, based on existing knowledge regarding
effectiveness, targeted to specific populations. Guidelines
or standards for the implementation of prevention
programmes are essential, particularly in countries where
prevention is strongly decentralised.
Contents of programmes and activities
An increase in programme-based approaches and
improved standardised information collection have
enabled the contents of, and trends in, prevention policies
to be reviewed and compared across the EU. The
information usually comes from national experts or expert
groups who have a reliable overview of their country’s
situation that allows them to come up with standardised
ratings or from quantitative data on monitored,
programme-based interventions that is available in some
Member States, e.g. Greece and Hungary.
For instance, most Member States have implemented
personal and social skills training in schools as a prevention
approach. Topics covered include decision-making, coping,
goal-setting and assertiveness, communicating and showing
empathy. This evidence-based technique, which is derived
from social learning theories (35), seems now to be an
important methodology in most Member States, even in
countries where programme-based approaches do not exist
(France, Luxembourg and Sweden) (Table 2). Estonia reports
the widespread use of a book that teaches social skills.
Information provision continues to play a central role in
drug prevention in many Member States (see Table 2). The
limited value of information provision in the prevention of
drug use is only slowly being acknowledged (see, for
example, the Swedish national report). Approaches based
solely on health education are also limited to influencing
cognitive processes and often lack concrete components of
behavioural and social interaction training. However,
these approaches are still widespread in some countries
despite our present understanding of effective drug
prevention.
There are two explanations for the continuance of such
approaches to drug prevention. One is the instinctive and
traditional presumption that providing information on
drugs and the risks associated with drug use will act as a
deterrent. The second explanation reflects a very recent
trend inspired by harm reduction movements and is based
on the belief that cognitive skills are more important than
behavioural approaches in teaching young people to
make informed decisions and choices in life. Advocates of
this technique believe that behavioural approaches to drug
prevention, such as improving life skills, are patronising
and demonise drug use (Ashton, 2003; Quensel, 2004)
(32) www.drugs.gov.uk/NationalStrategy/YoungPeople/Blueprint
(33) PrevNet (www.prevnet.de).
(34) www.forebyggingstiltak.no
(35) Behaviour is seen as a result of social learning by role models, norms, attitudes of ‘important others’ (Bandura, 1977). Negative attitudes to drug use
and protective self-efficacy can be learned or conditioned. This concept is the basis for peer models and the specific life skill model.
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the health sciences is that social factors (neighbourhood,
peer group, norms) and personal factors (temperament,
academic and emotional skills) are more influential in
shaping health and drug use behaviour than is mere
cognition.
and that giving young people the cognitive tools they
need, by providing information, is the best method.
Despite their different traditions, both approaches view
health behaviour, and specifically drug use, as a matter of
personal rational choice, whereas the broad consensus in
Table 2: School-based prevention in Europe
NB: n.a., no information available.
(1) It should be remembered that no common European definition of ‘quality standards and guidelines’ exists, and that the level of detail may vary, which 
influences comparability.
Quality standards/guidelines (1) Objectives
In place Mandatory Prerequisite Primary Secondary
for funding
Belgium fl Yes Yes Yes Very common Life skills Information
Belgium fr Yes Yes Yes n.a. Protective environment Educational relationship
Czech Republic Planned Yes Very common Self-esteem Protective environment
Denmark No No Information
Germany No Very common Life skills Information
Estonia No Sporadically n.a.
Greece Yes Yes Yes Very common Life skills Educational relationship
Spain Planned Yes Yes Very common Life skills Self-esteem
France Yes Seldom Information Life skills
Ireland Yes Yes Very common Life skills Self-esteem
Italy Yes Regular Information Life skills
Cyprus Planned Yes Yes Sporadically Protective environment Life skills
Latvia Planned Sporadically Information Life skills
Lithuania No Regular Information
Luxembourg Yes Yes Regular Educational relationship Life skills
Hungary Planned Regular Information Life skills
Malta No Very common Information Life skills
Netherlands Yes No Information
Austria Yes No Sporadically Life skills Protective environment 
Poland No Regular Life skills Information
Portugal Yes Yes Yes Sporadically Information Life skills
Slovenia Planned Sporadically Information Life skills
Slovakia No Seldom
Finland n.a. n.a. Provision of welfare services Information
Sweden No Regular Protective environment Social inclusion
United Kingdom Yes Very common Information Life skills
Norway No Regular Information Self-esteem
Bulgaria n.a. Sporadically Information Protective environment
Romania n.a. Sporadically
Personal
social skills
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The erroneous perception of drug use as normal and
socially acceptable among the peer population is the most
important cognitive element that can be influenced by
prevention. In fact, a lifetime prevalence of cannabis use
among young adults of 30 % means that more than two-
thirds of this population have never used cannabis, and
that is the true ‘normality’. However, despite the proven
benefit of techniques that address young people’s
normative beliefs (Reis et al., 2000; Taylor, 2000;
Cunningham, 2001; Cuijpers et al., 2002), they are rarely
used in Europe.
Selective prevention
National drug strategies and action plans are increasingly
and explicitly mentioning vulnerable groups to be
particularly targeted by prevention measures. This focus is
even stronger in the new Member States: Estonia (street
children, special schools), Cyprus, Hungary, Malta, Poland
(neglected children and young people from dysfunctional
families) and Slovenia.
Because the vulnerable groups targeted by selective
prevention often have considerable experience with legal
and illegal drugs, most selective prevention interventions
are restricted to the provision of tailor-made information,
individual counselling and creative or sports alternatives.
However, it should be remembered that the techniques
used in the comprehensive social influence programmes of
universal prevention are equally as effective, if not more
effective, in selective prevention. Normative restructuring
(e.g. learning that most peers disapprove of use),
assertiveness training, motivation and goal-setting, as well
as myth correction, have proved to be very effective
methods among vulnerable young people (Sussman et al.,
2004) but are rarely used in selective prevention in the EU.
However, intervention techniques in recreational settings
(see ‘Prevention in recreational settings’, p. 48) mostly take
the form of the provision of targeted information.
Selective prevention in schools
The main focus of selective prevention in schools is crisis
intervention and early identification of pupils with
problems. The aim is to find solutions at school level in
order to avoid at-risk pupils dropping out or being
expelled and thereby aggravating their situation.
Programme-based approaches are offered in Germany,
Ireland, Luxembourg and Austria (Leppin, 2004), while
Poland and Finland provide teacher training courses or
guidelines on how to recognise pupils with problems,
including drug use, and take appropriate action.
Traditional individualistic approaches include educational
psychology services (as in France and Cyprus), which
depend on (self)-referrals. Ireland has a new intensive
educational welfare service to work with schools and
families in educationally disadvantaged areas in order to
ensure that children attend school regularly.
Selective community-based approaches
Selective community-based approaches mostly target
vulnerable young people on the streets. In the Nordic
countries, the ‘Nightwalkers’ approach engages parent
groups in patrolling the streets. Austria has invested
heavily in improving the balance between drug prevention,
social education and social work structures through
courses, quality guidelines and joint seminars, e.g. for
youth social workers in recreational settings. The aim is
also to use youth social work structures for professional
drug prevention interventions. Along the same lines,
Norway boosts cooperation and strengthens
interdisciplinary efforts between school, child protection
services and social services. RAR (rapid assessment and
response) methods (36) — the speedy gathering of
information (statistical material) combined with interviews
(questionnaires, focus groups) and/or observations of the
problem area — are used in these projects in Norway, but
also in Germany and the Netherlands.
Interventions focusing on high-risk neighbourhoods have a
tradition in Ireland, the United Kingdom and, to a small
extent, the Netherlands and Portugal. However, Germany
(Stöver and Kolte, 2003, cited in the German national
report) and France have now also proposed action in this
area. It is new for these countries to target drug prevention
to particular geographical areas according to social
criteria.
Member States are also increasingly targeting specific
ethnic groups in their selective prevention policies 
(e.g. Ireland, Luxembourg, Hungary). For example, the
focus on ethnicity is an important aspect in Hungary,
where the Roma population is at high risk of drug-related
problems owing to its social and cultural characteristics
and disadvantageous living conditions. There, peer
training, self-help groups, supervision, various prevention
programmes and low-threshold services for Roma are
operated by non-governmental organisations (NGOs).
Vulnerable families
Universal family-based prevention, mostly evening events,
lectures, seminars and workshops for parents, is still
popular in many Member States (Germany, France, Cyprus
and Finland) despite the lack of evidence for its
effectiveness (Mendes et al., 2001). However, in Greece,
Spain, Ireland and Norway there have been interesting
(36) World Health Organisation, The rapid assessment and response guide on psychoactive substance use and especially vulnerable young people
(http://www.who.int/docstore/hiv/Core/acknowledgements.html).
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prevention measures aimed at young people with ADHD
are reported only from Germany and Sweden. In
Germany, current estimates of the prevalence of ADHD
suggest that 2 % to 6 % of people between the ages of 6
and 18 years are affected, making it one of the most
common chronic clinical pictures among children and
young people. In Sweden, the preventive strategy for these
children includes cognitive and social training, and
methodologies are disseminated through training of
prevention professionals. As almost all pre-school children
are reached by primary healthcare and most children go
to primary school, the majority of children at risk could be
identified through systematic screening and subsequent
individualised interventions.
The Italian action plan places a strong focus on
psychopathological conditions and serious behavioural
problems in children and adolescents which are predictive
of drug use and misuse if ignored at an early stage. The
problems identified include behavioural problems;
hyperactivity and attention deficit; anxiety accompanied
by mood disorders; bulimia and psychogenic obesity;
personality disturbances; interpersonal communication
problems; post-traumatic stress disorders; and panic
attacks. Both universal and selective prevention
approaches are foreseen as responses.
developments in selective prevention with families through
the introduction of innovative concepts that go beyond
families/parents with drug problems and recognise the
role of social, economic and cultural factors in drug use. In
the Netherlands, the evaluation of drug prevention projects
for immigrant parents concluded that a standardised
intervention offered via immigrant networks, with women
and men addressed separately, would be a feasible new
direction (Terweij and Van Wamel, 2004). In Norway,
‘parent management training’ (PMTO, the Oregon model),
originally a training method for families with children with
serious behavioural disorders, has been implemented and
evaluated in three municipalities. In another two countries,
the ‘Iowa strengthening families programme’ (ISFP) has
been implemented. This intensive family intervention
programme for families at risk combines teaching methods
for students (10–14 years) with an educational programme
for their parents, aiming at drug prevention through
strengthened family competence and family ties (Kumpfer
et al., 2003).
The need for indicated prevention
Indicated prevention focuses on individuals identified as
having risk factors for drug problems, for instance attention
deficit/hyperactivity disorder (ADHD). However, drug

and Denmark (44.6 %). Recent use was reported by
3–22 % of young adults, with the lowest figures in Greece,
Sweden, Poland and Portugal, and the highest in the
United Kingdom (19.5 %), France (19.7 %), and the
Czech Republic (22.1 %) and 11 countries reporting
recent use prevalence rates of between 7 % and 15 %.
Among 15- to 24-year-old Europeans, 9–45 % claim to
have tried cannabis, with rates in most countries falling in
the range 20–35 %. Recent use (in the last 12 months) was
reported by 4–32 %, with rates in most countries being in
the range 9–21 % (38).
Prevalence and patterns
Cannabis is by far the most commonly used illegal
substance in Europe. Recent population surveys indicate
that between 3 % and 31 % of adults (aged 15 to
64 years) have tried the substance at least once (lifetime
use). The lowest prevalence rates of lifetime use are found
in Malta (3.5 %), Portugal (7.6 %) and Poland (7.7 %) and
the highest in France (26.2 %), the United Kingdom
(30.8 %) and Denmark (31.3 %). In most countries (15 of
23 countries with information) lifetime prevalence lies
between 10 % and 25 %.
Between 1 % and 11 % of adults report having used
cannabis in the last 12 months, with Malta, Greece and
Sweden presenting the lowest prevalence rates and the
Czech Republic, France, Spain and the United Kingdom
the highest. Most countries (14) reported prevalence rates
of recent use of between 3 % and 7 %.
An estimate of the total number of adults (15 to 64 years)
using cannabis in the EU as a whole can be constructed
from the available national estimates. This exercise
suggests that around 20 % of the total population, or over
62 million people, have ever tried cannabis. This figure
falls to around 6 % of adults, or in excess of 20 million
people, when the more recent use of cannabis is
considered (last year prevalence). For comparison, in the
2003 United States national survey on drug use and health
(SAMHSA, 2003), 40.6 % of adults (defined as 12 years
and older) reported having tried cannabis or marijuana at
least once and 10.6 % reported having used it during the
previous 12 months. Among 18- to 25-year-olds, the
figures were 53.9 % (lifetime), 28.5 % (last 12 months)
and 17 % (last month) (37).
As is the case with other drugs, young adults consistently
report higher rates of use. Between 11 % and 44 % of
young Europeans aged 15 to 34 years report that they
have ever tried cannabis, with the lowest prevalence rates
being found in Greece, Portugal and Poland and the
highest in France (39.9 %), the United Kingdom (43.4 %)
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Estimating drug use in the population
Drug use in the general population is assessed through
surveys, which provide estimates of the proportion of the
population that has used drugs over defined periods of
time: lifetime use (experimentation), last 12 months’ use
(recent use) or last 30 days’ use (current use) (1).
The EMCDDA has developed a set of common core items
(‘European model questionnaire’, EMQ) that is
implemented in, or compatible with, most surveys in the EU
Member States. The EMQ is included in a report available
on the EMCDDA website (2). ‘Lifetime use’ may be of limited
value as an indicator of the current situation among adults
(although it could be a reasonable indicator among school
children), but in conjunction with other measures it can give
insight into aspects of patterns of use (continuation or
discontinuation of use) and the generational dynamics of
the spread of drug use. ‘Last 12 months’ use’ gives an
indication of recent drug use, although often this use will be
occasional, and ‘last 30 days’ use’ gives an indication of
more current use, which will include people using the drug
frequently.
(1) For more about the methodology of population surveys, and the
methodology used in each national survey, see the 2005 statistical
bulletin.
(2) Handbook for surveys about drug use among the general population
(http://www.emcdda.eu.int/?nnodeid=1380).
(37) Note that the age range in the US survey (12 years and over) is wider than the age range reported by the EMCDDA for EU surveys (15–64 years). On
the other hand, the age range for young adults (18–25 years) is narrower than the range used in most EU surveys (15–24 years).
(38) See Figure GPS-2 in the 2005 statistical bulletin.
(39) See the 2004 annual report (http://ar2004.emcdda.eu.int). The information refers to ‘use on 20 days or more during the past 30 days’, expressed also
as ‘daily or almost daily use’.
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As with other illicit drugs, rates of cannabis use are
notably higher among males than among females,
although the extent of this difference varies between
countries. The male–female ratio for lifetime experience
varies from 1.25:1 to 4:1 (1.25 to 4 men for each woman)
and for current use from approximately 2:1 to 6:1. Surveys
also indicate that cannabis use is more common in urban
areas or in areas with high population density. Thus,
national differences noted might, in part, reflect
differences in levels of urbanisation, although it has been
suggested that recreational drug use is spreading from
urban areas towards rural areas.
The fact that rates of recent use and current use are
substantially lower than lifetime experience rates indicates
that cannabis use tends to be occasional, or to be
discontinued after some time. In most EU countries,
20–40 % of those adults who have ever tried cannabis
report having used it during the previous 12 months, and
about 10–20 % report having used it during the last
30 days (‘continuation rates’).
In recent surveys, rates of use in the last month were
reported by 0.5–9 % of all adults (with many countries in
the range 2–4 %), by 1.5–13 % of young adults (with
many countries in the range 3–8 %) and by 1.2–16 % of
15- to 24-year-olds (with many countries in the range
5–10 %) (Figure 3). A very rough estimation will be that
1 in 10 to 20 young Europeans is a current user of
cannabis. The countries with the lowest current prevalence
rates included Malta, Greece, Sweden, Poland and
Finland, while the United Kingdom and Spain had the
highest.
In the 2004 annual report (EMCDDA, 2004a), data
presented on frequency of cannabis use in the last 30 days
suggested that approximately one quarter (19–33 %) of
those who had used cannabis in the last month were doing
so on a daily or almost daily basis (39), most of them young
males. It was estimated that among 15- to 34-year-old
Europeans, 0.9–3.7 % were daily cannabis users, and that
roughly 3 million people in Europe could be using the
substance daily or almost daily.
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Figure 3: Current use (last month) of cannabis among young adults (aged 15–24), measured by national surveys
NB: Data are from the most recent national surveys available in each country.
Some countries use a slightly different age range to the EMCDDA standard age range for young adults. Variations in age ranges may to a small extent account
for disparities between countries.
Sources: Reitox national reports (2004), taken from population surveys, reports or scientific articles. See also Table GPS-0 in the 2005 statistical bulletin.
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(40) Information that arrived too late to be included in the report gave an LYP among young adults in Spain of 20.1 % in the 2003 survey.
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2003/04, with other countries (France and Spain (40))
catching up. In Greece there was a reported decrease
between 1998 and 2004.
Among new Member States, the available evidence,
mainly from school surveys, suggests that there has been a
substantial increase in cannabis use in recent years in
many of them. This has mostly occurred since the mid-
1990s, and has been concentrated in urban areas and
among males and young adults. In Estonia and Hungary,
consecutive surveys among adults have allowed the
identification of recent trends (Figure 4).
A comparison of the results of the 1995, 1999 and 2003
ESPAD school surveys (Hibell et al., 2004) shows that, in
almost all Member States and candidate countries that
participated in the survey, the prevalence of lifetime use of
cannabis among 15- to 16-year-old school students
increased by 2 % or more (Figure 5). In more than half of
these countries, prevalence estimates have doubled or
trebled since 1995. The highest relative increases
occurred mainly in eastern European Member States that
had reported lifetime cannabis prevalence rates of less
than 10 % in 1995. In none of the countries surveyed by
ESPAD was there a continuous and noticeable decrease in
lifetime use of cannabis across the three surveys.
School surveys reveal that EU Member States can be
categorised into three distinct groups regarding trends in
the recreational and occasional use of cannabis. In the first
group (which includes Ireland and the United Kingdom),
lifetime prevalence is high (around 38–39 %) but has
remained stable over the past eight years. These countries
have long histories of cannabis use and high prevalence
rates of cannabis use developed during the 1980s and
1990s. In a second group of countries, lifetime prevalence
of cannabis use among school students has increased
substantially over the period (by up to 26 percentage
points). This group comprises all the new eastern European
Member States together with Denmark, Spain, France, Italy
and Portugal. In the third group, estimates of lifetime
prevalence among school students have remained at
relatively low levels (around 10 % and below). This group
includes Member States from both the north and south of
Europe (Finland, Sweden and Norway as well as Greece,
Cyprus and Malta).
Among adults, the picture is less clear because less
information is available, and what is available is more
heterogeneous, but a similar pattern emerges, with recent
cannabis use (last year use) high but stable in the United
Kingdom, some countries (e.g. Denmark, Germany,
Estonia, Spain and France) showing substantial increases
Trends
The lack of a long-term series of consistent surveys in most
EU countries presents a limit to the reliable identification of
drug trends. Many countries carry out consecutive surveys,
but these are not series in the strict sense — despite
progress in harmonisation, methods and sample sizes
differ between surveys and frequency may be irregular. In
addition, surveys are conducted in different years in
different countries, making it difficult to identify European
trends. Ideally, national population surveys would be
carried out in all Member States at the same time; this
would make it much easier to compare results at a national
level (over time) and at a European level (between
countries), facilitating evaluation of the achievement of the
European action plan on drugs.
What the available findings, obtained from different types
of surveys (national or local household surveys, conscript
and school surveys), reveal is that cannabis use increased
markedly during the 1990s in almost all EU countries,
particularly among young people, and that cannabis use
has continued to increase in recent years in some countries
(Figure 4). In the United Kingdom, which until 2000
exhibited the highest figures, cannabis use among young
adults remained relatively stable between 1998 and
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Figure 4: Trends in recent use (last year) of cannabis among
young adults (aged 15–34), measured by national surveys (1)
(1) Sample sizes (respondents) for the 15–34 age group for each country
and year are presented in Table GPS-4 in the 2005 statistical bulletin.
NB: Data taken from national surveys available in each country. Figures and
methodology for each survey can be consulted in Table GPS-4 in the 2005
statistical bulletin.
For young adults, the EMCDDA uses the range 15–34 years (Denmark and
UK from 16, Germany, Estonia (1998) and Hungary from 18). In France
the age range was 25–34 in 1992 and 18–39 in 1995.
Sources: Reitox national reports (2004), taken from population surveys, reports or
scientific articles. See also Table GPS-0 in the 2005 statistical bulletin.
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(41) http://www.emcdda.eu.int/?nnodeid=7022
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in recent years and other countries exhibiting lower
prevalence estimates and less clear trends (e.g. Greece,
Finland and Sweden). New school and adult surveys in the
next two to three years will help to throw more light on the
complex issue of the development of drug trends.
Prevention of cannabis use
Concern in some countries about increasing cannabis
consumption among young people has resulted in
discussions about whether drug testing would be a useful
control measure. Some countries have taken steps in this
direction, although drug testing measures remain
uncommon. In the Czech Republic, there have been reports
in the media of the use of urine testing and drug detection
sniffer dogs in schools. While there is some support for
these measures, an expert panel concluded that such
methods should not form any part of an effective primary
prevention strategy. In the United Kingdom, newly
launched guidelines for schools note a number of
important issues that need to be considered before
implementing a drug testing programme. These include
ensuring that appropriate consent is obtained from parents
(and pupils if they are deemed competent), considering
whether testing is consistent with the school’s pastoral duty
of care and taking into account the availability or
otherwise of appropriate support services. Any decision to
subject pupils to drug testing must be included in the
school’s drug policy. The EMCDDA website includes a
short report on drug testing in schools in the EU (41).
Cannabis is almost always included in universal (non-
targeted) drug prevention programmes. Attention given in
the media to the increasing use of cannabis among young
people, with the insinuation that cannabis use is
increasingly ‘normal’, emphasises the need to address
normative beliefs among young people. Unease about the
growing acceptance of cannabis use among young people
has resulted in the introduction of prevention programmes
that aim to address their beliefs about what constitutes
normal or acceptable behaviour. This issue is discussed in
more detail in Chapter 2. Many interventions consist
principally of providing information on cannabis through
media campaigns, leaflets or websites. However, some
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Figure 5: Lifetime prevalence of cannabis use among 15- to 16-year-old school students reported in the 1995, 1999 and 2003 rounds of
the ESPAD survey
NB: In 1995, surveys in countries marked with an asterisk were not strictly comparable with the ESPAD surveys. Spain did not participate in the ESPAD survey. The
data included here are based on a Spanish survey series in 1996, 1998 and 2002. Drug prevalence questions may be considered comparable to the ESPAD
questions, but other aspects of the method mean that the Spanish data are not strictly comparable.
Source: Hibell et al., 2004.
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(42) http://eddra.emcdda.eu.int/
(43) See the EDDRA website for further information on ‘Step by step’ (http://eddra.emcdda.eu.int/eddra/plsql/showQuest?Prog_ID=36) and ‘Early detection
and intervention with regard to problematic drug use and addiction’ (http://eddra.emcdda.eu.int/eddra/plsql/showQuest?Prog_ID=2088).
(44) See Tables TDI-2 (part i) and TDI-3 (part iii) in the 2005 statistical bulletin.
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interesting examples of selective prevention do exist, and
these can be found in the EMCDDA’s database of
evaluated prevention projects, EDDRA (42). These schemes
mostly target young cannabis users who have committed
drug offences and offer counselling, personal competence
training and multiagency support. Examples of these
schemes include ‘FRED’ (Germany), ‘MSF-Solidarité
Jeunes’ (Luxembourg), ‘Ausweg’ (Austria) and ‘youth
offending teams’ (YOTs) in the United Kingdom.
The high prevalence of cannabis use among young people
means that the use of the drug is often a central issue for
those working with school-aged children. One potentially
promising selective school-based prevention approach is
the ‘Step by step’ programme, which has been
implemented in Germany and Austria. This programme
helps teachers to identify and deal with drug consumption
and problem behaviours among their pupils (43).
A difficult issue for those engaging in the responses to
cannabis is where to draw the line between a prevention
perspective and a treatment perspective. Cannabis use is
influenced by social, peer and personal factors, and these
factors play an important part in an individual’s risk of
developing a long-term drug problem; thus, prevention
work often focuses on these areas rather than on the drug
itself (Morral et al., 2002). For example, an evaluation of
the ‘Ausweg project’, in Austria, found that young people
notified for first-time cannabis offences were less likely
than expected to exhibit personality deficits, illustrating the
importance of situational, social and peer influences,
rather than individual psychological problems, on drug use
(Rhodes et al., 2003; Butters, 2004). A number of projects
do focus, however, on cannabis and advise young people
on reducing their drug use. An example from Germany is
the ‘Quit the shit’ website (www.drugcom.de), which is an
innovative website-based counselling programme for
cannabis users.
Treatment demand data
Among the approximately 480 000 treatment demands
reported in total, cannabis is reported as the primary drug
in about 12 % of cases, making it the second drug after
heroin. Over the eight-year period 1996–2003, the
proportion of cannabis clients among new clients seeking
treatment for all drugs increased by at least two-fold in
many countries (44), with a similar rise in numbers of clients.
However, this analysis should be treated with caution as it
is based on a restricted number of countries that can
provide the data necessary for a time–trend comparison.
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Treatment demand indicator
Information on the number of people seeking treatment for a
drug problem provides a useful insight into general trends in
problem drug use and also offers a perspective on the
organisation and uptake of treatment facilities in Europe. The
EMCDDA’s treatment demand indicator (TDI) (1) (2) provides a
uniform structure for reporting the number and characteristics
of clients referred to drug treatment facilities. Although TDI
data can be regarded as providing a reasonably robust and
useful representation of the characteristics of clients referred
to specialised drug services, for a number of technical
reasons caution should be exercised in extrapolating findings
to the clientele across the overall provision of services. In
particular, the number of countries reporting each year varies
and therefore trends identified at the European level need to
be interpreted with caution. In addition, it should be
considered that data coverage may change by country (data
on units covered are reported in the statistical bulletin) and
treatment demand data partly reflect the availability of drug
treatment in the countries.
To facilitate interpretation and comparison of treatment
demand data, the following points should be borne in mind:
• Clients starting treatment for drug use for the first time are
referred to as ‘new clients’. This group is considered
analytically more important as an indicator of trends in
drug use. Analyses are also reported for all clients. This
group includes new clients as well as those who, having
interrupted or ended treatment in a previous year,
resumed it in the reporting year. Data on clients who
during the reporting period continued, without
interruption, treatment that had been begun in previous
years are not recorded.
• Two types of data are collected: summary data on all
types of treatment centres and detailed data by centre
type (outpatient treatment centres, inpatient treatment
centres, low-threshold agencies, general practitioners,
treatment units in prison, other types of centres). However,
for most countries, data are sparse for centre types other
than outpatient and inpatient treatment centres. For this
reason, analysis is often restricted to outpatient treatment
centres, for which data coverage is best.
• Qualitative and contextual information extracted from the
2004 Reitox national reports is also included to aid in the
interpretation of TDI data.
(1) For further details, see the EMCDDA’s web page on treatment
demand (http://www.emcdda.eu.int/?nnodeid=1420) and link to the
joint Pompidou Group–EMCDDA treatment demand indicator protocol
version 2.0.
(2) For details on data sources by country, see Table TDI-1 in the
2005 statistical bulletin.
(45) See also the selected issue on cannabis treatment demand in the EMCDDA 2004 annual report (http://ar2004.emcdda.eu.int). Data analysis is based
on clients demanding treatment in all treatment centres for the general distribution and the trends, and on outpatient treatment centres for profile of clients
and patterns of use.
(46) See Tables TDI-2 (part ii) and TDI-5 (part ii) in the 2005 statistical bulletin.
(47) See Tables TDI-4 (part ii) and TDI-5 (part ii) in the 2005 statistical bulletin.
(48) See Table TDI-3 (part iii) in the 2005 statistical bulletin.
(49) See Table TDI-22 in the 2005 statistical bulletin.
(50) See Table TDI-10 (part ii) in the 2005 statistical bulletin.
(51) See Table TDI-18 (part iv) in the 2005 statistical bulletin.
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Overall, after heroin, cannabis is also the second most
frequently cited drug in reports on clients entering
treatment for the first time (45). There are considerable
variations between countries, with cannabis being cited by
2–3 % of all clients in Bulgaria and Poland but by more
than 20 % of all clients in Denmark, Germany, Hungary
and Finland (46). In all countries from which data are
available, the proportion of clients seeking treatment for
cannabis use is higher among new clients than among all
clients, with only a few exceptions, where the proportions
are roughly equal (47). Nonetheless, over the eight-year
period 1996–2003, the proportion of cannabis clients
among clients seeking treatment for all drugs increased
from 9.4 % to 21.9 % (48). However, this analysis should
be treated with caution as it is based on a restricted
number of countries that can provide the data necessary
for a time–trend comparison.
Among drug users in treatment, males far outnumber
females. The highest male to female ratios are found
among new clients demanding treatment for cannabis use
(4.8 to 1). Higher male to female ratios are found in
Germany, Cyprus, Hungary and Slovakia and lower ratios
in the Czech Republic, Slovenia, Finland and Sweden.
These differences between countries may reflect cultural
factors or possibly differences in the organisation of
treatment services (49).
Those being treated for cannabis problems tend to be
relatively young; virtually all cannabis clients new to
treatment are under 30 years old. Teenagers in specialised
drug treatment are more likely to be recorded as having a
primary cannabis problem than are clients in other age
groups, with cannabis accounting for 65 % of treatment
demands among those younger than 15 years and 59 %
among those aged 15–19 years (50).
There are marked differences between countries in the
frequency of cannabis use among new clients. The highest
proportions of daily cannabis users are in Denmark and
the Netherlands among new cannabis clients, and the
highest proportions of occasional users or persons who
have not used cannabis in the last month prior to treatment
are found in Germany and Greece (51), probably reflecting
differences in referral to treatment. In Germany, about one
third of new cannabis clients use the drug occasionally or
have not used it in the month prior to treatment, but
elsewhere this group is about 11 % of clients, and about
60 % use it daily.
Seizures and market information
Production and trafficking
In 2003, cannabis continued to be the most widely
produced and trafficked illicit drug worldwide. However,
the global spread of cannabis production and the difficulty
of monitoring it make the estimation of how much is
produced problematic (UNODC, 2003a).
Large-scale production of cannabis resin is concentrated in
a few countries, in particular in Morocco, while trafficking
is widespread across a large number of countries (CND,
2004, 2005). Based on a survey of cannabis production
in Morocco carried out by the UNODC and the
Government of Morocco (2003), it is estimated that the Rif
region accounted for about 40 % of the global production
of cannabis resin in 2003 (INCB, 2005). Most cannabis
resin consumed in the EU originates in Morocco and enters
Europe mainly through the Iberian Peninsula, although the
Netherlands represents an important secondary
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Interpreting seizures and market data
The number of drug seizures in a country is usually
considered to be an indirect indicator of the supply and
availability of drugs, although it also reflects law
enforcement resources, priorities and strategies, as well as
vulnerability of traffickers to national and international
supply reduction strategies. Quantities seized may fluctuate
widely from one year to the next, for example if in one year
a few of the seizures are very large. For this reason, the
number of seizures is considered by several countries to be
a better indicator of trends. In all countries, the number of
seizures contains a high proportion of small seizures at the
retail level. The origin and destination of drugs seized may
indicate trafficking routes and producing areas, but this
information is not always known. The purity and price of
drugs sold at retail level are reported by most of the
Member States. However, data come from a range of
different sources, which are not always comparable or
reliable, making accurate comparisons between countries
difficult.
(52) This should be checked against missing 2003 data when available. Data on numbers of cannabis seizures in 2003 were not available for Italy, Cyprus,
the Netherlands and Romania; data on both number of cannabis seizures and quantities of cannabis seized in 2003 were not available for Ireland and the
United Kingdom.
(53) See Table SZR-1 (part i) in the 2005 statistical bulletin.
(54) See Table SZR-2 (part i) in the 2005 statistical bulletin.
(55) See Table PPP-1 (part i) in the 2005 statistical bulletin.
(56) See Table PPP-5 (part i) in the 2005 statistical bulletin.
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quantities, cannabis is also usually the most seized drug in
the EU, although in 2003 quantities of other drugs seized
were reported to be higher in a few countries —
amphetamines in Estonia and Luxembourg, heroin in
Hungary and cocaine in Poland. Historically, most
cannabis seizures in the EU have been made by the United
Kingdom, followed by Spain and France, and this is
probably still the case (52). However, for the past five years,
in terms of quantities, Spain has accounted for more than
half the total amount seized in the EU. At the EU level, the
number of cannabis seizures (53) has shown a more or less
upward trend since 1998, though partial reporting of data
from a few countries makes this uncertain, while
quantities (54) seized appear to have risen since 2000.
Price and potency
In 2003, the average retail price of cannabis resin in the
European Union varied from EUR 1.40 per gram in Spain
to EUR 21.50 per gram in Norway, while the price of
herbal cannabis ranged from EUR 1.10 per gram in Spain
to EUR 12 per gram in Latvia (55).
The potency of cannabis products is determined by their
content of tetrahydrocannabinol (THC), the primary active
constituent. In 2003, in countries from which data are
available, cannabis resin at retail level was reported to
have an average THC content that varied from less than
1 % (Poland) to 25 % (Slovakia), while herbal cannabis
potency ranged from 1 % (Hungary, Finland) to 20 %
(home-grown produced in the Netherlands) (56).
distribution centre for further transportation to EU countries
(Bovenkerk and Hogewind, 2002). Other countries
mentioned in 2003 as source countries for the cannabis
resin seized in the EU include Albania, Afghanistan, Iran,
Pakistan, Nepal and India (Reitox national reports, 2004;
INCB, 2005).
Global herbal cannabis production continues to be spread
across the world and potential production was estimated
as being at least 40 000 tonnes (CND, 2005). Herbal
cannabis seized in the EU in 2003 is reported to have
originated from a variety of countries including the
Netherlands and Albania, but also African countries
(Malawi, South Africa, Nigeria) and the USA (Reitox
national reports, 2004). In addition, some local (indoor or
outdoor) cultivation and production of cannabis products
takes place in most of the EU Member States (Reitox
national reports, 2004).
Seizures
Worldwide, a total of 1 347 tonnes of cannabis resin and
5 821 tonnes of herbal cannabis were seized in 2003.
Western and central Europe (70 %) and south-west Asia
and the Near and Middle East (21 %) accounted for most
cannabis resin seized, whereas quantities of herbal
cannabis seized were concentrated in the Americas (68 %)
and Africa (26 %) (CND, 2005). In terms of number of
seizures, cannabis is the most seized drug in all countries
of the EU except Estonia and Latvia, where in 2003 the
number of amphetamine seizures was higher. In terms of
42

(57) See Figure EYE-2 (part iv) in the 2005 statistical bulletin.
Prevalence and patterns of use
Traditionally, population surveys have shown that, after
cannabis, amphetamines are the most commonly used
illegal substance, albeit overall prevalence of
amphetamine use is clearly lower than that of cannabis.
This pattern now appears to be changing in many
countries, with ecstasy overtaking amphetamines and
taking second place after cannabis in both recent general
population surveys and school surveys. For example, the
2003 ESPAD school surveys (Hibell et al., 2004) found
that lifetime prevalence estimates for ecstasy use exceeded
those for amphetamine in 14 of the EU, Norway and
candidate countries (57). However, it is worth remembering
that ecstasy became popular only during the 1990s,
whereas amphetamine use has a longer history. This is
reflected in recent adult surveys, which have revealed
higher figures for lifetime experience of amphetamine use
in 11 countries and for ecstasy use in 10 countries, but
higher recent (last 12 months) use of ecstasy in
15 countries and of amphetamines in only five countries
(in two countries the reported figures were equal).
According to recent surveys, among all adults
(15–64 years), lifetime experience of amphetamine use in
EU Member States ranges from 0.1 % to 6 %, except in the
United Kingdom, where the figure is as high as 12 %.
Recent use is clearly lower, ranging from 0 % to 1.5 %,
with Denmark, Estonia and the United Kingdom at the
higher end of the scale.
A similar picture emerges among the young adults group
(15–34 years) in population surveys, among which group
lifetime experience of amphetamine use ranges from 0.1 %
to 10 %, with the United Kingdom reporting an
exceptionally high rate of 18.4 %. Recent use ranges from
0 % to 3 %, with Denmark, Estonia and the United
Kingdom again at the top end of the scale (Figure 6).
Although lifetime use figures for the United Kingdom are
considerably higher than those found in other countries,
the prevalence of recent amphetamine use (use in the last
12 months) is very similar to rates reported in other
countries and overall is continuing to fall.
In terms of prevalence of use, in almost all countries some
form of synthetic drug is the second most commonly
reported substance used. Overall rates of use of these
substances in the general population are typically low, but
prevalence rates among younger age groups are
significantly higher, and the use of these drugs may be
particularly high in some social settings and/or among
some subcultural groups.
Among the synthetic drugs used in Europe are both
stimulants and hallucinogenic substances. Of the latter,
lysergic acid diethylamide (LSD) is by far the most well
known, but overall consumption levels have been low and
somewhat stable for a considerable time. Some evidence
is emerging of increasing interest in naturally occurring
hallucinogens, and this topic is covered elsewhere in this
report.
The term amphetamine-type stimulants (ATS) is used to
refer to both the amphetamines and the ecstasy group
of drugs. Amphetamines is a generic term used to
describe a number of chemically related drugs which
stimulate the central nervous system, the two most
important of which, in terms of the European illicit drug
market, are amphetamine and methamphetamine.
Of these, amphetamine is by far the most commonly
available, although, globally, levels of methamphetamine
use are increasing. To date, significant methamphetamine
use in Europe appears to be restricted to the Czech
Republic, although sporadic reports from elsewhere
underline the importance of monitoring as this is a drug
known to be associated with a range of severe health
problems.
The best-known member of the ecstasy group of drugs is
3,4-methylenedioxy-methamphetamine (MDMA), but other
related analogues are also sometimes found in ecstasy
tablets. These drugs are sometimes known as entactogens,
meaning to ‘touch within’, and comprise synthetic
substances that are chemically related to amphetamines
but which differ to some extent in their effect, as they
combine some of the effects more typically found in
hallucinogenic substances.
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(58) See Chapter 2 for a detailed analysis of the results of the 2003 ESPAD schools survey.
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New data on the use of amphetamines among 15- to 
16-year-old school students are reported in the 2003
ESPAD surveys (58). Lifetime prevalence of amphetamine
use ranges from less than 1 % to 7 %; the highest national
estimates for recent use and current (last 30 days) use of
the drug are 4 % and 3 % respectively.
Ecstasy has been tried by about 0.2–6.5 % of the adult
population, with figures for most countries lying in the
range 1–4 %. Recent use is reported by 0–2.5 % of adults,
with the Czech Republic, Spain and the United Kingdom
presenting the highest prevalence figures.
Among young adults (15–34 years), 0.6–13.6 % report
experience of ecstasy use. Recent use (last 12 months’
prevalence) is reported by 0.4–6 %, with the Czech
Republic, Estonia, Spain and the United Kingdom
presenting the highest prevalence rates (Figure 7).
As ecstasy use is predominantly a youth phenomenon, 
it is useful to analyse prevalence rates among rates 15- to 
24-year olds and 15- to 16-year-old school students.
Among the 15–24 age group, lifetime experience rates
range from 0.4 % to 13 %, while recent use figures range
from 0.3 % to 11 %. Furthermore, as rates of drug use in
this age group are higher in males than in females, most
countries report lifetime experience rates among 15- to 
24-year-old males in the range 4–16 % and recent use
rates among males of 2–8 %. Finally, figures for current
use (use in the last 30 days), which would include regular
use, were reported by seven countries and ranged from
2 % to 5 %, suggesting that 1 in 20–50 males aged
15–24 years use ecstasy regularly. These figures are likely
to be higher in urban areas and, in particular, in people
frequenting discos, clubs or dance events (Butler and
Montgomery, 2004).
Estimates of prevalence of ecstasy use are considerably
lower for 15- to 16-year-old school students than for 15- to
24-year-olds. Lifetime ecstasy prevalence among the
school students surveyed ranges from 0 % to 8 %, with
even lower rates of recent use (0–4 %) and current use
(0–3 %). In most countries, estimates of current use lie
between 1 % and 2 %, with little difference between the
sexes (Hibell et al., 2004).
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Figure 6: Recent use (last year) of amphetamines among young adults at selected ages, 15–34 and 15–24, measured by population surveys
NB: Data are from the most recent national surveys available in each country (see Table GPS-4 for the 15–34 age group).
Some countries use a slightly different age range to the EMCDDA standard age range for young adults. Variations in age ranges may to a small extent account
for disparities between countries.
Sources: Reitox national reports (2004), taken from population surveys, reports or scientific articles. See also Table GPS-0 in the 2005 statistical bulletin.
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(59) Note that the age range in the US survey (12 years and over) is wider than the age range reported by the EMCDDA for EU surveys (15–64 years). 
On the other hand, the age range of young adults (18–25 years) is narrower than the range used in most EU surveys (15–24 years).
Annual report 2005: the state of the drugs problem in Europe
recently stabilised (2002/03), albeit at relatively high
levels (Figure 9).
As mentioned above, ecstasy use now exceeds
amphetamine use in many countries; however, this is far
from representing a decline in amphetamine use. In most
countries able to provide information from consecutive
surveys, amphetamine use (recent use among young adults)
has, in fact, increased. A notable exception is the United
Kingdom, where a substantial decrease in amphetamine
use has been observed since 1998. This may explain why,
in the United Kingdom, lifetime experience prevalence is
high compared with the more moderate levels of recent use
recorded. It can be speculated that the decrease in
amphetamine use has to some extent been compensated by
increases in cocaine and ecstasy use (see Figures 8 and 9).
For comparison, in the 2003 United States national survey
on drug use and health (SAMHSA, 2003), 4.6 % of adults
(considered to be those aged 12 years and older) reported
lifetime experience with ecstasy and 0.9 % reported recent
use. Among 18- to 25-year-olds in the same survey,
14.8 % reported lifetime experience, 3.7 % recent use and
0.7 % current use (last month) (59).
Trends
Population surveys show an increase in recent use of
amphetamine (Figure 8) and ecstasy (Figure 9) among
young adults in most countries with information for
consecutive surveys. For ecstasy, the exceptions are
Germany and Greece, where levels have not increased,
and the United Kingdom, where use of these drugs has
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Figure 7: Lifetime prevalence and recent (last year) use of ecstasy among young adults at selected ages, 15–34 and 15–24, measured
by population surveys
NB: Data are from the most recent national surveys available in each country (see the 2005 statistical bulletin Tables GPS-2 for lifetime prevalence and GPS-4 for recent
use among the 15–34 age group).
Some countries use a slightly different age range to the EMCDDA standard age range for young adults. Variations in age ranges may to a small extent account
for disparities between countries.
Sources: Reitox national reports (2004), taken from population surveys, reports or scientific articles. See also Table GPS-0 in the 2005 statistical bulletin.
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(60) See Tables TDI-4 (part ii) and TDI-5 (part ii) in the 2005 statistical bulletin.
(61) See Table TDI-24 in the 2005 statistical bulletin.
(62) See Table TDI-23 in the 2005 statistical bulletin.
(63) See Tables TDI-11 (part i) and TDI-11 (part v) in the 2005 statistical bulletin.
(64) See Tables TDI-10 (part i) and TDI-10 (part v) in the 2005 statistical bulletin.
(65) See Table TDI-18 (part iii) in the 2005 statistical bulletin.
(66) See Table TDI-17 (part iii) in the 2005 statistical bulletin.
Chapter 4: Amphetamine-type stimulants, LSD and other synthetic drugs
Treatment demand data
Use of ATS is rarely the primary reason for attending drug
treatment. However, there are some exceptions: in the Czech
Republic, Finland and Sweden, ATS, specifically
amphetamines rather than ecstasy, account for anything
between 18 % and more than 50 % of all primary treatment
demands. In the Czech Republic, more than 50 % of reported
treatment demands relate to a primary methamphetamine
problem. This is reflected too in new treatment demands, with
the addition of Slovakia (60). Moreover, 11 % of new
European clients demanding treatment and reporting data cite
ATS as a secondary drug (61).
Comparison of data from 2002 and 2003 reveals that the
upward trend in the number of ATS users continued
(+3.5 %); between 1996 and 2003, the number of clients
seeking treatment for ATS increased from 2 204 to 5 070
in 12 EU countries.
Among new clients seeking treatment at outpatient centres
for ATS use, 78.5 % are using amphetamines and 21.4 %
MDMA (ecstasy) (62). The highest proportion of ecstasy
clients are found in Hungary, the Netherlands and the
United Kingdom.
Almost one third of ATS users seeking treatment are aged
15–19 years and another third are between 20 and
24 years (63). The large majority of ATS clients first use the
drug between 15 and 19 years of age (64).
Among ATS clients in treatment, there are equal numbers
of occasional and daily users. In the countries where the
proportion of amphetamine clients is higher, most clients
use the drug 2 to 6 times a week (65).
The main route of administration of amphetamines and
ecstasy is oral (58.2 %); however, around 15 % of clients
inject the drug; in some countries, more than 60 % of ATS
clients are current injectors of amphetamines (Czech
Republic and Finland) (66).
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Figure 9: Trends in recent use (last year) of ecstasy among young
adults (aged 15–34), measured by population surveys (1)
(1) Sample sizes (respondents) for the 15–34 age group for each country
and year are presented in Table GPS-4 in the 2005 statistical bulletin.
NB: Data taken from national surveys available in each country. Figures and
methodology for each survey can be consulted in Table GPS-4 in the 2005
statistical bulletin.
For young adults, the EMCDDA uses the range 15–34 years (Denmark and
UK from 16, Germany, Estonia (1998) and Hungary from 18).
Sources: Reitox national reports (2004), taken from population surveys, reports or
scientific articles. See also Table GPS-0 in the 2005 statistical bulletin.
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Figure 8: Trends in recent use (last year) of amphetamines among
young adults (aged 15–34), measured by population surveys (1)
(1) Sample sizes (respondents) for the 15–34 age group for each country
and year are presented in Table GPS-4 in the 2005 statistical bulletin.
NB: Data taken from national surveys available in each country. Figures and
methodology for each survey can be consulted in the Table GPS-4 in the
2005 statistical bulletin.
For young adults, the EMCDDA uses the range 15–34 years (Denmark and
UK from 16, Germany, Estonia (1998) and Hungary from 18). In France
the age range was 18–39 in 1995.
Sources: Reitox national reports (2004), taken from population surveys, reports or
scientific articles. See also Table GPS-0 in the 2005 statistical bulletin.
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(67) See EMCDDA annual report 2004 (http://ar2004.emcdda.eu.int/en/page038-en.html) for a more detailed discussion of ecstasy-related deaths.
(68) See ‘Interpreting seizures and market data’, p. 41.
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reduced frequency of adulterated pills in western Europe
and continuing concerns over the legality of the practice.
In the Czech Republic, however, pill testing projects
continued and were, in fact, the subject of media debate.
Prevention in recreational settings
Selective prevention projects in recreational settings are
increasingly reported by the new Member States,
especially the Czech Republic, Cyprus (mobile information
unit in nightlife venues), Hungary (three organisations),
Poland and Slovenia.
Typically, the content of interventions remains unchanged
and is similar in most Member States, taking the form of
anti-drug discos, art performances, theatre, media support
(films, cartoons, etc.), seminars, mobile exhibitions and
travel experiences (Luxembourg national report).
Structural approaches remain important. In Italy, the
Netherlands and Scandinavia, networking is considered a
prerequisite for drug prevention, the aim being to influence
nightlife culture. To this end, prevention professionals liaise
with the owners of premises typically used for recreational
drug use (including coffee shops in the Netherlands) and
others involved in the nightlife scene, such as doorkeepers
and bar staff. In Sweden, such interventions are being rolled
out to large cities other than Stockholm. A study of similar
schemes in the Netherlands concluded, ‘visitors and
organisers of parties behave considerably more responsibly
on illegal drugs than expected’ (Pijlman et al., 2003).
Integrated approaches such as these also have the
advantage of deflecting public attention away from incidents
and medical emergencies involving illegal drugs at large
parties and focusing awareness on the overall risks of the
club setting. Safer nightlife guidelines fall into this category
but are not yet widespread in Europe (Calafat et al., 2003).
Individual online counselling through websites is a
relatively new approach adopted in Austria and Germany
(www.drugcom.de). Along the same lines, in Austria, 
e-mail counselling is available at the new Vienna Drug
Assistance call centre, and quality standards have been
developed (FSW, 2004). However, most drug prevention
websites simply provide expert advice and do not include
discussion forums, as robust evidence of the effectiveness
of such consumer-led peer-to-peer communities does not
exist (Eysenbach et al., 2004).
Seizures and market information (68)
As the United Nations Office on Drugs and Crime (UNODC,
2003a) reports, the production of ATS — ‘synthetic drugs
including the chemically related amphetamine,
Deaths related to ecstasy
Compared with opiate-related deaths, deaths involving
ecstasy are relatively unusual but, in some countries, not
negligible, and monitoring of these deaths could be
improved. The description ‘ecstasy-related death’ could
mean that ecstasy was mentioned on the death certificate
or that it was found in the toxicological analysis (often
along with other drugs) (67).
Although reporting is not harmonised, data from the 2004
Reitox national reports suggest that deaths involving
ecstasy are rare in most EU countries, especially deaths
involving ecstasy alone. In 2003, several countries
reported ecstasy-associated deaths: Austria (one death
involving ecstasy only), Czech Republic (one death
probably due to an MDMA overdose), France (eight cases
associated with ecstasy), Germany (two cases associated
with ecstasy alone and eight involving ecstasy in
combination with other drugs — with corresponding
figures of 8 and 11 in 2002), Portugal (detected in 2 % of
drug-related deaths) and the United Kingdom (ecstasy
‘mentioned’ on 49 death certificates in 2000, 76 in 2001
and 75 in 2002). The Netherlands reported seven deaths
due to acute psychostimulant intoxication, although the
substance involved was not reported.
Few countries report data on hospital emergencies
involving ecstasy. In Amsterdam, the number of non-fatal
emergencies (Dutch national report) attributable to ecstasy
use remained stable between 1995 and 2003 (as did those
associated with amphetamines), whereas emergencies
caused by hallucinogenic mushrooms and gamma-
hydroxybutyrate (GHB) increased. In Denmark (national
report), the number of hospital contacts attributable to
intoxication with stimulants increased from 112 cases in
1999 to 292 cases in 2003; of these hospital contacts, the
number associated with ecstasy use increased markedly
from 1999 to 2000 but with no clear trend subsequently,
whereas the number of contacts associated with
amphetamine use increased steadily over the period.
Prevention
Mobile prevention projects are adapting to fragmentation
of the ‘rave’ culture, so that the target group of young
recreational drug users may still be reached, for instance
through contact points for every ‘scene’. Among the
countries where pill testing existed, the practice has been
discontinued in Germany and Portugal. In the Netherlands,
pill testing is carried out only in laboratories, and in
France the abandonment of on-site pill testing has been
proposed. Among the reasons for these changes are the
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(69) This situation should be checked against 2003 UK data when available. Data on numbers of amphetamine seizures in 2003 were not available for Italy,
Cyprus, the Netherlands and Romania; data on both number of amphetamine seizures and quantities of amphetamines seized in 2003 were not available
for Ireland and the United Kingdom.
(70) See Table SZR-7 (part i) in the 2005 statistical bulletin.
(71) See Table SZR-8 (part i) in the 2005 statistical bulletin.
(72) This should be checked against missing 2003 data — in particular for the United Kingdom — when available.
(73) See Table PPP-4 (part i) in the 2005 statistical bulletin.
(74) See Table PPP-8 (part i) in the 2005 statistical bulletin.
(75) See Table PPP-4 (part i) in the 2005 statistical bulletin.
(76) See Table PPP-8 (part i) in the 2005 statistical bulletin.
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methamphetamine and ecstasy’ — is difficult to quantify
because ‘it starts with readily available chemicals, in easily
concealed laboratories’. However, the annual global
production of ATS is estimated at about 520 tonnes
(UNODC, 2003b). Global seizures of ATS peaked in 2000
at 46 tonnes and, following a subsequent decline, increased
again, to 34 tonnes, in 2003 (CND, 2004, 2005).
Amphetamine
Based upon the number of laboratories dismantled,
worldwide amphetamine production remains concentrated
in Europe. In 2003, amphetamine laboratories were
uncovered in eight EU countries (Belgium, Germany,
Estonia, Lithuania, Luxembourg, the Netherlands, Poland,
the United Kingdom). Most of the amphetamine seized in
the EU in 2003 originated from the Netherlands, followed
by Poland and Belgium. In addition, there are reports of
amphetamine being produced in Estonia and Lithuania
and then targeted at Nordic countries. Trafficking in
amphetamine remains mainly intraregional (Reitox
national reports, 2004; CND, 2005).
Similarly, most amphetamine seizures are made in Europe.
Western and central Europe accounted for 82 % of the
total amount of amphetamine seized worldwide in 2003,
with eastern and south-eastern Europe accounting for 13 %
and countries in the Near and Middle East for 3 % (CND,
2005). Over the last five years, the main amphetamine-
seizing country in the EU has been the United Kingdom (69).
In the EU as a whole, the number of amphetamine
seizures (70), which had previously shown an increasing
trend, peaked in 1998, while quantities of amphetamine
seized (71) peaked in 1997. Numbers of amphetamine
seizures increased again in 2001 and 2002 but, based on
trends in countries from which data are available, they
may have stabilised or decreased in 2003. Quantities
seized have been fluctuating also, but seem to be on the
increase since 2002 (72).
In 2003, average amphetamine prices at user level varied
from less than EUR 10 per gram in Belgium, Estonia,
Greece, Latvia, Hungary, the Netherlands and Slovakia to
EUR 37.5 per gram in Norway (73). The average retail
purity of amphetamine in 2003 ranged from 7.5 %
(Germany) to 50 % (Norway) (74).
Methamphetamine
At a global level, the most important ATS in terms of
quantities manufactured and trafficked is
methamphetamine. In 2003 the greatest quantities
continued to be produced and seized in east and south-
east Asia (China, Myanmar, the Philippines, Thailand),
followed by North America (United States) (CND, 2005).
Methamphetamine production in Europe is on a much
smaller scale. In 2003, clandestine methamphetamine
laboratories were detected and reported by the Czech
Republic, Germany, Lithuania and Slovakia (Reitox
national reports, 2004; CND, 2005). In the Czech
Republic, production of methamphetamine has been
reported since the early 1980s (UNODC, 2003a); most is
destined for local consumption, although some of it is
smuggled to Germany and Austria (Czech national report,
2004). In 2003, the Czech authorities reported an
increase in the production of ‘pervitin’ (local
methamphetamine) from branded pharmaceutical products
as a result of a lack of ephedrine (the precursor of
methamphetamine) on the local black market. Although
data on methamphetamine seizures are not systematically
collected by the EMCDDA, the Czech Republic, Germany,
Lithuania and Norway report having made such seizures
in 2003. In addition, Denmark reported that
methamphetamine is increasingly common in the illicit
drug market, and Latvia reported an increased quantity
(0.8 tonnes) of ephedrine seized in 2003 (compared with
2002) (Reitox national reports, 2004).
In 2003, the retail price of ‘pervitin’ in the Czech Republic
was reported to range from EUR 16 to EUR 63 per
gram (75), while purity varied between 50 % and 75 % (76).
Ecstasy
Globally, Europe remains the main centre of ecstasy
production, although its relative importance appears to be
declining as ecstasy manufacture has spread to other parts
of the world in recent years, notably to North America and
east and south-east Asia (CND, 2005; INCB, 2005). In
2003, the number of ecstasy laboratories detected
worldwide decreased (CND, 2005); in the EU, such
laboratories were reported to have been uncovered in
Belgium, Estonia, Lithuania and the Netherlands (Reitox
49
(77) This should be checked against missing 2003 data when available. Data on numbers of ecstasy seizures in 2003 were not available for Italy, Cyprus,
the Netherlands and Romania; data on neither number of ecstasy seizures nor quantities of ecstasy seized in 2003 were available for Ireland and the United
Kingdom.
(78) See Table SZR-9 (part iv) in the 2005 statistical bulletin.
(79) See Table SZR-10 (part i) in the 2005 statistical bulletin.
(80) See Table PPP-4 (part i) in the 2005 statistical bulletin.
(81) This range is based on data from a few countries only, namely Denmark, Germany, France, Luxembourg and the Netherlands.
(82) The small number of LSD seizures should be noted in order to avoid overinterpreting variations from one year to another.
(83) This should be checked against missing 2003 data when available. Data on numbers of LSD seizures in 2003 were not available for Italy, Cyprus, the
Netherlands and Poland; data on both number of LSD seizures and quantities of LSD seized in 2003 were not available for Ireland, Malta, Slovenia, the
United Kingdom, Bulgaria and Romania.
(84) See Table SZR-11 (part i) in the 2005 statistical bulletin.
(85) See Table SZR-12 (part i) in the 2005 statistical bulletin.
(86) See Table PPP-4 (part i) in the 2005 statistical bulletin.
(87) The 1997 joint action concerning the information exchange, risk assessment and the control of new synthetic drugs (OJ L 167, 25.6.1997) defines new
synthetic drugs as ‘synthetic drugs that are not currently listed in any of the Schedules to the 1971 United Nations Convention on Psychotropic Substances,
which pose a comparable serious threat to public health as the substances listed in Schedules I or II thereto, and which have a limited therapeutic value’. It
relates to end products as distinct from precursors.
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Estonia and Lithuania, reported that a high percentage
(94 % and 76 % respectively) of tablets analysed
contained amphetamine and/or methamphetamine as the
only psychoactive substances. The MDMA content of
ecstasy tablets varies greatly from batch to batch (even
among those with the same logo) both between and within
countries. In 2003, the average MDMA content of ecstasy
tablets ranged from 54 to 78 mg (81). Other psychoactive
substances found in tablets sold as ecstasy in 2003
included MDA, MDE, PMA, PMMA, DOB, 5-MeO-DIPT, 
4-MTA and 1-PEA (Reitox national reports, 2004).
LSD
LSD is manufactured and trafficked to a much smaller
extent than ATS. Until 2000, most EU seizures of LSD
occurred in the United Kingdom, but since then
Germany (82) has accounted for the highest number of
seizures (83). Over the period 1998–2002, at EU level,
both the number of LSD seizures (84) and the quantities (85)
seized decreased steadily — except for a plateau in
2000. However, in 2003, for the first time in nine years,
both the number of LSD seizures and amounts intercepted
increased. Exceptionally high quantities were seized in
Spain, France and Poland. This might point to a revival of
LSD trafficking (and possibly use) in the EU. In 2003, the
average cost to users of a unit of LSD ranged from EUR 4
in the United Kingdom to EUR 25 in Italy (86).
Early-warning system information
The principal aim of the European early-warning system
(EWS) in the framework of the EU 1997 joint action on
new synthetic drugs (87) is the rapid collection, analysis and
exchange of information on new synthetic drugs as soon
as they appear on the European drug scene. The EWS
comes under the auspices of the EMCDDA through the
Reitox network, and operates in close cooperation with
national reports, 2004; CND, 2005). Ecstasy seized in the
EU is reported to originate mainly from the Netherlands,
followed by Belgium, although Estonia and the United
Kingdom are also mentioned as source countries (Reitox
national reports, 2003).
Ecstasy trafficking is still strongly concentrated in western
Europe, although, like production, trafficking has spread
throughout the world in recent years (UNODC, 2003a). In
terms of quantities seized, in 2003 western and central
Europe accounted for 58 %, followed by Oceania with
23 % (CND, 2005). In 2002, the Netherlands, for the first
time, overtook the United Kingdom as the EU country
seizing most ecstasy (77).
The number of ecstasy seizures (78) at EU level increased
rapidly over the period 1998–2001. However, since
2002 numbers of seizures have decreased and, based
upon trends in countries from which data are available,
this decline seems likely to have continued in 2003.
Quantities of ecstasy intercepted (79) increased steeply from
1998 to 2000 and since then at a slower pace. In 2003,
however, quantities seized decreased in most of the
countries reporting data. However, the apparent decline in
EU ecstasy seizures (both numbers and quantities) in 2003
has to be confirmed against missing 2003 data — in
particular from the United Kingdom — once they are
available.
In 2003, the average cost of an ecstasy tablet at street
level varied from less than EUR 5 (Hungary, the
Netherlands) to EUR 20–30 (Greece, Italy) (80).
In 2003, most tablets sold as illicit drugs were found,
when analysed, to contain only ecstasy (MDMA, the active
substance) and ecstasy-like substances (MDEA, MDA) as
the psychoactive ingredients. This was the case in
Denmark, Spain, Hungary, the Netherlands, Slovakia and
Norway, where more than 95 % of tablets analysed
contained these substances. However, two countries,
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(88) Atropine, an anticholinergic agent, is a naturally occurring alkaloid of Atropa belladonna. Severe intoxication may be fatal.
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Europol, which provides relevant law enforcement
information through its network of national units (ENUs).
In 2004, the EMCDDA was notified by Member States of
six new synthetic drugs, bringing the total number of
monitored substances to more than 25. These include ring-
substituted phenethylamines (mostly from the 2C group as
well as TMA-2, 4-MTA, PMMA, etc.), tryptamines (such as
DMT, AMT, DIPT and various derivatives) and piperazines
(including BZP, mCPP). Information on various other
substances, including some cathinones (such as substituted
pyrrolidines), was also collected and exchanged.
However, the European Commission and the European
Council were not asked to sanction a risk assessment of
any new substance because there was insufficient
evidence of individual/public health or social risks.
Ketamine and GHB, both of which underwent risk
assessment in 2000, continue to be monitored through the
EWS. Although there are indications that use of these two
substances in recreational settings could spread
significantly, the available evidence is not yet sufficient to
quantify prevalence or identify trends at EU level.
Ketamine identifications were reported from Belgium,
Denmark, Greece, France, Hungary, the Netherlands,
Sweden, the United Kingdom and Norway. Most of the
seizures were of white powder, but France and the United
Kingdom also reported seizures/acquisitions of ketamine
in liquid form. The highest numbers of detections in body
fluids and specimens were reported by Sweden and
Norway (51 and 30 respectively), but neither country
distinguished between medical and illegal use.
GHB identifications, including seizures of its precursors
GBL and 1,4-BD (chemicals that are commercially widely
available), were reported from Belgium, the Czech
Republic, Denmark, Estonia, France, the Netherlands,
Sweden, Finland, the United Kingdom and Norway. GHB
has been seized in both powder and liquid form.
In the last two months of 2004, several cases of
intoxication due to consumption of cocaine adulterated
with relatively high doses of atropine (88) were reported in
Belgium, France, Italy, and the Netherlands. As soon as
the risk of combined cocaine/atropine intoxication
became apparent, the EMCDDA issued an alert to the
EWS partners, advising them to inform their networks and,
in particular, the relevant health authorities on the signs of
cocaine/atropine intoxication so that it can be diagnosed
at an early stage. As a result, several Member States also
chose to release early warnings to their networks or public
health authorities.
In May 2005, the EWS was further strengthened through
a Council Decision (2005/387/JHA) that replaced the
1997 joint action. The Council decision extends the scope
of action to all new psychoactive substances (both
narcotic drugs and synthetic drugs). In addition, the
mechanism allows for the inclusion of medicinal products
in the exchange of information on new psychoactive
substances.
International action against production
and trafficking of synthetic drugs
Increasingly, EU and international cooperation has
recognised the importance of monitoring and control of the
precursor chemicals necessary for the production of
controlled substances. By increasing the vigilance on
chemicals necessary for the production of drugs like
heroin, cocaine and ecstasy, measures can be
implemented to disrupt or inhibit supply. Currently, there
are three major international programmes in this area:
Operation Purple, concerned with potassium
permanganate, used in the production of cocaine;
Operation Topaz monitoring international trade in acetic
anhydride, a precursor used in the production of heroin;
and Project Prism, which is focused on backtracking
investigations into seizures of precursors of amphetamine-
type stimulants at ports of entry or illicit drug laboratory
sites. A total of 20 227 transactions have been notified to
the INCB and examined under these operations during the
past two years and some evidence exists that these actions
have impacted on drug production.
Project Prism is particularly important in consideration of
the production of synthetic drugs within the EU. This is a
challenging area in which to work because among the
large number of chemicals that can be used for the
production of ATS are many substances that are required
for or are by-products of legitimate commercial activities.
Areas of interest to the Prism project include the monitoring
of international trade in safrole, used in the production of
ecstasy; preventing diversion of pharmaceutical
preparations containing pseudoephedrine; and locating
laboratories involved in the illicit manufacture of 1-phenyl-
2-propanone. Despite the difficulties of working in this
area, Project Prism appears to have facilitated better
international cooperation, resulting in successful
interdiction activities. An example of which, noted by the
INCB (2005) in their recent report, was the cooperation
between China and Poland that led to the identification of
a major case of smuggling of 1-phenyl-2-propanone into
Poland.
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The AWF component provides for the collection and
analysis of high-level synthetic drug- and precursor-related
criminal intelligence. Priority is given to investigating
criminal groups and/or significant modi operandi.
The EILCS collates photographic and technical information
from synthetic drug production sites and related chemical
waste dumps, enabling the investigation of links between
seized equipment, materials and chemicals, initiating
information exchange, back-tracking investigations,
forensic examination for evidential purposes plus the
identification and targeting of facilitators and associated
criminal groups. Europol, via the EILCS, is the European
focal point for ‘Project Prism — Equipment’, the United
Nations INCB global back-tracking programme on
tableting machines and other synthetic drug production
equipment.
The EELS collates modus operandi, photographic and
basic forensic information on significant seizures, enabling
the identification of matches between seizures, and with
seized punches, initiating law enforcement information
exchange, further investigation and forensic profiling for
evidential purposes and the targeting of criminal groups.
The Europol synthetic drug production equipment
catalogue and Europol ecstasy logo catalogue are
updated and published on a regular basis.
Measures against production and trafficking
of synthetic drugs in Europe
In accordance with the implementation plan on actions to
be taken in regard to the supply of synthetic drugs, the
Commission, in cooperation with Europol, prepared a
report in December 2003 describing the current status of
major multilateral projects on the mapping of distribution
networks and of experiences gained in this field at EU
level, in the Member States and in candidate countries.
The report pointed out the key elements in such projects
that appear to be essential to the achievement of
operational benefits. It also concluded that there is
‘potential benefit of combining information and
intelligence from a variety of synthetic drug related areas
within an inclusive and integrated strategy.’
In December 2004, Europol merged Projects CASE and
Genesis to form project Synergy, comprising an analytical
work file (AWF) supported by 20 Member States and some
third states, the Europol Illicit Laboratory Comparison
System (EILCS) and the Europol Ecstasy Logo System
(EELS). The project continues to support the Comprehensive
Action against Synthetic Drugs in Europe (CASE), a
Swedish initiative on amphetamine profiling, plus the
European Joint Unit on Precursors (EJUP), comprising
experts from six Member States.
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(89) These very rough estimates are simply based on taking prevalence values in the middle of the range of national prevalence rates (see Table GPS-1 in the
2005 statistical bulletin). Note that several countries with large populations (Germany, Spain, Italy, the Netherlands and the United Kingdom) have
comparatively high prevalence rates, in several cases higher than the range used for the computation.
(90) Note that the age range in the US survey (12 years and over) is wider than the age range reported by the EMCDDA for EU surveys (15–64 years). On
the other hand, the range 18–25 years is narrower than the range used in most EU surveys (15–24 years).
In a recent multicity study, the vast majority (95 %) of what
were defined as socially integrated users (recruited in
discos, clubs or private contacts) snorted cocaine; only a
small fraction had ever smoked or injected the substance
(Prinzleve et al., 2004).
A very rough estimate of recent use (last year prevalence)
of cocaine, assuming an average prevalence of about 1 %
of all adults, will give a figure of between 3 and
3.5 million people in Europe. Rates of current use result
in a rough estimate of about 1.5 million users (89).
As a point of comparison from outside Europe, in the 2003
United States national survey on health and drug use
(SAMHSA, 2003), 14.7 % of adults (12 years or older)
reported lifetime experience of cocaine use and 2.5 %
reported having used cocaine during the previous
12 months (90). Among 18- to 25-year-olds, the figures
were 15 % (lifetime), 6.6 % (last 12 months) and 2.2 %
(last month). For males aged 18–25 years, the figures
were 17.4 %, 8.2 % and 2.9 % respectively. Overall, the
lifetime prevalence of cocaine use is greater among the
general population in the USA than in the higher
prevalence countries in Europe. However, this difference is
not as apparent for more recent use measures, with some
European countries now reporting estimates in excess of
the American figures.
Trends in cocaine use
Clear-cut European trends in cocaine use, based on
population studies, are still difficult to identify (see section
on cannabis trends). However, warnings about increases
in cocaine use in Europe have come from several sources,
including local reports, focused studies conducted in
dance settings, reports of increases in seizures indicators
and some increases in indicators related to problems
(deaths, emergencies).
Recent cocaine use among young people increased
substantially in the United Kingdom from 1996 until 2000,
Prevalence and patterns of cocaine use
According to recent national population surveys, between
0.5 % and 6 % of the adult population report having tried
cocaine at least once (i.e. lifetime prevalence), with Italy
(4.6 %), Spain (4.9 %) and the United Kingdom (6.8 %)
being at the upper end of this range. Recent cocaine use
(last 12 months) is, in general, reported by less than 1 %
of adults; in most countries, the range is between 0.3 %
and 1 %. In Spain and the United Kingdom, recent
prevalence rates are higher than 2 %.
Although cocaine prevalence figures are much lower than
comparable figures for cannabis, levels of use among
younger adults can be higher than the population average.
Lifetime experience among 15- to 34-year-olds ranges from
1 % to 11.6 %, with the highest levels again being found
in Spain (7.7 %) and the United Kingdom (11.6 %). Recent
use ranges between 0.2 % and 4.6 %, with Denmark,
Ireland, Italy and the Netherlands all having rates of 
about 2 %; in Spain and the United Kingdom the figure
is over 4 %.
Cocaine use is higher among males. For instance, surveys
from Denmark, Germany, Spain, Italy, the Netherlands and
the United Kingdom found that, among males aged
15–34 years, lifetime experience was between 5 % and
13 %. In six countries, recent use was higher than 3 %,
with Spain and the United Kingdom reporting rates of
6–7 % (Figure 10).
Among the general population, cocaine use either is
discontinued after a period of experimentation during
young adulthood or is occasional, occurring mainly at
weekends and in recreational settings (bars and discos).
But, in some countries, some forms of regular use may
be not negligible. Current use (in the last 30 days) is
reported by 1.5–4 % of young males (15–34 years old)
in Spain, Italy, the Netherlands and the United Kingdom.
In urban areas, rates of cocaine use are likely to be
substantially higher.
Chapter 5
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(91) Information that arrived too late to be included in the report suggests a stabilisation in 2003 surveys (last-year prevalence among young adults 4.8 %
compared with 4.6 % in 2001).
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but has remained relatively stable since then, although
moderate increases have been observed in recent years,
and in Spain (91) from 1999 to 2001. Less marked
increases were observed in Denmark, Italy, Hungary, the
Netherlands and Austria (in local surveys) and, with
oscillations over the 1990s, in Germany (Figure 11).
Deaths related to cocaine
There have been growing concerns about the health risks
of cocaine use, particularly because of the trend of
increasing recreational use observed in some countries,
especially in settings (discos, clubs) frequented by youth
groups. Despite the difficulties in estimating the number of
cocaine-related deaths, this measure may act as a valuable
indicator of increased risk or help to identify risky patterns
of use. Although acute deaths in which cocaine is present
without opiates seem to be infrequent in Europe, it is likely
that current statistics are inadequate in recording cocaine-
related deaths. The information that is available about
cocaine deaths at the European level is limited and is
reported in different forms. Cocaine use is frequent among
opiate users, and it is common to find cocaine in
toxicological analyses of cases of opiate overdoses, in
addition to other substances such as alcohol and
benzodiazepines.
Several countries reported information about cocaine
deaths in 2003 (Reitox national reports): Germany
(25 cases involving cocaine alone and 93 involving
cocaine in combination with other drugs; in 2002, the
corresponding figures were 47 and 84), France (10 deaths
due to cocaine alone and one associated with a medicine),
Greece (two cases due to cocaine), Hungary (four deaths
due to cocaine overdose), the Netherlands (17 deaths due
to cocaine in 2003, with an increasing trend between
1994, two cases, and 2002, 37 cases), Austria (cocaine
was found in 30 % of drug-related deaths, but alone in only
three cases and in one case in association with gas),
Portugal (cocaine was found in 37 % of drug-related
deaths) and the United Kingdom (‘mentions’ of cocaine in
death certificates increased from 85 in 2000, to 115 in
2001 and 171 in 2002, with an eightfold increase over the
period 1993–2001). In its 2003 Reitox national report,
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Figure 10: Recent use (last year) of cocaine among all young adults and among young males, measured by national surveys
NB: Data are from the most recent national surveys available in each country (see Table GPS-4 in the 2005 statistical bulletin).
Some countries use a slightly different age range to the EMCDDA standard age range for young adults. Variations in age ranges may to a small extent account
for disparities between countries.
Sources: Reitox national reports (2004), taken from population surveys, reports or scientific articles. See also Table GPS-0 in the 2005 statistical bulletin.
0
2
4
6
8
%
All young adults (15–34) Young males (15–34)
D
en
m
ar
k
(2
00
0;
 1
6–
34
 n
 =
 4
 1
41
)
G
er
m
an
y
(2
00
3;
 1
8–
34
 n
 =
 3
 7
75
)
Es
to
ni
a
(2
00
3;
 1
5–
34
 n
 =
 6
46
)
G
re
ec
e
(2
00
4;
 1
5–
34
 n
 =
 2
 6
20
)
Sp
ai
n
(2
00
1;
 1
5–
34
 n
 =
 6
 9
15
)
Fr
an
ce
(2
00
2;
 1
5–
34
 n
 =
 7
24
)
Ire
la
nd
(2
00
2/
03
; 1
5–
34
 n
 =
 n
.a
.)
Ita
ly
(2
00
3;
 1
5–
34
 n
 =
 5
 2
31
)
La
tv
ia
(2
00
3;
 1
5–
34
 n
 =
 n
.a
.)
H
un
ga
ry
(2
00
3;
 1
8–
34
 n
 =
 2
 3
19
)
N
et
he
rla
nd
s
(2
00
0/
01
; 1
5–
34
 n
 =
 6
 6
87
)
Po
la
nd
(2
00
2;
 1
6–
34
 n
 =
 n
.a
.)
Po
rtu
ga
l
(2
00
1;
 1
5–
34
 n
 =
 6
 4
06
)
Sl
ov
ak
ia
(2
00
2;
 1
8–
34
 n
 =
 n
.a
.)
Fi
nl
an
d
(2
00
2;
 1
5–
34
 n
 =
 1
 2
40
)
U
ni
te
d 
Ki
ng
do
m
 (E
&
W
)
(2
00
3/
04
; 1
6–
34
 n
 =
 8
 5
90
)
N
or
w
ay
(1
99
9;
 1
5–
34
 n
 =
 7
94
)
(92) Data analysis is based on clients demanding treatment in all treatment centres for the general distribution and the trends, and on outpatient treatment
centres for profiles of clients and patterns of use.
(93) See Table TDI-5 (part ii) in the 2005 statistical bulletin. Data for Spain refer to 2002.
(94) See Table TDI-4 (part ii) in the 2005 statistical bulletin.
(95) See Table TDI-24 in the 2005 statistical bulletin.
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In addition, cocaine may be a contributing factor in deaths
due to cardiovascular problems (arrhythmias, myocardial
infarction and cerebral haemorrhages; see Ghuran and
Nolan, 2000), particularly in users with predisposing
conditions, and many of these deaths may pass
unreported.
Treatment demand data (92)
After opiates and cannabis, cocaine is the most common
drug reported as the principal drug used by those entering
drug treatment and accounts for about 10 % of all
treatment demands across the EU. However, this overall
figure reflects a wide variation between countries: in most
countries treatment demands related to cocaine use are
quite low, but in Spain and the Netherlands the proportion
of all clients who ask for treatment for cocaine use is 26 %
and 38 % respectively (93). In most countries, the
percentages of new clients demanding treatment for
primary cocaine use are higher than for all clients
overall (94). Cocaine is also reported as a secondary drug
by 13 % of new clients seeking treatment in outpatient
treatment centres (95).
Many countries report increases in cocaine use among
clients seeking treatment; from 1996 to 2003, the
proportion of new clients demanding treatment for cocaine
use grew from 4.8 % to 9.3 %, and the number of new
clients asking for treatment for primary cocaine use rose
from 2 535 to 6 123. In the Netherlands, in 2003, for the
first time, new clients demanding treatment for cocaine use
exceeded those demanding treatment for opiate use. From
an analysis of treatment data produced in London, during
the period 1995/96 to 2000/01, the number of clients
using cocaine more than doubled (GLADA, 2004), albeit
from a low baseline (735 to 1 917).
These data are probably influenced by a small but
growing crack cocaine (smokable cocaine base) problem,
of which there have been indications from both the
Netherlands and the United Kingdom, where the number
of crack cocaine clients has increased in recent years.
Although the numbers of problematic users are low, they
tend to be concentrated in a few major urban areas and
therefore are most visible in reports from city-based
monitoring.
Crack cocaine users tend to have a different social
background from users of cocaine powder. Crack cocaine
users are more likely to be socially disadvantaged, and
Spain reported that, in 2001, cocaine was present in 54 %
of all drug-related deaths; in 39 cases (8 % of all drug-
related deaths) death occurred in the absence of opiates, of
which 21 were caused by cocaine only and five were
caused by cocaine and alcohol.
Despite the limitations of the available information,
cocaine seems to have played a determinant role in
between 1 % and 15 % of drug-related deaths in countries
that were able to make the differentiation between drug
types causing death, with several countries (Germany,
Spain, France and Hungary) reporting figures of around
8–12 % of drug-related deaths. Although it is very difficult
to extrapolate these results to the whole of Europe, this
could mean several hundreds of cocaine-related deaths per
year at EU level. Although the numbers are much lower
than deaths caused by opiates, cocaine-related death is a
serious and possibly increasing problem; in the few
countries where trends can be estimated, they tend to show
an increase.
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Figure 11: Trends in recent use (last year) of cocaine among
young adults (aged 15–34), measured by population surveys (1)
(1) Sample sizes (respondents) for the 15–34 age group for each country
and year are presented in Table GPS-4 in the 2005 statistical bulletin.
(2) In Denmark, the value for 1994 corresponds to ‘hard drugs’.
NB: Data taken from national surveys available in each country. Figures and
methodology for each survey can be consulted in Table GPS-4 in the 2005
statistical bulletin.
For young adults, the EMCDDA uses the range 15–34 years (Denmark and
UK from 16, Germany, Estonia (1998) and Hungary from 18). In France
the age range was 25–34 in 1992 and 18–39 in 1995.
Sources: Reitox national reports (2004), taken from population surveys, reports or
scientific articles. See also Table GPS-0 in the 2005 statistical bulletin.
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(96) See Table TDI-22 in the 2005 statistical bulletin and Differences in patterns of drug use between women and men
(http://www.emcdda.eu.int/?nnodeid=7293).
(97) See Table TDI-10 (part i) in the 2005 statistical bulletin.
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there is some evidence to suggest that ethnic minority
populations may be particularly vulnerable to crack
cocaine problems: two thirds of black people requesting
drug treatment in London are primary crack cocaine users
(GLADA, 2004) and 30 % of crack cocaine clients in the
Netherlands have a non-Dutch background. Despite
worries about crack cocaine, it should be remembered
that, although the drug is associated with particular
damage to both the individuals who use it and the
communities in which they live, this problem remains
highly localised in Europe. It should be noted that crack
cocaine clients are mainly reported by two countries (the
Netherlands and the United Kingdom).
Overall, most cocaine treatment demands in Europe are
not related to crack cocaine. Around 70 % of new cocaine
clients are using cocaine hydrochloride (cocaine powder)
(most sniffing the drug) and the remaining 30 % are using
crack cocaine. Around 5 % of new cocaine clients report
injecting cocaine.
New clients asking for treatment for primary cocaine use
are predominantly males (3.7:1 male to female ratio).
Differences between countries are found in the gender
distribution (96). A qualitative research study carried out in
Italy on clients requesting treatment for use of stimulants,
mainly cocaine, reports that women almost equal men
among consumers, but among people demanding
treatment for cocaine and other stimulants the male to
female ratio is strongly biased towards males (Macchia
et al., 2004).
New clients using cocaine as the primary drug are on
average older than other drug consumers (mean age of
30 years, with most in the 20–34 year age group); a
smaller, although important, proportion of clients is
reported to be between 35 and 39 years (97).
Cocaine is often used in combination with another
subsidiary drug, often cannabis (40 %) or alcohol (37 %).
Local studies of drug injectors suggest that, in some areas,
the combination of heroin and cocaine within an injection
is becoming more popular (sometimes referred to by drug
injectors as ‘speedballing’). If this is the case, it is not
evident in the overall treatment demand data from most
countries, in which only a small proportion of clients report
the combined use of heroin and cocaine. However, this is
not true for all countries; for example, in the Netherlands,
an analysis of treatment demand data for cocaine users
suggests that many cocaine clients are polydrug consumers
and that the largest group is composed of those using both
cocaine and heroin (Mol et al., 2002).
Treatment of problem cocaine use
There is no well-established and widespread
pharmacological treatment available for users with
cocaine problems as there is for those suffering from
opiate drug problems. Medicines for systematic relief may
sometimes be prescribed to cocaine users, but they are
usually short-lived and targeted at reducing problems
related to cocaine use, for example anxiety or sleep
disturbances. Longer-term treatment options for cocaine
users are generally carried out within generic drug
services. However, overall treatment options for those with
cocaine problems appear to be poorly developed
(Haasen, 2003). This may be starting to change as some
countries begin to develop new treatment responses
targeting those with cocaine problems, an example being
the development of specific services for crack cocaine use
being developed in England (NTA, 2003).
Most of the scientific literature on treating cocaine
problems is from American studies and therefore may not
reflect the European context. Unfortunately, evaluation of
treatment for problem cocaine use remains scarce in the
EU, in part simply reflecting the fact that, historically,
cocaine problems were encountered relatively rarely by
treatment services. One European systematic review of
literature on cocaine treatment (Rigter et al., 2004) noted
that treatment compliance by problem cocaine users is
generally low and relapse rates are high. Some evidence
exists that psychotherapy could help to reduce
consumption, and no strong evidence was found for the
effectiveness of acupuncture for treating cocaine problems.
However, overall, these findings should be viewed in the
context of simply an absence of a strong European
evidence base to guide therapeutic interventions in this
area. For example, it is not even clearly known whether
specific cocaine-targeted interventions are more effective
than enrolling those with cocaine problems in more
generic non-drug-specific treatment programmes.
Furthermore, it remains an open question whether it is
possible to develop a pharmacological treatment for
problem cocaine users that can become the ‘standard
treatment option’ in the way that methadone and
buprenorphine have become standard approaches in the
treatment of problem opiate use. It should be noted that
there are important differences in the mechanisms by
which opiate drugs and stimulants such as cocaine act on
the body, which means that therapeutic options to treat
drug problems are likely to differ. Some interesting work is
currently being conducted in the USA to develop
interventions that would temporarily block the effect of
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(98) See ‘Interpreting seizures and market data’, p. 41.
(99) This should be checked against missing 2003 data when available. Data on numbers of cocaine seizures in 2003 were not available for Italy, Cyprus,
the Netherlands and Romania; data on both number of cocaine seizures and quantities of cocaine seized in 2003 were not available for Ireland and the
United Kingdom.
(100) See Table SZR-5 (part i) in the 2005 statistical bulletin.
(101) See Table SZR-6 (part i) in the 2005 statistical bulletin.
(102) See Table PPP-3 (part i) in the 2005 statistical bulletin.
(103) See Table PPP-7 (part i) in the 2005 statistical bulletin. Note that the average purity estimates of cocaine in the Czech Republic and Poland in 2003 are
based on small numbers of samples (n = 5 and 6 respectively).
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western Africa (INCB, 2005). The main points of entry into
the EU remained Spain, the Netherlands and Portugal
(Reitox national reports, 2004; CND, 2005; INCB, 2005).
Seizures
Seizures data indicate that cocaine is the third most
trafficked drug in the world after herbal cannabis and
cannabis resin. In terms of volume seized — 490.5 tonnes
worldwide in 2003 — most trafficking in cocaine
continued in 2003 to be in the Americas (82 %) and
Europe. The latter accounted for 17 % of total cocaine
quantities seized worldwide, an increase compared with
the previous year (CND, 2005). Within Europe, most
quantities of cocaine seized are recovered in the western
states. In the last five years, Spain has consistently been
the EU country with the highest level of cocaine seizures. In
2003, it accounted for more than half the EU total of both
number of seizures and quantities seized (99).
Over the period 1998–2002, the number of cocaine
seizures (100) increased in all countries except Germany
and Portugal. Over the same period, quantities of cocaine
seized in the EU (101) fluctuated, although the trend has
been upward. However, based upon trends in countries
from which data are available, numbers of cocaine
seizures at the EU level seem to have decreased in 2003
(notably in Spain), whereas amounts of cocaine seized
rose substantially (especially in Spain and the
Netherlands). Seizures of particularly large amounts of
cocaine appear to have been made in 2003 in the EU.
Although seizures of crack cocaine have been reported by
some EU countries, they are sometimes not distinguishable
from cocaine seizures. Thus, the trends in cocaine seizures
reported above might include crack cocaine.
Price and purity
The average price (102) of cocaine at retail level varied
widely across the EU in 2003, from EUR 34 per gram in
Spain to EUR 175 per gram in Norway.
Compared with heroin, the average purity of cocaine at
user level is high, varying in 2003 from 32 % in the Czech
Republic and Germany to 83 % in Poland (103).
cocaine use on the user, and it will be interesting to see
whether new treatment options become available from this
work in the future.
Reducing health-related harm
Over the past few years, measures aimed at the prevention
and reduction of health-related harm associated with the
use of cocaine and crack cocaine have increased rapidly,
and new cocaine and crack-specific information has been
produced, especially on the Internet. Telephone helplines
in Belgium, France and Portugal have received more
information requests about cocaine and crack cocaine use
than ever before, although the percentage of these calls
still remains far lower than those concerning legal drugs
and cannabis. More training on how to respond
adequately to problems arising from cocaine and crack
cocaine use in a number of settings where this is a recent
phenomenon (the weekend scene in Dublin or the techno-
scene in Vienna) is available for staff working at drug
services.
Specialised counselling and offers of treatment for cocaine
and crack cocaine users exist in big urban centres, for
example in Frankfurt (Suchthilfezentrum Bleichstrasse:
www.drogenberatung-jj.de), Barcelona (Hospital Vall
d’Hebron: www.vhebron.es), Vienna (ChEck iT!:
www.checkyourdrugs.at) and London
(www.cracklondon.org.uk).
Seizures and market information (98)
Production and trafficking
Colombia is by far the largest source of illicit coca in the
world, followed by Peru and Bolivia. Global production of
cocaine in 2003 has been estimated at 655 tonnes, to
which Colombia contributed 67 %, Peru 24 % and Bolivia
9 % (CND, 2005). Most of the cocaine seized in Europe
comes directly from South America (Colombia) or via
Central America and the Caribbean. In 2003, Brazil and
Venezuela, in particular, were reported as transit countries
for cocaine imported into the EU, alongside Argentina,
Costa Rica and Curaçao (Reitox national reports, 2004;
CND, 2005). Other transit areas were southern and
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(104) For more detail, see the methodological notes on problem drug use in the 2005 statistical bulletin.
Problem drug use
Problem drug use (PDU) is defined operationally as
‘injecting drug use or long duration/regular use of opiates,
cocaine and/or amphetamines’ (104). Variations in
definitions and methodological uncertainties mean that
obtaining reliable estimates in this area is difficult, and
caution should be used when interpreting differences
between countries or over time.
Problem drug use can be subdivided into important
groupings. A general distinction can be made between
The regular and sustained use of heroin, drug injecting
and, in some countries, the intensive use of stimulants
account for a substantial proportion of drug-related health
and social problems in Europe. The number of individuals
exhibiting this kind of behaviour is low relative to the
population overall, but the impact of problem drug use is
considerable. To help understand the scale of this problem
and to allow trends to be monitored over time, the
EMCDDA is working with the Member States to redefine
the concept of ‘problem drug use’ and to develop
strategies to measure both its scale and its impact.
Chapter 6
Heroin and injecting drug use
60
Figure 12: Estimates of the prevalence of problem drug use, 1999–2003 (rate per 1 000 population aged 15–64)
NB: CR, capture–recapture; TM, treatment multiplier; PM, police multiplier; MI, multivariate indicator; TP, truncated Poisson; CM, combined methods. For more details
see Tables PDU-1, PDU-2 and PDU-3 in the 2005 statistical bulletin. The symbol indicates a point estimate and a bar indicates an uncertainty interval, which can
be either a 95 % confidence interval or an interval based on sensitivity analysis (see Table PDU-3). Target groups may vary slightly owing to different methods
and data sources; therefore comparisons should be made with caution. The Spanish estimate does not include problem cocaine use; a higher estimate is available
in Tables PDU-2 and PDU-3, which takes this group into account but which may not be as reliable.
Sources: National focal points. See also EMCDDA (2003).
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(105) See Table PDU-1 in the 2005 statistical bulletin.
(106) See Figure PDU-4 in the 2005 statistical bulletin.
(107) See Figure PDU-2 in the 2005 statistical bulletin.
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heroin use, which has historically accounted for most PDU
in the majority of EU countries, and problem use of
stimulants, which predominates in Finland and Sweden,
where the majority of problem drug users are primary
amphetamine users. Similarly, in the Czech Republic,
methamphetamine users have traditionally formed a
significant proportion of problem drug users.
Problem drug use is becoming more diverse. For example,
polydrug use problems have become progressively more
important in most countries, whereas some countries where
opiate problems have historically predominated now
report changes towards other drugs. In Spain, estimates of
problem opiate users are declining, and an increase has
been observed in cocaine-related drug problems; however,
reliable time trends of PDU that include problematic
cocaine use are not available. Germany and the
Netherlands report an increasing proportion of crack
cocaine users among their problem drug populations,
although the overall estimate of problem drug users in the
Netherlands remains unchanged.
Prevalence
Estimates of the prevalence of problem drug use at national
level over the period 1999–2003 range between two and
ten cases per 1 000 population aged 15–64 (based on
midpoints of estimates) or up to 1 % of the adult
population (105). Prevalence appears to differ greatly
between countries, although when different methods have
been used within one country the results are largely
consistent. Higher estimates are reported by Denmark,
Spain, Ireland, Italy, Luxembourg, Austria, Portugal and the
United Kingdom (6–10 cases per 1 000 inhabitants aged
15–64 years), and lower rates are reported by Germany,
Greece, the Netherlands and Poland (fewer than four cases
per 1 000 inhabitants aged 15–64 years) (Figure 12).
Among the new countries of the EU and the candidate
countries, well-documented estimates are available from
only the Czech Republic, Poland and Slovenia, where
figures are in the low to middle range at 3.6, 1.9 and 
5.3 per 1 000 population aged 15–64 respectively. The
weighted average rate of PDU in the EU is probably
between four and seven cases per 1 000 population aged
15–64 years, which works out at 1.2–2.1 million problem
drug users in the EU, of whom some 850 000 to 1.3 million
are active injectors. However, these estimates are far from
robust and will need to be refined as more data become
available from the new Member States.
Local and regional estimates suggest that the prevalence of
PDU can vary greatly between cities and regions. The
highest local prevalence estimates in the period
1999–2003 are reported from Ireland, Portugal and the
United Kingdom, with rates per 1 000 reaching
16 (Dublin), 17 (Beja), 24 (Aveiro) and 25 (parts of
London), up to 29 (Dundee) and 34 (Glasgow)
(Figure 13). Geographic variability is, however, marked at
the local level, with prevalence in another part of London
being estimated at 6 per 1 000. This suggests the need to
increase the availability of reliable local prevalence
estimates in many other countries, where particularly high
(or low) local or regional prevalence rates may exist but
are not being measured.
Although there have been considerable improvements in
estimation techniques, a lack of reliable and consistent
historical data complicates the assessment of trends in
problem drug use. Reports from some countries of changes
in estimates that are supported by other indicator data
suggest that there has been an increase in PDU since the
mid-1990s (EMCDDA, 2004a); however, in some
countries, this appears to have stabilised in more recent
years. Repeated estimates are available for 1999 to 2003
from 16 countries (counting Denmark and Sweden, both
with data from 1998–2001, and the United Kingdom,
where data are for 1996–2001). Of these 16 countries,
six reported an increase in PDU estimates (Denmark,
Austria, Finland, Sweden, United Kingdom and Norway),
five reported a stable prevalence or a decrease (Czech
Republic, Germany, Greece, Ireland and Slovenia) and
five (Spain, Italy, Luxembourg, the Netherlands and
Portugal) reported different trends depending on the
estimation method used, which may partly refer to different
target groups among problem drug users (106).
Drug injecting
Injecting drug users (IDUs) are at very high risk of
experiencing adverse consequences. It is therefore
important to consider drug injection separately, as a core
category of PDU.
Despite its importance for public health, few countries
provide national or local estimates of injecting drug use.
Available national-level estimates range between one and
six cases per 1 000 population aged 15–64, suggesting
important differences between countries in the prevalence
of IDU (107). Luxembourg reports the highest national
estimates of IDU, with rates of about six cases per
1 000 population aged 15–64, whereas Greece reports
the lowest IDU estimate, with just over one case per 1 000.
Although prevalence estimates for injecting drug use are
scarce, there is evidence of increasing prevalence after
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(108) See Figure PDU-5 in the 2005 statistical bulletin.
(109) See Figure PDU-3 in the 2005 statistical bulletin.
(110) See Table TDI-24 in the 2005 statistical bulletin.
(111) See Table TDI-5 (part ii) in the 2005 statistical bulletin. 
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primary drug is not recorded — and over half (54 %) of
these opiate clients are known injectors, with 10 % being
of unknown injecting status. Opiates are also reported to
be the secondary drug for around 10 % of new clients (110).
In many countries, opiates (largely heroin) remain the
principal drug for which clients seek treatment, but relevant
differences are found between countries. Dividing the EU
countries broadly into three groups, depending on the
extent to which the treatment population is characterised
by those with heroin problems, shows the following:
• below 40 % — Czech Republic, the Netherlands,
Poland, Finland, Sweden;
• 50–70 % — Denmark, Germany, Spain, Ireland,
Cyprus, Latvia, Slovakia, Romania;
• over 70 % — Greece, France, Italy, Lithuania,
Luxembourg, Malta, Slovenia, United Kingdom,
Bulgaria (111).
1999 in Norway, while in Portugal different estimation
methods suggest different trends (108).
Analysis of injecting rates among heroin users in treatment
suggests marked differences in rates between countries as
well as varying trends over time (109). In some countries
(Spain, the Netherlands and Portugal), a relatively small
proportion of heroin users inject, whereas in most other
countries injection of heroin is still the norm. In some long-
standing EU countries from which data are available
(Denmark, Greece, Spain, France, Italy and the United
Kingdom), rates of injecting among heroin users in
treatment have declined. However, in most of the new
Member States, at least where data exist, almost all heroin
users in treatment are injectors.
Treatment demand data
Of the total treatment requests made, 60 % are known to
be for opiate treatment, although in many cases the
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Figure 13: National and local estimates of the prevalence of problem drug use, 1999–2003 (rate per 1 000 population aged 15–64)
NB: Black square = samples with national coverage; blue triangle = samples with local/regional coverage.
Target groups may vary slightly owing to different methods and data sources; therefore comparisons should be made with caution. For more details see 
Tables PDU-1, PDU-2 and PDU-3 in the 2005 statistical bulletin. The pattern of local prevalence estimates depends much on availability and location of studies;
however, if available, local estimates can suggest that prevalence is different from the national average in specific cities or regions.
Sources: National focal points. See also EMCDDA (2003).
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(112) See Table TDI-3 (part i) in the 2005 statistical bulletin.
(113) See Table TDI-22 in the 2005 statistical bulletin.
(114) See Table TDI-10 (part iii) in the 2005 statistical bulletin.
(115) See Table TDI-11 (part ii) in the 2005 statistical bulletin.
(116) See Table TDI-18 (part i) in the 2005 statistical bulletin. Only Germany reports 70 % of new clients using opiates occasionally or not having used them in
the last month.
(117) Only countries for which data were available.
(118) See Table TDI-17 (part i) in the 2005 statistical bulletin.
Chapter 6: Heroin and injecting drug use
The prevalence of opiate clients who continue in treatment
for many years is reported to be increasing, while the
incidence of new opiate treatment demands is decreasing
(Reitox national reports, 2004; Drug Misuse Research
Division, 2004). For some countries, trends in heroin use
among new clients in treatment can be tracked from 1996
to 2003, and these show an overall decline in absolute
numbers seeking treatment.
The relative contribution of opiate treatment to the size of the
new-to-treatment population has decreased more markedly,
owing to an increase in the number of reported clients with
problems primarily related to other drugs. This, in turn, may
be due to a switch from heroin to cocaine use by some
opiate clients (Ouwehand et al., 2004), differentiation of the
treatment system, which has become more accessible for
other problematic drug users, or the reduced recruitment of
new problem users (Dutch national report).
Differences in this trend in the last decade are found
between countries, with a strong decrease in heroin clients
in Denmark, Germany, the Netherlands, Slovakia and
Finland and some increase in the United
Kingdom and Bulgaria (112).
Data analysis on new clients attending outpatient treatment
centres allows a more detailed description of the profile of
opiate users. There are 2.8 men for every woman asking
for new treatment for primary opiate use; however, gender
ratios vary considerably by country, from 5:1 to 2:1, with
the exceptions of Cyprus, where the male to female ratio is
very high (11:1), and Sweden, where it is very low (0.9:1)
and women outnumber men among opiate users (113).
Most opiate users are aged between 20 and 34 years, and in
the age group 30–39 years more than half the clients seek
treatment for opiate use. The reported trend is towards an
ageing opiate clientele; for example, in the Netherlands
around 40 % of new opiates clients are over 40 years old.
The exceptions are Slovenia and Romania, where a very
young population (15–19 years) of opiate clients is found (114).
Most opiate clients report having used opiates for the first
time when they were between 15 and 24 years old, with
around 50 % of clients first using the drug before the age
of 20 (115). Comparing the age at first use with the age at
first treatment, the time lag between first use and first
demand for treatment is generally between 5 and
10 years. An early age at onset of opiate use is often
associated with a range of behavioural problems and
social deprivation (United Kingdom national report).
In most countries, between 60 % and 90 % of opiate
clients use the drug daily, whereas some clients have not
used opiates in the last month or used them only
occasionally; this is probably explained by clients
stopping use of the drug before entering treatment (116).
Forty per cent of clients inject the drug and another 40 %
smoke or inhale it. Differences in the method of use are
reported between old and new Member States (117)
(Figure 14), with the proportion of opiate injectors being
higher than 60 % in the new Member States and lower
than 60 % in the old Member States (with the exception of
Finland, where the proportion of opiate injectors among
clients is 78.4 %). The proportion of injectors among
opiate clients is lowest in the Netherlands (8.3 %) (118).
Many new clients use opiates as well as another drug,
often cannabis (47 %) or alcohol (24 %). However,
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Figure 14: New outpatient clients injecting opiates as a proportion
of the total number of new opiates clients by country, 2003
NB: Only countries where there are clients with opiates as primary drug and/or
countries supplying data are reported.
Source: Reitox national reports (2004).
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(119) See Table TDI-25 (part ii) in the 2005 statistical bulletin. See also the selected issue on buprenorphine. Each client may report the use of up to four
secondary drugs.
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HIV and AIDS
Recent trends in reported HIV cases
HIV has shown strong epidemic spread among IDUs in the
new EU Member States of the Baltic region, following
massive epidemics in eastern Europe (EuroHIV, 2004) (see
box ‘HIV and AIDS in eastern Europe’). Rates of newly
diagnosed cases peaked in Estonia and Latvia in 2001,
and in Lithuania in 2002, but more recently rates have
fallen dramatically. This pattern is typical of HIV epidemics
among IDUs. It arises because the core group of IDUs at
highest risk all become infected in a short period of time,
following which incidence falls because of a lack of
susceptible IDUs and then stabilises at a level that depends
on the rate of recruitment of new IDUs at high risk.
However, an additional effect of behaviour change cannot
be excluded and, if true, this could in part be the result of
specific interventions (see ‘Prevention of drug-related
infectious diseases’, p. 66).
In the EU-15 countries, rates of newly diagnosed HIV cases
have remained low in recent years, with the exception of
Portugal. However, comparisons at the EU level are
incomplete as HIV case reporting data remain unavailable
(Spain and Italy) or are only starting to become available
(France) for some of the countries most affected by AIDS.
Portugal showed a very high rate of 88 per million in
2003, but also a large decrease since 2000 (when the
rate was 245 per million). This decrease has to be
interpreted with caution as European data reporting was
only implemented in Portugal in 2000.
HIV seroprevalence
Seroprevalence data from IDUs (per cent infected in
samples of IDUs) are an important complement to HIV case
reporting data. Repeated seroprevalence studies and
routine monitoring of data from diagnostic tests can
validate trends in case reporting and can also provide
more detailed information on specific regions and settings.
However, the prevalence data are from a variety of
sources that, in some cases, may be difficult to compare,
and they should therefore be interpreted with caution.
The recent increases recorded in the HIV case reporting
are mostly confirmed by the available seroprevalence
data; for example, in Latvia, prevalence in national
treatment samples of tested IDUs rose from 1.5 % (5/336)
in 1997 to 14 % (302/2 203) in 2001 and then fell to
7 % (65/987) in 2003. In Austria, where HIV case
reporting data for IDUs are not available, HIV prevalence
among national samples of (direct) drug-related deaths
suggests some increase, to 7 % (11/163) in 2003 from
marked differences are found between countries: in the
Czech Republic and Slovakia, almost half the clients use
opiates together with stimulants other than cocaine; in
Greece and Malta, 18 % and 29 % of clients, respectively,
use opiates with cocaine as a secondary drug; in Finland,
among opiate users (mainly users of buprenorphine) 37 %
report the use of hypnotics and sedatives (mainly
benzodiazepines) as secondary drugs (119).
Drug-related infectious diseases
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HIV and AIDS in eastern Europe
Human immunodeficiency virus (HIV) has shown massive
and recent epidemic spread among IDUs in Russia and the
Ukraine, as it has in the EU Member States of the Baltic
region. In 2001, the rate of newly diagnosed infections
related to intravenous drug use peaked in Estonia and in
the Russian Federation, at 991 and 333 cases per million
population respectively. However, in the Ukraine, the peak
was reached earlier in 1997, at 146 cases per million, as
a result of widespread IDU-related transmission, after which
rates of new IDU-related HIV diagnoses declined but more
recently have increased again.
The incidence of AIDS among IDUs is increasing rapidly in
Latvia and the Ukraine, suggesting that access to and
coverage of antiviral treatment is probably insufficient (see
‘Highly active antiretroviral therapy in the WHO European
region’, p. 65).
HIV infections newly diagnosed in injecting drug users in
selected EU countries, Russia and Ukraine, by year of report
Source: European Centre for the Epidemiological Monitoring of AIDS
(EuroHIV) (2004).
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(120) See Figure INF-3 in the 2005 statistical bulletin.
(121) The data for Italy and Portugal are not limited to IDUs and may thus underestimate prevalence among IDUs.
(122) See Tables INF-1 and INF-8 in the 2005 statistical bulletin. 
(123) See Table INF-8 in the 2005 statistical bulletin. 
(124) IDUs aged under 25: 33 % infected among 55 young IDUs in Poland and 20 % among 107 young IDUs in Latvia.
(125) See Table INF-10 and Figures INF-4 and INF-5 in the 2005 statistical bulletin. 
(126) See Figure INF-16 in the 2005 statistical bulletin.
(127) See Figures INF-26 and INF-27 in the 2005 statistical bulletin.
(128) See Figure INF-1 in the 2005 statistical bulletin.
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1 % (1/117) in 1998, but numbers are small and the trend
is not statistically significant.
In 2002 and 2003, HIV prevalence among IDUs, mostly
those in drug treatment, showed wide variation within and
between countries, ranging from 0 % in Bulgaria,
Hungary, Slovenia and Slovakia to a maximum of 37.5 %
(54/144) in one city in Italy (2003, Bolzano — users in
treatment and prisons) (120). The highest prevalence rates in
national samples (over 10 % in 2002–03) were found in
Italy, Latvia and Portugal (121); in Spain, data for 2001
suggest a very high prevalence, but more recent data are
lacking (122). The highest prevalence rates in regional and
local samples (over 20 % in 2002–03) were reported from
Spain, Italy, Latvia and Poland (123), although recent data
have not been provided from some countries and areas
with high prevalence in previous years. In Latvia and
Poland, local studies suggest recent transmission of HIV,
based on the very high prevalence among young IDUs (124).
In the case of the Polish study, this recent transmission is
confirmed by a prevalence of 23 % among a sample of
127 new injectors (125).
Time trends in prevalence also differ between countries.
Although there have been recent outbreaks in the Baltic
region, HIV seroprevalence data from samples of IDUs
suggest a decrease since the mid-1990s in some of the
most affected countries (Spain, France and Italy), followed
by a stabilisation in recent years (126). However, if
seroprevalence is high and stable, transmission is likely to
continue. Data for new IDUs strongly suggest ongoing, and
even increased, transmission in Spain between 1999 and
2000. In some other countries (France 2001–03, Portugal
1999–2000) local and regional data on new and young
IDUs suggested some (increased) transmission, but sample
sizes are too small for the trends to be statistically
significant (127). On the other hand, it should be noted that
in several countries HIV prevalence among IDUs remained
very low during 2002–03. HIV prevalence was less than
1 % in the Czech Republic, Greece (national data),
Hungary, Slovenia, Slovakia, Finland, Romania (data for
only 2001), Bulgaria and Norway (data for Oslo). In some
of these countries (e.g. Hungary), both HIV prevalence and
hepatitis C virus (HCV) prevalence are among the lowest in
the EU, suggesting low levels of injecting risk (see section
‘Hepatitis B and C’ below).
AIDS incidence
In Latvia, the incidence of AIDS related to IDU increased
from zero cases in 1997 to an estimated 19 cases per
million population in both 2002 and 2003 (128). However,
the EU country with the highest incidence remains
Portugal, with 33 cases per million, although this figure
has been decreasing since 1999. AIDS incidence due to
IDU in the EU peaked in the early 1990s and declined
thereafter. The most affected country used to be Spain,
where incidence peaked at 124 cases per million in 1994,
but by 2003 this figure had declined to an estimated
16 per million.
The decline in AIDS incidence in the late 1990s is the
result of the introduction in 1996 of highly active
antiretroviral therapy (HAART), which prevents the
development of AIDS in people infected with HIV (see box
on HAART). In the case of IDUs, HIV prevention measures
may also have played an important role and, in some
countries, a decrease in the number of injectors may have
been a factor (see ‘Drug injecting’, p. 61).
Annual incidence data show that, until 2002, the greatest
number of new cases of AIDS in the EU could be attributed
to intravenous drug use; subsequently, this mode of
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Highly active antiretroviral therapy in the WHO
European region
WHO estimates of the coverage of highly active
antiretroviral therapy (HAART) suggest that, in the EU and
most of central Europe, over 75 % of persons in need of
treatment have access to HAART.
However, among the Baltic states, coverage is estimated to
be ‘poor’ in Estonia and Lithuania (25–50 %) and ‘very
poor’ in Latvia (under 25 %). Coverage is estimated to be
‘very poor’ in most countries of eastern Europe.
Coverage estimates specific for IDUs are not available, but
studies have shown that IDUs are often at higher risk of
inadequate access to HAART than people infected by other
routes.
Source: WHO Regional Office for Europe, Health for All Database
(www.euro.who.int/hfadb) (accessed 8 March 2005).
(129) See Figure INF-2 in the 2005 statistical bulletin. 
(130) See Tables INF-2 and INF-11 in the 2005 statistical bulletin.
(131) See also Figure INF-21 in the 2005 statistical bulletin and Matheï et al., 2005.
(132) See Table INF-12 in the 2005 statistical bulletin.
(133) See Table INF-13 and Figures INF-7 and INF-8 in the 2005 statistical bulletin. 
(134) See Tables INF-3, INF-14 and INF-15 in the 2005 statistical bulletin. 
(135) See Figures INF-9, INF-10, INF-22 and INF-23 in the 2005 statistical bulletin.
(136) See Figure INF-14 in the 2005 statistical bulletin.
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Prevalence data from young IDUs (aged under 25) are
available from only a few countries and, in some cases,
sample sizes are small. Where available, the highest
prevalence among young IDUs in 2002–03 (over 40 %) is
found in samples from Greece, Austria and Poland and the
lowest prevalence (under 20 %) in samples from Hungary,
Slovenia, Finland and the United Kingdom (132). Data on
HCV prevalence among new injectors (injecting for less
than two years) are even more limited but what information
is available for 2002–03 shows that the highest
prevalence (over 40 %) is in samples from Belgium and
Poland and the lowest prevalence (under 20 %) in samples
from the Czech Republic, Greece and Slovenia (133).
Hepatitis C notification data for the period 1992–2003
suggest that, in those countries providing data, IDUs
account for the large majority of notified cases of
hepatitis C (notifications are mostly limited to diagnosed
cases of acute infection) (Figure 17).
The prevalence of hepatitis B virus (HBV) markers also
varies greatly both within and between countries (134). The
most complete data are for anti-HBc, which indicates a
history of infection and, among those testing negative, the
potential for vaccination. In 2002–03, IDU samples with
prevalence over 60 % were reported from Belgium,
Estonia and Italy, while samples with prevalence under
30 % were reported from Belgium, Spain, Italy, Austria,
Portugal, Slovenia, Slovakia and the United Kingdom (135).
Hepatitis B notification data for the period 1992–2003,
for those countries from which data are available, suggest
that the proportion of IDUs has been increasing (136). In the
Nordic region, the great majority of notified acute cases of
hepatitis B occur among IDUs, and hepatitis B outbreaks
have coincided with increases in drug injecting in several
countries (Blystad et al., 2005).
For a brief overview of other drug-related infectious
diseases, see the 2004 annual report
(http://ar2004.emcdda.eu.int/en/page074-en.html).
Prevention of drug-related infectious diseases
Although the national policies of Member States vary,
reflecting their individual drug situation and political context,
there is also increasing evidence of a consensus emerging at
the European level on the key elements necessary for an
effective response to combating HIV and other infectious
transmission was overtaken by heterosexual sex, reflecting
changes in the epidemiology of HIV in the preceding years
(Figure 15). It should be noted, however, that infection
patterns can differ greatly between individual
countries (129).
Hepatitis B and C
The prevalence of antibodies against hepatitis C virus
(HCV) among IDUs is, in general, extremely high, although
there is wide variation both within and between
countries (130). Among samples of IDUs, prevalence rates of
over 60 % in 2002–03 are reported from Belgium,
Estonia, Greece, Italy, Poland, Portugal and Norway,
while samples with prevalence under 40 % are reported
from Belgium, the Czech Republic, Greece, Hungary,
Austria, Slovenia, Slovakia, Finland and the United
Kingdom (Figure 16) (131).
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Figure 15: AIDS cases by transmission group and year of
diagnosis (1987–2003) adjusted for reporting delays, EU
NB: Data shown for the three main transmission groups and for cases with no
transmission group reported.
HBM, homosexual and bisexual men; IDU, injecting drug users; HC,
heterosexual contact.
Countries not included are France, the Netherlands (data not available for
the whole period) and Cyprus (no data available).
Source: EuroHIV; data reported by 31 December 2003.
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(137) In two recent conferences, European government representatives have confirmed their partnership in the fight against HIV/AIDS and defined measures to
strengthen their responses in this area (Dublin Declaration, February 2004, and Vilnius Declaration, September 2004). All key EU documents on HIV/AIDS
can be found on the European Commission’s public health website (http://europa.eu.int/comm/health/ph_threats/com/aids/keydocs_aids_en.htm).
(138) See Table NSP-2 in the 2005 statistical bulletin.
(139) See ‘Needle and syringe availability’ in the 2005 statistical bulletin.
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diseases among IDUs (137). Appropriate responses include
enhanced access to drug treatment (WHO, 2005), the
development of low-threshold services and the provision of
sterile equipment and education programmes, although it
should be noted that there are differences between countries
with respect to the emphasis placed on these different service
elements. Of particular importance is that there should be
sufficient availability of oral substitution treatment for
injecting opioid users, as this significantly reduces drug-
related behaviour with a high risk of HIV transmission
(Gowing et al., 2005; Sullivan et al., 2005).
Needle and syringe availability
Needle and syringe programmes (NSPs) started in the
European Union in the mid-1980s as an immediate
response to the threat of an HIV epidemic among drug
injectors and expanded rapidly over the course of the
1990s (Figure 18). In 1993, publicly funded programmes
already existed in more than half of the current 25 EU
Member States and in Norway. Today, NSPs are available
in Bulgaria, Romania and Norway as well as in all EU
countries, except Cyprus, where sterile equipment is,
however, freely obtainable at pharmacies and an official
NSP is under consideration (138). Once such programmes
have been introduced to a country, the geographical
coverage of outlets for NSPs generally increases
continually. Many countries have now achieved full
geographical coverage, with pharmacies being a crucial
partner in several Member States. However, in Sweden, the
two programmes started in 1986 in the south of the country
remain the only ones; and in Greece, the number of NSPs is
limited and they are only available in Athens (139).
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Figure 16: National and local estimates of HCV prevalence among injecting drug users, 2002–2003
NB: Black square, samples with national coverage; blue triangle, samples with local/regional coverage.
Differences between countries have to be interpreted with caution owing to different types of settings and/or study methods; national sampling strategies vary.
Data for Spain and Portugal and some of the data for Czech Republic include non-IDUs and therefore may underestimate prevalence among IDUs (proportion of
non-IDUs in the samples not known).
Data for Portugal, Slovenia and Slovakia are limited to prevalence among IDUs in treatment and may not be representative of prevalence among IDUs who are
not in treatment.
Sources: Reitox national focal points (2004). For primary sources, study details and data before 2002, see Table INF-11 in the 2005 statistical bulletin.
0
10
20
30
40
50
60
70
80
90
100
%
Be
lg
iu
m
C
ze
ch
 R
ep
ub
lic
Es
to
ni
a
G
re
ec
e
Ita
ly
H
un
ga
ry
A
us
tri
a
Po
la
nd
Po
rtu
ga
l
Sl
ov
en
ia
Fi
nl
an
d
U
ni
te
d 
Ki
ng
do
m
N
or
w
ay
Annual report 2005: the state of the drugs problem in Europe
NSPs are usually integrated firmly into the work of low-
threshold drug counselling agencies (see box ‘Making
services more accessible’), outreach work and the care for
the homeless in the EU countries and Norway. As agencies
that have a low threshold of access are successful in
reaching hidden populations of active drug users, they can
be an important starting point for contact, prevention,
education and advice, as well as for referrals to treatment.
It is also increasingly recognised that low-threshold
services can be a vital platform for offering basic medical
care, infectious disease screening and vaccination and
antiviral treatment to members of the community who, for a
variety of reasons, may find it difficult to access more
formal healthcare services.
Needle and syringe programmes are described as a
predominant approach to the prevention of infectious
diseases among drug users in 16 EU Member States and
Norway and a common approach in a further six; and it is
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Figure 17: Notified cases of hepatitis C, percentage of cases
reported as IDU, 1992–2003
(1) The data are not for the national level.
NB: A, acute cases; AC, acute and chronic cases; C, chronic cases.
Source: Reitox national focal points.
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Figure 18: Introduction of needle and syringe programmes
in 23 EU countries, Norway and Bulgaria
Source: Reitox national reports, 2004.
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Making services more accessible
The term ‘low-threshold’ describes an implementation
setting that aims to make it easier for drug users to get
access to social and health services. To lower their
threshold of access, agencies are placed in specific
locations and have opening hours that are adapted to their
clients’ needs, including late evening or night-time opening.
Low-threshold agencies often also deliver their services
through outreach workers. The use of the agencies’ services
requires little bureaucracy and often no payment and is not
linked to an obligation on the clients’ part to be or to
become drug-free. Such agencies target current users who
have never been in contact with other drugs and health
services and those who have lost this contact. Their services
are targeted towards the ‘hard-to-reach’ groups and
specific high-risk groups of users and also experimental
users (for example, through delivering their services in
clubs and discos or other party settings). The low-threshold
setting can apply to street agencies, drop-in day centres
and field healthcare stations and also to emergency
shelters. Within a comprehensive system of care, these
agencies, because of their easy accessibility, have an
important role in reaching out to the more ‘hidden’ or
‘difficult-to-reach’ populations of drug users. Besides
motivating users to seek treatment and making referrals,
they often deliver ‘survival-oriented’ services, including
food, clothes, shelter, sterile injecting equipment and
medical care. They are core settings for disseminating
health promotion messages and increasing knowledge and
skills regarding safe use among those who use drugs either
experimentally or in a dependent or problematic way.
Increasingly, they deliver treatment services too.
(140) See the EMCDDA website for an overview of national responses to infectious diseases (http://www.emcdda.eu.int/?nnodeid=10212).
(141) See the EMCDDA website for a list of key reviews (http://www.emcdda.eu.int/?nnodeid=5777).
(142) For more information on hepatitis, see the EMCDDA website (http://www.emcdda.eu.int/?nnodeid=10192).
(143) Report on the 14th global advisory group: expanded programme on immunisation, 14–18 October 1991, Antalya, Turkey, endorsed by the World
Health Assembly in 1992.
(144) See Hepatitis B vaccination table (http://www.emcdda.eu.int/?nnodeid=10192).
(145) Consultant study on hepatitis C treatment guidelines for injecting drug users (http://www.emcdda.eu.int/?nnodeid=5826).
(146) This is the definition agreed by the EMCDDA group of national experts: see methodological notes ‘Drug-related death EMCDDA definition’ in the 2005
statistical bulletin and DRD standard protocol, version 3.0 (http://www.emcdda.eu.int/?nnodeid=1419). Most countries have national case definitions that
at present are the same as the EMCDDA or relatively similar, although some countries include cases due to psychoactive medicines or non-overdose deaths,
generally as a limited proportion (see ‘National definitions of drug-related deaths’ in the 2005 statistical bulletin). 
(147) See Table DRD-1 in the 2005 statistical bulletin.
(148) See Tables DRD-2 and DRD-3 in the 2005 statistical bulletin.
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considered a priority policy response to infectious diseases
among drug users in two thirds of EU countries (140).
Evidence on effectiveness of needle and syringe
programmes
Scientific research into the effectiveness of NSPs in
reducing HIV/AIDS among IDUs dates back to the
1980s (141). A review of the literature, published by the
WHO in 2004, concludes that there is compelling
evidence that increasing the availability and utilisation of
sterile injecting equipment by IDUs reduces HIV infection
substantially and that there is no evidence of any major
unintended negative consequences (WHO, 2004).
However, the review concluded that, by themselves, NSPs
are not enough to control HIV infection among IDUs, and
that these programmes must be supported by a range of
complementary measures in order to control HIV infection
among and from IDUs. Reviewing the cost-effectiveness of
NSPs, de Wit and Bos (2004) conclude that NSPs seem to
be cost-effective in preventing the spread of HIV and have
additional and worthwhile benefits apart from reducing
HIV, such as bringing a difficult-to-reach population of drug
users into contact with health and social services.
Hepatitis prevention
Those who inject drugs are at very high risk of acquiring
HBV and HCV infection, and 50–80 % of drug users
become infected within five years of starting to inject,
which can result in chronic infections that can damage and
ultimately destroy the liver (EMCDDA, 2004b). While no
vaccine is currently available against hepatitis C, hepatitis
B can be effectively prevented by vaccination (142).
Several EU countries have introduced or reintroduced
hepatitis B into national immunisation programmes in the
past decade, and the vaccination is now part of the routine
vaccination schedules for children in most EU countries.
So far, only Denmark, the Netherlands, Sweden,
the United Kingdom and Norway have not followed the
WHO recommendation (143).
Although it will be some decades until no substantial at-risk
populations are left, targeted vaccination programmes for
drug users are currently implemented in most EU countries
and Norway. To reach their target populations,
vaccination is made available to drug users at easily
accessible contact points and also increasingly in
prisons (144).
Hepatitis B immunisation campaigns are often combined
with hepatitis A vaccinations and hepatitis C virus
counselling, testing and referral. Even though hepatitis C
treatment is offered in all countries, access can in practice
be difficult for drug users. As official medical guidelines
are considered an important tool in steering the provision
of hepatitis C treatment, in 2003–04 they were the subject
of an analysis by the EMCDDA (145). Most guidelines
recommend that drug users be treated after they have
come off drugs or have been stable on an oral substitution
treatment for a period of time that can vary from three
months to two years. The more recent the guidance
documents are, the more likely they are to take into
account research showing the benefits for drug users of a
multidisciplinary approach to treatment by teams of
hepatologists and drug use specialists. The recent increase
in national guidance is likely to improve treatment options
and enhance outcomes for drug users.
Drug-related deaths
Heroin deaths
In this section, the term ‘drug-related deaths’ is used to
refer to deaths caused directly by the consumption of one
or more drugs and generally occurring shortly after the
consumption of the substance or substances. These deaths
are known as ‘overdoses’, ‘poisonings’ or ‘drug-induced
deaths’ (146).
Opiates are present in most cases of ‘drug-related deaths’
caused by illegal substances reported in the EU, although
in many cases other substances are also identified during
the toxicological examination, in particular alcohol,
benzodiazepines and, in some countries, cocaine (147).
Between 1990 and 2002, EU countries reported 7 000–
9 000 deaths due to overdoses each year (148), adding up
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(149) The figure for AIDS deaths refers to the western area of WHO Europe and includes deaths in several non-EU countries, e.g. Switzerland, Iceland and Israel.
(150) See Figure DRD-2 in the 2005 statistical bulletin.
(151) See Figure DRD-7 in the 2005 statistical bulletin.
(152) See Figure DRD-8 in the 2005 statistical bulletin.
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and Norway also reported significant numbers of cases
associated with the presence of methadone.
As is the case with all opiates, methadone is a potentially
toxic substance, but research has shown that substitution
treatment reduces the risk of overdose mortality among
programme participants. Several studies have indicated
that deaths in which methadone is implicated are more
likely to be the result of illicit rather than prescribed use,
and others have found a higher risk during the initial
phases of methadone maintenance treatment. These
findings suggest the need to ensure good quality standards
in substitution programmes.
Fentanyl and buprenorphine deaths
In recent years, the Baltic countries have reported some
deaths in which fentanyl was found in the toxicological
investigation, frequently concomitantly with heroin. In its
national report, Sweden reported 13 deaths related to
fentanyl among IDUs in 2003, compared with only
occasional cases in previous years. For information about
the role of buprenorphine in drug-related deaths, see the
selected issue on buprenorphine.
Trends in acute drug-related deaths
Trends in drug-related deaths vary from country to
country (151), and even from region to region, as a result of
differences in the course of the heroin epidemic, in the
prevalence of its use, in risk behaviours (e.g. proportion of
injectors, polydrug use), in provision of treatment and
support services for drug users and, perhaps, in the
availability and characteristics of heroin. Differences in the
organisation and policies of the medical emergency
services can also play an important role.
With these limits in mind, some general trends can be
identified for the EU, in particular for the EU-15 Member
States, where longer and more systematic series of data
are available. Overall, a marked increase in drug-related
deaths was observed during the 1980s and early 1990s.
During the period 1990–2000, and despite decreases in
some countries, the overall increasing trend continued in
Europe, although at a lower rate. In 2000, 8 930 deaths
were reported, compared with 6 426 in 1990 (a 40 %
increase) (152). In most of the longer-standing Member
States, an ageing trend can be observed among overdose
victims, suggesting an ‘ageing cohort effect’, which could
be related to a decline in the recruitment of young addicts
(Figure 19).
to more than 100 000 deaths during this period. These
figures can be considered a minimum estimate because
under-reporting is likely to occur in many countries.
Overdosing with opiates is one of the leading causes of
death among young people in Europe, particularly among
males in urban areas (EMCDDA, 2004c). At present,
overdose is also the main cause of death among opiate
users in the EU as a whole; for instance, in 2001, the 
EU-15 Member States reported 8 347 drug-related deaths,
compared with 1 633 deaths from AIDS among IDUs
(EuroHIV, 2004) (149), although the costs and possible
longer-term problems of HIV infection should not be
overlooked.
The majority of drug users who overdose are men,
accounting for 60–100 % of cases, and in most countries
the proportion ranges between 75 and 90 %. Most
overdose victims are in their 20s or 30s, with a mean age
in the mid-30s (range 22–45 years). The mean age is
lowest in several of the new Member States (Estonia, Latvia
and Lithuania) and Romania, in many of which the
proportion of overdose victims younger than 25 years is
relatively high, which may reflect a younger heroin-using
population in these countries (150).
Methadone deaths
Several countries reported the presence of methadone in a
substantial proportion of drug-related deaths in the 2004
Reitox national reports. The information is provided in
accordance with national terminology and, in some cases,
it is difficult to assess exactly what role methadone played
in the death; some cases are genuine methadone
intoxications, but in others the presence of the substance is
merely noted. Denmark reported that methadone was
present in 49 % of deaths from intoxication (97 out of
198 cases, of which 64 cases involved methadone alone).
Germany reported that 23 % of cases were attributed to
‘substitution substances’, of which 3 % were such
substances alone (55 cases) and 20 % in combination with
alcohol and narcotic drugs (354 cases), while in 2002
these figures were 30 % overall (7 % alone and 23 % in
combination). The United Kingdom reported 418 cases
with ‘mention’ of methadone, although this does not mean
a causal relationship. Other countries reported the
presence of methadone in drug-related deaths less
frequently: France (eight cases alone or in association),
Austria (found in 10 % of fatalities), Portugal (detected in
3 % of cases) and Slovenia (four deaths due to
methadone). In the 2003 Reitox national reports, Ireland
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(153) Figures for Belgium and Ireland in 2002 are not included (there were 88 cases in Ireland in 2001).
(154) On the basis of a simple statistical Poisson model. Police data from Norway also suggest a clear decrease in 2003.
(155) See Figure DRD-9 in the 2005 statistical bulletin.
(156) See Figure DRD-6 in the 2005 statistical bulletin. 
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Since 2000, however, many EU countries have reported a
decline in the numbers of drug-related deaths. Among the
EU-15 Member States and Norway, the total number fell
from 8 930 in 2000 to 8 394 in 2001 (a 6 % decrease)
and 7 122 cases in 2002 (153) (a further 15 % decrease).
Only 10 countries reported information for 2003, and so
inferences for trends in the EU should be made with
caution. However, on the basis of those 10 countries, a
5 % decrease was observed in 2003, or only one-third of
the decrease that occurred in 2002. Of the 10 countries
supplying information for 2003, three reported increases,
one reported no change, and six reported decreases, of
which those in Greece (22 %) and Italy (17 %) could be
considered significant (154). These developments should
raise serious concerns, as it is possible that the factors
responsible for the decline in drug-related deaths between
2000 and 2002 (a reduction of almost 20 %) were
abrogated in 2003; this is particularly important as drug-
related deaths are still at historically high levels —
approximately the same as in the early 1990s (Figure 20).
Overall, drug-related deaths among people younger than
25 years old have been decreasing relatively steadily
since 1996, indicating a possible decrease in the number
of young injectors (Figures 19 and 20), the result of a
decreasing or stable trend in most of the EU-15 Member
States, except France, Sweden and Norway. However, in
several new Member States, a clear increase in the
proportion of victims younger than 25 years was observed
between the mid-1990s and 2000–02, suggesting
increasing recruitment of young users (155). In addition, the
decrease observed at EU-15 level since 2000 has taken
place mainly among men (a 21.9 % decrease). Women
have exhibited a much smaller decrease (14.5 %), and in
2003, in contrast to men, the decreasing trend among
women appears to have been reversed (156).
Identification of trends in the new Member States is difficult
because of the limited information available. Although
there are differences from country to country, the available
information suggests that drug-related deaths started to
increase more clearly in the early to mid-1990s. This is
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Figure 20: Overall trend in acute drug-related deaths in the 
EU-15 Member States and trend in the proportion of drug-related
death victims under 25 years old, 1990–2003
(1) The figure for 2003 is provisional, since only 10 countries provided data
for 2003. The figure for 2003 is based on those countries which provided
data for both 2002 and 2003.
NB: Index: 1990 = 100. Numbers of cases per country per year are presented
in Table DRD-2 (parts i and v) in the 2005 statistical bulletin.
Belgium did not provide data for 1998–2001 and Ireland for 2002. A
computation method, defined in EMCDDA (2001), has been used to make
corrections for this situation.
Sources: Reitox national reports (2004), taken from general mortality registries or
special registries (forensic or police), based on national definitions as
presented in Table DRD-6 in the 2005 statistical bulletin.
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Figure 19: Trends in mean age of acute drug-related deaths
victims in some of the EU-15 Member States, 1990–2001/03
NB: The figure represents data from countries that reported mean age of victims
in most years during the reporting period.
Information based on ‘national definitions’ as presented in Table DRD-6
in the 2005 statistical bulletin. In England and Wales, the ‘drug strategy
definition’ is used.
Sources: Reitox national reports (2004), taken from national mortality registries or
special registries (forensic or police).
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(157) See Figure DRD-9 in the 2005 statistical bulletin.
(158) Considering only cases under EMCDDA ‘Selection D’, which includes illegal drugs. The national definition includes many cases resulting from
psychoactive medicines (75 %).
(159) Mortality of drug users in the EU: coordination of implementation of new cohort studies, follow-up and analysis of existing cohorts and development of
new methods and outputs. EMCDDA report CT.00.EP.13, 2002 (http://www.emcdda.eu.int/?nnodeid=1419).
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deaths from overdose and external causes such as suicide
and violence (Dutch national report).
In addition, living conditions and factors other than drug use
per se (homelessness, mental illness, violence, poor nutrition,
etc.) may contribute substantially to the high mortality
among drug users. Studies have shown that mortality among
psychiatric patients is four times higher than that of the
general population (Korkeila, 2000) and that mortality
among homeless people is also three to four times higher
than in the general population (Hwang, 2001).
Reduction in drug-related deaths
Response policies
The 2000–04 EU policy target of a substantial reduction in
drug-related deaths found a considerable level of
also supported by the increase in the proportion of victims
younger than 25 years old that occurred between the mid-
1990s and 1999–2000 in most of the countries supplying
information (157). In the new Member States from which
data are available, the number of victims younger than
25 increased substantially more than the total number from
1996 until very recently (Figure 21), supporting the view
of a more recent epidemic. Since 2000, deaths due to
illegal substances have stabilised or decreased in
Bulgaria, the Czech Republic (158), Latvia (in 2003) and
Hungary. Overall, a degree of stabilisation appears to
have occurred in recent years, but this finding has to be
considered with caution as the quality and coverage of
reporting are still limited in many countries. The probable
increase in heroin use that took place during the 1990s in
many of the new Member States might have been
compensated for by increases in the provision of treatment
services in more recent years, or other factors, but it is
difficult to predict the future trend (Figure 21).
It can be concluded that, despite positive developments
from 2000 until 2002, possibly related to factors such as a
shift away from injection among opiate users in a number
of countries and increased treatment provision, and the
possible stabilisation or decline in the number of opiate
users, the current figures remain high from a longer-term
perspective, and there are indications that the
improvement may not continue.
Overall mortality among opiate users
Opiate users have an overall mortality that is up to
20 times or more higher than that of the general
population of the same age. This increased mortality is
particularly high among injectors. Despite the low
prevalence of opiate addiction, this condition has a
significant impact on the mortality of young adults in
Europe (Bargagli et al., 2004).
Causes of mortality among opiate users include not only
overdoses, but also AIDS and other infectious diseases,
and external causes of death (accidents, violence,
suicides, etc.). The main cause of death among cohorts
with a low prevalence of HIV infection is overdose. AIDS
deaths have decreased substantially in recent years, even
among cohorts with a high prevalence of HIV infection,
due to increased availability of HAART treatment after
1995 (see above for the overall figures in Europe) (159).
As opiate users age, mortality progressively increases as
deaths from chronic conditions (such as cirrhosis, cancer,
respiratory diseases, endocarditis, AIDS) are added to
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Figure 21: Overall trend in acute drug-related deaths in new
Member States and candidate countries and trend in proportion of
victims under 25 years old, 1996–2003
(1) The figure for 2003 is provisional.
NB: The countries included are Czech Republic, Estonia, Latvia, Lithuania,
Hungary, Malta, Slovenia and Bulgaria.
Index: 1996 = 100. Numbers of cases per country per year are presented
in Table DRD-2 (part ii) in the 2005 statistical bulletin.
It is important to remember that the index has been computed using data
from a limited number of countries. Also note that the Czech Republic and
Estonia account for a substantial proportion of victims younger than 25.
Estonia did not provide data for 1996 and 2003, Hungary for 2002 and
Czech Republic for 1996 to 2000. The computation method is detailed
in EMCDDA (2001).
Sources: Reitox national reports (2004), taken from general mortality registries or
special registries (forensic or police), based on national definitions as
presented in Table DRD-6 in the 2005 statistical bulletin.
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(160) See the overview table: Strategies and selected measures to reduce drug-related deaths (http://www.emcdda.eu.int/?nnodeid=10697).
(161) See the EU drug strategy 2005–2012 (http://www.emcdda.eu.int/?nnodeid=6790).
(162) http://eldd.emcdda.eu.int/?nnodeid=5173&pluginMethod=eldd.showlegaltextdetail&id=2603&lang=en&T=2
(163) European report on drug consumption rooms (http://www.emcdda.eu.int/?nnodeid=1327).
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acceptance among Member States. Eight of the 
EU-15 Member States (Germany, Greece, Spain, Ireland,
Luxembourg, Portugal, Finland and the United Kingdom)
plus four new EU countries (Cyprus, Latvia, Lithuania and
Poland) have included a reduction in drug-related deaths
in their national strategy documents (160). The fact that
several new Member States still lack reliable information
on the number of drug-related deaths is, however, an
important obstacle to the establishment of an adequate
response policy.
The new EU drug strategy (2005–12) places a high
priority on improving access to a range of services that
can reduce the morbidity and mortality associated with
drug dependence, and the number of drug-related deaths
has been chosen as one of the main indicators of progress
towards this aim in the first four-year action plan
(2005–08) (161).
Interventions
A major intervention in terms of its impact on drug-related
deaths is adequate provision of treatment, especially
substitution treatment (WHO, 1998; ACMD, 2000; Brugal
et al., 2005). During the 1980s, and to an even greater
extent in the 1990s, substitution treatment underwent a
rapid expansion in Europe, especially in EU Member
States with a high prevalence of heroin injecting.
Currently, more than half a million heroin users in the EU
— which is between one quarter and half of the estimated
target group of heroin users — are enrolled in substitution
treatment programmes.
In countries where more than half the problem drug-using
population is in substitution treatment, reductions in the
levels of drug injecting and related risk behaviours are
likely, with a consequent reduction in overdose deaths.
In 2003, the European Council recommended to EU
Member States a number of measures to reduce the
number of drug-related deaths (162). Besides the provision of
treatment for drug addiction, these include the
improvement of education and the dissemination of
information on overdose risk and management among
drug users and their peers and families; and proactive
strategies to reach those who are out of contact with
services through outreach work and easily accessible,
attractive drug services. The level of implementation of the
recommendation and the effects thereof are under close
assessment by the Commission with a report expected
in 2006.
The demographic profile of overdose victims shows that
untreated older heroin users are at the greatest risk of
dying from a drug overdose. A specific measure that is
effective in reaching this priority group is the establishment
of supervised drug consumption facilities (163). Such
services currently operate in 15 German and 15 Dutch
cities as well as in Madrid, Barcelona and Bilbao (Spain)
and Oslo (Norway).
Opiate treatment
In simple terms, the options available for the treatment of
problem opiate use can be divided into three general
categories: medically assisted treatment (MAT), drug-free
treatment and withdrawal treatment (the last mentioned
will not be explored here). However, addressing issues of
dependence and withdrawal is only one aspect of
successfully treating opiate problems. Helping the
individual re-enter society through social integration, i.e.
finding work and secure housing, and developing the
necessary social and coping skills to avoid relapse, are
likely to be equally important in ensuring a positive
outcome in the longer term. Numerous studies have noted
that those with opiate drug problems often have multiple
treatment contacts and that therapeutic goals, especially
abstinence, may not necessarily be achieved in an
individual’s first treatment contact, but may be gained
through repeated therapeutic interventions.
Medically assisted treatment
Medically assisted treatment (MAT) includes both
substitution treatment with agonists (methadone,
buprenorphine, dihydrocodeine, heroin, slow-release
morphine) and, although much less widely used, treatment
with antagonists (for example, naltrexone).
Methadone is available in almost all Member States (see
Table 3) and continues to be the most commonly prescribed
substitution treatment in Europe. However, in recent years,
treatment options have widened. Buprenorphine is now
available in 18 of the 26 countries for which information is
available. Treatment with other agonists, as well as treatment
with antagonists (naltrexone, naloxone or clonidine), is less
frequently used across the EU. A study on the introduction of
controlled heroin prescriptions is currently under way in
Belgium, and Austria has received an expert opinion on
heroin-assisted treatment of chronic opiate addicts, based on
the results of existing international programmes.
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consequently it is not possible to determine aggregate
figures for the EU as a whole.
However, some countries do have reliable data or
estimates on the number of clients receiving substitution
treatment from general practitioners, thereby adding
important information to the overall estimates of clients in
substitution treatment in the EU. Clients receiving
methadone treatment through their general practitioner in
2003 numbered 8 500 in France, 2 682 in Ireland,
The latest figures show that in 2003 there were more than
450 000 clients in substitution treatment in specialised
units in the EU (Table 4), of whom more than 90 % were
receiving methadone. In addition to these were clients
receiving other kinds of substitution treatment (such as
dihydrocodeine, slow-release morphine or heroin) and
those who received substitution treatment in settings such
as at their general practitioner. Unfortunately, reliable
data on these aspects of substitution treatment are not
currently available in many Member States and
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Table 3: Applied substances in medically assisted treatment in Europe (including trials)
Country Methadone Buprenorphine Dihydrocodeine Slow-release Heroin Naltrexone/ Clonidine
morphine naloxone
Belgium X X X X X
Czech Republic X X
Denmark X X
Germany X X X X X
Estonia X X
Greece X X X
Spain X X X
France X X X
Ireland X
Italy X X X X
Cyprus
Latvia X
Lithuania X X X
Luxembourg X X X
Hungary X
Malta X X X X
Netherlands X X X X X
Austria X X X X
Poland X
Portugal X X X X
Slovenia X
Finland X X
Sweden X X
United Kingdom X X X X X X
Bulgaria X X
Romania X
Norway X X
NB: No information is available for Slovakia or Turkey.
Source: Standard table on drug-related treatment availability.
Chapter 6: Heroin and injecting drug use
851 in Luxembourg and 930 in the Netherlands. In
addition, in the Czech Republic and France, 1 200 and
70 000 clients, respectively, were receiving buprenorphine
treatment through their general practitioner. It is estimated
that a total of 81 743 clients were receiving substitution
treatment at their general practitioner in these five
countries. Bearing in mind that there are more than
450 000 clients in substitution treatment in specialised
units, the total number of clients receiving substitution
treatment has now passed the half million mark at around
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Table 4: Estimates of clients in substitution treatment in Europe in 2003
Country Clients in methadone treatment Clients in buprenorphine treatment Total of clients in substitution treatment 
in specialised units in specialised units in specialised units
Belgium 1 922 48 1 970
Czech Republic 368 204 572
Denmark 4 971 484 5 455
Germany 65 000 9 000 74 000
Estonia 60 13 73
Greece 2 018 275 2 293
Spain 88 678 36 88 714
France 15 000 13 000 28 000
Ireland (1) 5 561 0 5 561
Italy 79 065 7 113 86 178
Cyprus 0 0 0
Latvia 67 0 67
Lithuania 332 n.a. 332
Luxembourg 133 10 143
Hungary 750 0 750
Malta 698 0 698
Netherlands 12 000 n.a. 12 000
Austria (2) 1 796 1 667 6 413 (3)
Poland 865 0 865
Portugal 9 765 2 743 12 508
Slovenia 1 909 0 1 909
Finland 170 430 600
Sweden 800 1 300 2 100
United Kingdom 128 000 n.a. 128 000
Bulgaria 380 0 380
Romania 400 0 400
Norway 1 947 484 2 431
Total (4) 422 655 36 807 462 412 (3)
(1) This is the number of cases rather than individuals treated in the year.
(2) In Austria, around 46 % of clients are receiving substitution treatment other than methadone and buprenorphine, which have been added to give the correct
total. The proportional breakdown is based on first treatments.
(3) The higher aggregated total is due to an estimated 2 950 clients in substitution treatment with drugs other than methadone and buprenorphine in Austria (pre-
dominantly slow-release morphine).
(4) n.a. = no information. In calculating totals, ‘no information’ has been given the value of 0, and hence the numbers presented are minimum values.
NB: No information is available for Slovakia or Turkey.
Source: Standard table on drug-related treatment availability. 
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rare, and reliable, clear, quantitative data for this method
of treatment are scarce. Although it is not possible to make
an accurate comparison with MAT, reports from Member
States indicate that MAT is the principal form of treatment
for problem opiate users in the majority of EU Member
States and at an aggregated EU level. However, some
countries report a general preference for drug-free
treatment rather than MAT (Estonia, Cyprus, Lithuania,
Poland and Finland). In a number of countries, notably
Greece, Spain and Norway, levels of MAT and drug-free
treatment appear to be similar.
New developments in quality assurance
Several countries (Germany, Austria and Portugal) have
issued manuals for medical staff involved in drug-related
treatment. Efforts in the framework of the United Kingdom
government’s drug strategy have shown that, by investing
in budget, organisation, monitoring and staff, waiting lists
can be reduced and more problem drug users can gain
access to and remain in treatment. In England, 41 % more
problem drug users were in contact with drug treatment
services in 2003–04 than in 1998–99, and waiting times
have been cut by two thirds since 2001. In 2003–04,
72 % of clients had either successfully completed
structured treatment or were retained in treatment,
compared with 57 % in 2002–03 (NTA, 2004).
The setting in which drug-free treatment is provided varies
considerably. In one group of countries (Germany, Greece,
Spain, France, Cyprus, Luxembourg, Netherlands, Poland,
Slovenia, the United Kingdom) drug-free treatment of
problem opiate users takes place predominantly in
outpatient settings, whereas a smaller group of countries
report predominant use of inpatient settings (Ireland, Italy,
Austria) and others show no clear predominance (Sweden,
Norway).
Social reintegration
Social reintegration is defined as ‘any social intervention
with the aim of integrating former or current problem drug
users into the community’. The three ‘pillars’ of social
reintegration are (1) housing; (2) education; and 
(3) employment (including vocational training). Other
measures, such as counselling and leisure activities, may
also be used.
Social reintegration is a less well-established response to
problem drug use than is treatment and, consequently,
monitoring and reporting in this field are more patchy.
Some countries report qualitative assessments of their
efforts in the field of social reintegration; however, none
530 000. Again, as the information is incomplete, the
figure of 530 000 represents a minimum estimate of the
number of drug users in substitution treatment.
The level of availability of substitution treatment differs
markedly between the EU-15 and the new Member States
and candidate countries. Although they account for more
than 20 % of the total population, the new Member States
and candidate countries account for only 1.3 % of clients
in substitution treatment (not including Turkey, where no
data regarding substitution treatment are available). Of the
new Member States, only two, the Czech Republic and
Slovenia, provide estimates of the prevalence of problem
drug use, and in both these countries substitution treatment
is available for a smaller proportion of problem drug users
(16 % and 26 % respectively) than is average for the 
EU-15 (35 %). Despite the lack of estimates of the
prevalence of problem drug use in other new Member
States and candidate countries, the level of substitution
treatment is far behind that in the EU-15 Member States.
Considering the high risk of spread of infectious diseases
in some countries and the preventive role that MAT can
play in limiting this (see, for instance, UNODC, 2002), the
situation is a cause for concern.
Two distinct trends in MAT have emerged in recent years.
The first is a continuation of the trend of increasing
availability of substitution treatment, although the increase
is becoming less pronounced. In addition, there has been
a diversification in substances provided; for example, the
number of countries reporting use of buprenorphine has
risen to 14 in 2003, compared with six in 1999/2000.
A third, although less distinct, trend is that of increasing
involvement of general practitioners in the provision of
MAT. Involvement of general practitioners was reported
in only three of the 15 Member States (Belgium, France,
the United Kingdom) in 2000/2001 (Solberg et al., 2002)
but is now found in 10 of the EU-15 Member States
(Belgium, Germany, France, Ireland, Italy, Luxembourg,
Netherlands, Austria, Sweden and the United Kingdom)
as well as three of the new Member States
(Czech Republic, Malta and Slovenia).
Drug-free treatment
Drug-free treatment involves the application of
psychosocial and educational techniques to achieve long-
term abstinence from drugs. Traditionally, drug-free
treatment has been residential and long term, e.g. in
therapeutic communities. Today, it is often also offered in
community-based settings.
Unlike MAT, for which centralised national registers exist in
many Member States, registers of drug-free treatment are
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(164) See ‘Interpreting seizures and market data’, p. 41.
(165) Although this should be checked against missing 2003 data when available. Data on numbers of heroin seizures in 2003 were not available for Italy,
Cyprus, the Netherlands and Romania; data on both number of heroin seizures and quantities of heroin seized in 2003 were not available for Ireland and
the United Kingdom.
(166) See Table SZR-4 (part i) in the 2005 statistical bulletin.
(167) See Table SZR-3 (part i) in the 2005 statistical bulletin.
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reports good coverage. The countries reporting (Estonia,
Ireland, Malta, the Netherlands, Sweden, Romania and
Norway) all identify deficiencies in their social
reintegration services and/or programmes. One exception
to the rule is Greece, where there is both a relatively wide
fan of social reintegration programmes and reliable data
on the number of clients they reach.
Seizures and market information (164)
Production, trafficking and seizures of opiates
Afghanistan has become by far the world leader in the
supply of illicit opium, especially as the total area under
cultivation increased again in 2004. Global production
of illicit opium in 2004 was estimated to be about
4 850 tonnes (4 766 tonnes in 2003), to which
Afghanistan contributed 87 % and Myanmar 8 %. Global
opium production has remained stable over the last five
years, except in 2001, when a ban on opium poppy
cultivation in Afghanistan, enforced by the Taliban regime,
resulted in a dramatic but short-lived decline. Global
potential manufacture of heroin was estimated at
485 tonnes in 2004 (477 tonnes in 2003) (CND, 2005).
Heroin consumed in the EU is predominantly manufactured
in Afghanistan (increasingly) or along trafficking routes for
opium, notably in Turkey (UNODC, 2003a; INCB, 2005),
and enters Europe by two major trafficking routes. The
historically important Balkan route continues to play a
crucial role in heroin smuggling. Following transit through
Pakistan, Iran and Turkey, the route then diverges into a
southern branch, through Greece, the former Yugoslav
republic of Macedonia (FYROM), Albania, part of Italy,
Serbia, Montenegro and Bosnia–Herzegovina; and a
northern branch, through Bulgaria, Romania, Hungary and
Austria. The INCB (2005) reports that, in 2003, the
northern branch of the Balkan route became the dominant
one for heroin trafficking. Since the mid-1990s, heroin has
increasingly been smuggled to Europe through the ‘silk
route’ via central Asia, the Caspian Sea and the Russian
Federation, Belarus or Ukraine (Reitox national reports,
2004; UNODC, 2003a; CND, 2005; INCB, 2005).
Although these routes are the most important, several
countries in eastern and western Africa and the Americas
have made seizures of heroin destined for Europe in 2003
(CND, 2005; INCB, 2005).
In addition to imported heroin, some opiate drugs are
produced within the EU. This is mainly confined to the
limited production of home-made poppy products
(e.g. poppy straw, poppy concentrate from crushed poppy
stalks or heads) in a number of eastern EU countries such
as Estonia, Latvia and Lithuania (Reitox national reports,
2004). In particular, such products seem to have regained
popularity in 2003 in Estonia.
In volume terms, in 2003, Asia (56 %) and Europe (34 %)
continued to account for most of the heroin seized
worldwide. Europe’s share is on the increase, in particular
because of increased heroin seizures in eastern and south-
eastern European countries (CND, 2005). Since 1998, the
EU country accounting for the greatest number of seizures
and quantity of heroin seized has been the United
Kingdom, followed by Spain in terms of number of seizures
and Italy in terms of quantities intercepted (165). In 2002,
the United Kingdom was responsible for about 30 % of
both heroin seizures and the total amount of heroin seized
in the EU.
Quantities of heroin seized (166) in the EU have generally
been on the increase over the last five years, with a
plateau in 2000–02, while, overall, numbers of seizures
have been declining during the same period. Based upon
trends in countries from which data are available, both
seizures and quantities of heroin intercepted in the EU
seem to have decreased in 2003 (167).
Seizures of fentanyl and methylfentanyl — synthetic
opiates that are up to 100 times more potent than heroin
— were reported again in 2003 in Estonia, while Latvia
reported its first seizure of 3-methylfentanyl in 2003 and
Austria its first seizure of fentanyl in January 2004. In
Estonia, the poor quality of the heroin available on the
local market has been compensated for since 2002 by the
introduction of these two synthetic opiates, under the
names ‘white Chinese’, ‘white Persian’ or ‘synthetic heroin’
(Reitox national reports, 2004).
Although data on seizures of benzodiazepines — usually
used as substitutes by heroin users — are not
systematically collected by the EMCDDA, Spain, Lithuania,
Sweden and Norway reported having made such seizures
(in particular of Rohypnol) in 2003.
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(168) See Table PPP-2 (part i) in the 2005 statistical bulletin.
(169) See Table PPP-6 (part i) in the 2005 statistical bulletin.
(170) Small sample number for Norway (n = 8).
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price of white heroin ranged from EUR 25 (Slovakia) to
EUR 216 (Sweden) per gram (168). This price differential is
likely to reflect the purity of the drug being sold.
In 2003, the average purity of brown heroin at street level
in the EU varied from 6 % in Austria to 40 % in Malta.
Data on purity of white heroin were reported by only a few
countries (169); it ranged on average from 6 % in Finland to
70 % in Norway (170).
Price and purity of heroin
In Europe, heroin occurs in two forms: the commonly
available brown heroin (its chemical base form) and the
less common and more expensive white heroin (a salt
form), which typically originates from south-east Asia. In
2003, in the EU the average street price of brown heroin
was reported to vary between EUR 27 per gram in
Belgium and EUR 144 per gram in Sweden, while the
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Buprenorphine: treatment, misuse and prescription
practices, in EMCDDA annual report 2005:
selected issues
In the past 10 years, buprenorphine has increasingly
become available in Europe as an alternative to methadone
for the treatment of opiate dependence. First developed as
an analgesic, buprenorphine was suggested for use in the
treatment of opiate dependency in the late 1970s.
Buprenorphine’s introduction for opiate treatment in the 
EU-15 Member States and its expansion in these countries
and into the new Member States is described.
Comparisons are made between buprenorphine and
methadone in terms of efficacy and costs. The provision of
buprenorphine treatment in Europe is described, and
comparisons are made between Member States in which
buprenorphine is the principal substance used in the
treatment of opiate dependency and those where medically
assisted treatment (MAT) is mainly carried out with
methadone. Among the findings is that around 20 % of
clients in MAT in the EU today receive buprenorphine,
although most of these clients are in one country (France).
Overall, buprenorphine has spread to many countries, but
the actual number of clients is still limited in the majority of
Member States.
Buprenorphine is looked at from the perspective of potential
misuse. The first indications are that misuse of
buprenorphine is prevalent in only a few countries, and is
uncommon elsewhere. Some evidence is reported that
relates misuse of buprenorphine to specific populations or
age groups, or attempts to identify distinct groups of
buprenorphine misusers. Although deaths due to
buprenorphine misuse are very rare, some deaths are
reported by scientific literature and by some European
countries. Reports of deaths related to buprenorphine
misuse are compared with those related to methadone
misuse.
The selected issue draws conclusions about the relative
merits of buprenorphine and methadone in the treatment of
opiate dependency. Buprenorphine is identified as
representing an opportunity to make MAT more widely
available and more easily accessible.
This selected issue is available in print and on the Internet
in English only (http://issues05.emcdda.eu.int).

(171) The term ‘reports’ for drug law offences is in quotation marks because it describes different concepts in different countries (police reports of suspected
drug law offenders, charges for drug law offences, etc.). For an exact definition for each country, refer to the methodological notes on definitions of ‘reports’
for drug law offences in the 2005 statistical bulletin. (NB: The term ‘arrests’ was used in annual reports until 2001.)
(172) See Table DLO-1 (part i) in the 2005 statistical bulletin. Data on ‘reports’ for drug law offences in 2003 were not available for Denmark, Germany,
Ireland, Latvia, Slovakia and the United Kingdom.
(173) See Table DLO-2 in the 2005 statistical bulletin.
(174) In Portugal, remaining drug law offences are related to ‘drug dealing/trafficking’, as offences of drug use/possession for use were decriminalised in July 2001.
(175) In Norway, no distinction is drawn between ‘drug dealing/trafficking’ alone and ‘drug use/dealing and trafficking’. Therefore, remaining drug law
offences are related to ‘drug use’ alone.
Drug-related crime
Drug-related crime is taken as referring to crimes
committed under the influence of drugs; those committed in
order to finance drug use; those occurring in the context of
the functioning of illicit drug markets; and those against
drug legislation. Routine data are available in the EU only
on the last type of crime — drug law offences.
‘Reports’ (171) of drug law offences reflected differences in
national legislation, in the ways in which the laws are
applied and enforced and in the priorities and resources
allocated by criminal justice agencies to specific crimes. In
addition, information systems on drug law offences vary
considerably between countries, especially in relation to
reporting and recording practices, i.e. what is recorded
and when and how. These differences make comparisons
between EU countries difficult.
Between 1998 and 2003, the number of ‘reports’ of drug
law offences increased in most EU countries. Increases
were particularly marked (twofold or more) in Estonia and
Poland. However, the number of ‘reports’ decreased in
2003 in Belgium, Spain, Italy (since 2001), Hungary,
Malta, Austria and Slovenia (since 2002) (172).
In most EU Member States, the majority of reported drug
law offences continued to be related to drug use or
possession for use (173), ranging from 39 % of all drug law
offences in Poland to 87 % in Austria and the United
Kingdom. In the Czech Republic and Luxembourg, 91 %
and 46 %, respectively, of reported drug law offences
were related to dealing or trafficking, whereas in Italy and
Spain — where drug use and possession for use are not
criminal offences — all drug offences were related to
dealing or trafficking. Finally, in Portugal (174) and
Norway (175), 59 % of offences were related to drug use
and trafficking together.
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Drug use and crime: some data
In a survey carried out in 2004 in the Czech Republic,
police officers working in regional headquarters estimated
that approximately 40 % of ordinary thefts and
approximately 30 % of burglaries had been committed in
order to buy drugs. In the same country, routine data on
recorded crime showed that, in 2003, 0.7 % of all offences
were committed while the offenders were under the
influence of narcotic or psychotropic substances, alcohol
excluded (Czech national report).
In Finland, during 2000–03, the proportion of homicides
and assaults committed by offenders under the influence of
illicit drugs was much lower than the proportion committed
by offenders under the influence of alcohol (6 % compared
with 64 % of homicides and 2 % compared with 71 % of
assaults) (Lehti and Kivivuori; cited in the Finnish national
report). Although the presence of drugs in robbery offences
seems to have increased in the last decade, the presence of
alcohol in robbery offences is still more common (43 % of
robbery offences involve alcohol compared with 9 % that
involve drugs).
In Germany, ‘direct economic compulsive crimes’ —
criminal offences committed in order to obtain narcotic
drugs or substitute or alternative drugs — decreased in
2003 to 2 568 cases, of which over 70 % were related
to forgery of prescriptions or theft of prescription forms
(BKA, 2004).
In Latvia, routine data from the Ministry of the Interior
showed that 2.8 % of all detected crimes in 2003 (3.1 % in
2002) were committed by offenders who were under the
influence of narcotic substances (Latvian national report).
(176) See Table DLO-4 in the 2005 statistical bulletin.
(177) The law to decriminalise drug use and possession for use was passed in November 2000 and came into effect in July 2001.
(178) See Table DLO-3 in the 2005 statistical bulletin.
(179) In the Netherlands, ‘hard drugs’ are defined as drugs that pose unacceptable public health risks, such as heroin, cocaine, ecstasy and LSD.
(180) The following countries provided a breakdown by drug or drug offences over time: Belgium, the Czech Republic, Germany, Spain, France, Ireland, Italy,
Lithuania, Luxembourg, Malta, the Netherlands (only ‘soft drugs’/cannabis and ‘hard drugs’), Austria, Portugal, Slovenia, Sweden and the United Kingdom.
(181) See Table DLO-5 in the 2005 statistical bulletin.
(182) See Table DLO-6 in the 2005 statistical bulletin.
(183) See Table DLO-7 in the 2005 statistical bulletin.
(184) See Table DUP-1 in the 2005 statistical bulletin.
(185) See Table DUP-5 (annex) in the 2005 statistical bulletin.
(186) See Table DUP-3 in the 2005 statistical bulletin.
(187) See Table DUP-2 in the 2005 statistical bulletin.
(188) See Table DUP-4 in the 2005 statistical bulletin.
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In all countries from which data are available, except
Portugal, the proportion of all drug law offences accounted
for by those related to drug use or possession for use
increased over the five-year period 1998–2003 (176). The
rate of increase was generally slow, but more marked
upward trends were evident in Belgium, Luxembourg and
Slovenia, and in Ireland until 2001. In Portugal, the
proportion of use-related offences started to decrease in
2000, one year before drug use and possession for use
were decriminalised in July 2001 (177). In 2003, decreases
were reported in the Czech Republic, Luxembourg, Austria
and Slovenia.
In most of the Member States, cannabis continued to be the
illicit drug most often involved in reported drug law
offences (178). In the countries where this was the case,
cannabis-related offences in 2003 accounted for 39 %
(Italy) to 87 % (France) of all drug law offences. In the
Netherlands, offences involving ‘hard drugs’ (179) were
predominant (58 %), whereas in the Czech Republic the
majority of drug law offences related to amphetamines
(48 %). The relative proportion of drug law offences
related to any specific drug is influenced by a number of
factors, including the operational priorities of law
enforcement agencies and explicit or implicit strategic
decisions to target different types of drug law offences
differentially.
Since 1998, the proportion of drug offences involving
cannabis (180) has been increasing in Germany, Spain,
France, Ireland, Lithuania, Luxembourg, Malta and
Portugal, whereas it has remained stable overall in
Belgium, the Czech Republic, the Netherlands, Slovenia,
Sweden and the United Kingdom, and has been
decreasing in Italy and Austria (181).
Over the same period, the proportion of heroin-related
offences decreased in all EU countries from which data are
available, except Austria and the United Kingdom, where
it increased (182). In contrast, cocaine-related offences have
increased as a proportion of all drug offences since 1998
in all countries providing data except Germany, which
reported downward trends (183).
Drug users and prison
Drug users in prison
National routine information on type and pattern of drug
use among prisoners is scarce and patchy. Much of the
data available in the EU comes from ad hoc studies based
on samples of varying size, the results of which (and
trends) are very difficult to extrapolate.
Drug users are strongly overrepresented among the prison
population compared with the general population. In most
studies in the EU, lifetime prevalence of drug use among
prisoners is reported to be over 50 %; however, it varies
widely, from 22 % to 86 %, between prison populations,
detention centres and countries (184). In the EU, the
prevalence of regular drug use or dependence prior to
imprisonment ranges from 8 % to 73 % (185).
The majority of drug users reduce or stop their drug use on
admission to prison. However, many prisoners continue to
use drugs after incarceration, and some start using drugs
(and/or injecting drugs) in prison. Available studies show
that between 8 % and 60 % of inmates report having used
drugs while in prison, and 10–42 % report regular drug
use (186).
Lifetime prevalence of injecting drug use among prisoners
is generally reported to be between 15 % and 50 %;
however, some studies have reported values as low as 1 %
or as high as 69 %. Where comparable data are
available (Austria 1999, England and Wales 1997–98),
they show that young offenders are less likely to inject than
adults and that, among the prison population, women are
more likely to inject than men (187). Based on several studies
in the EU, Bird and Rotily (2002) have shown that around
one third of adult male prisoners are drug injectors. Data
provided by the Reitox focal points show that between
0.2 % and 34 % of inmates (188) have injected drugs while
in prison. This raises issues of access to sterile injection
equipment and hygienic sharing practices among the
prison population and the potential spread of infectious
diseases.
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long waiting lists for treatment; Sweden reports
overcrowded prisons and reduced prison staff levels; and,
in Romania, appropriate legislation is lacking. In Cyprus,
even though there is no integrated support programme for
imprisoned drug users, some prevention measures are
taken.
Education and training activities represent general
prevention strategies. In most EU and candidate countries,
such activities have been carried out for both drug users in
prisons and prison staff. Among the countries reporting
such activities are Estonia, Spain, Cyprus, Hungary,
Slovenia and Romania (Reitox national reports).
Another preventive element is the establishment of drug-
free units within prisons. Participation is on a voluntary
basis, generally after written declarations to accept certain
conditions, for example periodic urine testing, have been
signed by imprisoned drug users. Such units exist in all 
EU-15 Member States. In the ‘new’ Member States, drug-
free units have been established in most countries. An
Assistance and treatment for drug users in prison
In all Member States and candidate countries, there are
systems of one kind or another in place to ensure that
assistance for drug users in prison is available, although
the variety of services and their availability differs
considerably. A notable trend is the increasing
acknowledgement of the fact that prisoners have the same
rights as the rest of the population concerning access to
healthcare, including assistance and treatment for drug
users (WHO Regional Office for Europe, 2002; Irish,
Lithuanian and Finnish national reports). Among the
services that should be made available to prisoners are
strategies for prevention, including drug-free programmes,
detoxification treatments, methadone and other substances
treatments, counselling and education.
However, countries report various problems with the
provision of adequate assistance. For instance, the
availability of services is precarious in Estonia; no specific
services are available for drug users in Latvia; Poland has
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Alternatives to imprisonment: targeting offending
problem drug users in the EU, in EMCDDA annual
report 2005: selected issues
Prison is a particularly detrimental environment for problem
drug users and there is a broad political consensus on the
principle of treatment as an alternative to prison. The
alternatives to prison that may be offered to drug-using
offenders cover a range of sanctions that may delay, avoid,
replace or complement prison sentences for those drug
users who have committed an offence normally sanctioned
with imprisonment by national law. The selected issue
focuses on those measures that have a drug-related
treatment component.
Since the 1960s, UN and EU agreements, strategies and
action plans have several times reaffirmed and
strengthened the principle of providing treatment,
education and rehabilitation as an alternative to conviction
and punishment for drug-related offences. This has been
translated into national legislation in EU Member States,
and the criminal justice systems as well as health and social
services systems have been adapted accordingly. Young
drug users are especially vulnerable to getting into a
vicious circle of drugs and crime, and there is a particular
determination to avoid imprisonment for young offenders.
The implementation of alternative measures to
imprisonment, however, faces certain difficulties due to the
different administrative systems involved and their different
underlying principles. Efforts are made to bridge the gap
between the judicial and the health and social services
systems through coordination structures and initiatives,
i.e. between police, courts and prisons and drug treatment
services. Often, informal cooperation mechanisms at local
level have been forerunners to more stable institutionalised
forms.
Recourse to alternatives to prison increased during the last
decades in the EU-15 Member States and has recently even
stagnated in some, whereas legislation and implementation
of alternatives began later in the new Member States.
Usually, the mainstream treatment system is called on to
ensure the treatment of offenders with problematic drug
use. In most countries, treatment is usually provided in
residential settings, but the possibility also exists to follow
outpatient treatment programmes.
European evaluation studies of treatment as an alternative
to prison are rare and partly inconclusive. However,
consistent with other treatment research, retention in
treatment proves to be a key indicator of success and drop-
out rates are one of the biggest problems for alternatives to
prison. Evidence suggests that it is the quality of treatment
provided and not the route of the client into treatment that is
important for treatment success. Treatment as an alternative
to prison seems to work best if the addicts are motivated for
treatment and if care facilities follow good clinical
standards and have enough and qualified staff.
This selected issue is available in print and on the Internet
in English only (http://issues05.emcdda.eu.int).
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evaluation of the drug-free zone in one Austrian prison
showed that prisoners released from the drug-free
zone were sentenced again significantly less often
than prisoners released from normal units in the prison
(35 % compared with 62 %).
The most common treatment modality in prisons is drug-
free treatment, which exists in all Member States (except
Cyprus and Latvia), although availability varies. Treatment
centres within the community provide support and
treatment as well as aftercare in many countries, e.g.
Belgium, the Czech Republic, Greece, Luxembourg and the
United Kingdom.
In most countries, the availability of substitution
maintenance treatment inside prison is not the same as its
availability outside prison. Only in Spain is maintenance
treatment widespread, with 18 % of all prisoners, or 82 %
of problem drug users in prison, receiving this treatment.
Luxembourg also has high coverage. Countries reporting
considerable increases in the availability of medically
assisted treatment include France, mainly with
buprenorphine, and Ireland (Reitox national reports).
In the Netherlands, medically assisted treatment is
available only for short-term detainees who used
methadone before imprisonment, whereas in Poland the
first programme of methadone treatment with 14 clients
was introduced in a remand prison.
New developments in combating the spread
of infectious diseases in prison
In Estonia, the situation regarding the prevention of the
spread of HIV improved in 2003. The number of primary
HIV tests increased 2.6-fold compared with 2002,
although the number of positive tests increased only
slightly. Pre- and post-test counselling services also
improved in terms of quantity as well as quality. In
Romania, programmes aimed at preventing the spread
of HIV/AIDS in penitentiaries and among prisoners were
developed in cooperation with some international non-
governmental organisations (NGOs).
Spain is the only country systematically implementing
needle and syringe exchange programmes in prisons.
In 2003, these programmes distributed a total of
18 260 syringes. Implementation of similar programmes
is not foreseen in other Member States and candidate
countries.
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The European Monitoring Centre for Drugs and Drug Addiction (EMCDDA)
is one of the European Union’s decentralised agencies. Established in 1993
and based in Lisbon, it is the central source of comprehensive information
on drugs and drug addiction in Europe.
The EMCDDA collects, analyses and disseminates objective, reliable and
comparable information on drugs and drug addiction. In doing so, it
provides its audiences with an evidence-based picture of the drug
phenomenon at European level.
The Centre’s publications are a prime source of information for a wide
range of audiences including policy-makers and their advisors;
professionals and researchers working in the drugs field; and, more
broadly, the media and general public.
The annual report presents the EMCDDA’s yearly overview of the drug
phenomenon in the EU and is an essential reference book for those seeking
the latest findings on drugs in Europe.
